U.S. patent application number 16/435929 was filed with the patent office on 2021-11-18 for therapeutic and diagnostic methods relating to cancer stem cells.
This patent application is currently assigned to Children's Medical Center Corporation. The applicant listed for this patent is Children's Medical Center Corporation. Invention is credited to Markus H. Frank, Natasha Y. Frank.
Application Number | 20210355210 16/435929 |
Document ID | / |
Family ID | 1000005940987 |
Filed Date | 2021-11-18 |
United States Patent
Application |
20210355210 |
Kind Code |
A9 |
Frank; Markus H. ; et
al. |
November 18, 2021 |
THERAPEUTIC AND DIAGNOSTIC METHODS RELATING TO CANCER STEM
CELLS
Abstract
The present invention relates in part to the discovery of genes
that are deregulated in cancer stem cells (e.g., melanoma stem
cells). In some aspects, methods for treating individuals having
melanoma are provided; the methods involve modulating (e.g.,
inducing, inhibiting, etc.) the activity of the cancer stem cell
associated genes. In other aspects, cell surface genes that are
upregulated in melanoma stem cells are targeted for the selective
isolation, detection, and killing of cancer stem cells in melanoma.
Other aspects of the invention relate to reagents, arrays,
compositions, and kits that are useful for diagnosing and treating
melanoma.
Inventors: |
Frank; Markus H.;
(Cambridge, MA) ; Frank; Natasha Y.; (Cambridge,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Children's Medical Center Corporation |
Boston |
MA |
US |
|
|
Assignee: |
Children's Medical Center
Corporation
Boston
MA
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20200385464 A1 |
December 10, 2020 |
|
|
Family ID: |
1000005940987 |
Appl. No.: |
16/435929 |
Filed: |
June 10, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14868126 |
Sep 28, 2015 |
10316085 |
|
|
16435929 |
|
|
|
|
13128915 |
Aug 9, 2011 |
|
|
|
PCT/US2009/006089 |
Nov 13, 2009 |
|
|
|
14868126 |
|
|
|
|
61114490 |
Nov 14, 2008 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K 2317/622 20130101;
C12N 2310/14 20130101; A61K 51/1096 20130101; C07K 16/2803
20130101; C07K 2317/76 20130101; G01N 33/57419 20130101; C12N
2310/122 20130101; C12N 2310/3513 20130101; C07K 2317/24 20130101;
A61K 38/1709 20130101; C12N 15/1138 20130101; C07K 2317/55
20130101; C07K 2317/51 20130101; C07K 2317/56 20130101; G01N
33/57415 20130101; G01N 33/57434 20130101; C07K 2317/54
20130101 |
International
Class: |
C07K 16/28 20060101
C07K016/28; A61K 38/17 20060101 A61K038/17; C12N 15/113 20060101
C12N015/113; G01N 33/574 20060101 G01N033/574; A61K 51/10 20060101
A61K051/10 |
Goverment Interests
FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with Government support under Grant
5R01CA113796-03 from the National Cancer Institute. The Government
has certain rights to this invention.
Claims
1. A method for diagnosing cancer in an individual, comprising:
determining an expression level of a cancer stem cell
(CSC)-associated gene in Table 5 in a test sample from the
individual; and comparing the expression level of the
CSC-associated gene to a reference value, wherein results of the
comparison are diagnostic of cancer.
2-21. (canceled)
22. A method for isolating a cancer stem cell, comprising:
contacting a sample with an agent that binds a polypeptide encoded
by a CSC-associated gene in Table 4, wherein the polypeptide is
expressed on the surface of the cancer stem cell, and wherein, if
the sample contains the cancer stem cell, the agent binds to the
polypeptide; and isolating the agent from the sample.
23-31. (canceled)
32. A method for treating an individual having, or at risk of
having, cancer, comprising: administering a therapeutically
effective amount of a composition that induces the expression of a
CSC-associated gene selected from the group set forth in Table 2 or
7.
33-42. (canceled)
43. A method for treating an individual having, or at risk of
having, cancer, comprising: administering a therapeutically
effective amount of a composition that targets a product of a
CSC-associated gene selected from the group set forth in Table 1 or
8.
44-65. (canceled)
66. A method of delivering a therapeutic agent to a cancer stem
cell, comprising: contacting a cancer stem cell with an isolated
molecule that selectively binds to a polypeptide encoded by a
CSC-associated gene selected from the group set forth in Table 4
conjugated to a therapeutic agent in an effective amount to deliver
the therapeutic agent to the cancer stem cell.
67-75. (canceled)
76. An isolated molecule that selectively binds to a polypeptide
encoded by a CSC-associated gene set forth in Table 4, and that is
conjugated to a therapeutic agent.
77. The isolated molecule of claim 76, wherein the CSC-associated
gene is selected from the group consisting of: ANK2, NCKAP1L,
PTPRE, PTPRS, SBF1, SCN3A, SGCA, SGCB, SLC2A11, SLC2A8, SLC4A1,
STX3, and TBC1D8.
78. The isolated molecule of claim 76, wherein the therapeutic
agent is selected from: a toxin, a small-interfering nucleic acid,
and a chemotherapeutic agent.
79. The isolated molecule of claim 76, wherein the isolated
molecule is an antibody or antigen-binding fragment.
80. The isolated molecule of claim 76, wherein the isolated
molecule is an isolated receptor ligand of the polypeptide.
81. The isolated molecule of claim 79, wherein the antibody or
antigen-binding fragment is a monoclonal antibody, polyclonal
antibody, human antibody, chimeric antibody, humanized antibody,
single-chain antibody, a F(ab').sub.2, Fab, Fd, or Fv fragment.
82-84. (canceled)
Description
RELATED APPLICATION
[0001] This application claims priority under 35 U.S.C. .sctn. 119
from U.S. provisional application Ser. No. 61/114,490, filed Nov.
14, 2008, the contents of which are incorporated herein in their
entirety.
FIELD OF INVENTION
[0003] The present invention relates in part to methods for
treating individuals having cancer. The methods involve modulating,
e.g., inducing or inhibiting, the activity of genes that are
deregulated in cancer stem cells. In some aspects, cell surface
genes that are upregulated in cancer stem cells are targeted for
selective isolation, detection, or killing of cancer stem cells in
melanoma. Other aspects of the invention relate to reagents,
arrays, compositions, and kits that are useful for diagnosing and
treating cancer.
BACKGROUND OF INVENTION
[0004] Self-renewing cancer stem cells (CSCs) initiate tumours and
drive malignant progression by generating and supporting
replication of more differentiated non-stem cell progeny. (M.
Al-Hajj, et al., Proc Natl Acad Sci USA 100 (7), 3983 (2003); D.
Bonnet and J. E. Dick, Nat Med 3 (7), 730 (1997); C. A. O'Brien, et
al., Nature 445 (7123), 106 (2007); L. Ricci-Vitiani, et al.,
Nature 445 (7123), 111 (2007); S. K. Singh, et al., Nature 432
(7015), 396 (2004); T. Schatton and M. H. Frank, Pigment cell &
melanoma research 21 (1), 39 (2008)). The mechanisms by which CSCs
cause tumour formation and growth and the potential role of
CSC-specific differentiation plasticity in tumourigenicity are
currently unknown. We recently identified a subpopulation of CSC
based on expression of the chemoresistance mediator ABCB5
(ATP-binding cassette, sub-family B (MDR/TAP), member 5) (N. Y.
Frank, A et al., Cancer Res 65 (10), 4320 (2005); Y. Huang, et al.,
Cancer Res 64 (12), 4294 (2004)) within human malignant melanoma
(T. Schatton, et al., Nature 451 (7176), 345 (2008)), a highly
aggressive and drug-resistant cancer. (T. Schatton and M. H. Frank,
Pigment cell & melanoma research 21 (1), 39 (2008); L. Chin, L.
A. Garraway, and D. E. Fisher, Genes Dev 20 (16), 2149 (2006).)
ABCB5.sup.+ Malignant Melanoma Initiating Cells (MMIC) correlate
with clinical disease progression and can be specifically targeted
to abrogate tumour growth. (T. Schatton, et al., Nature 451 (7176),
345 (2008)). Consistent with these findings, the ABCB5 gene is also
preferentially expressed by in vitro self-renewing melanoma
minority populations (G. I. Keshet, et al., Biochem Biophys Res
Commun 368 (4), 930 (2008)) and by melanoma cell lines of
metastatic as opposed to primary, radial growth phase tumour origin
(J. F. Sousa and E. M. Espreafico, BMC cancer 8, 19 (2008)).
SUMMARY OF INVENTION
[0005] The present invention relates in part to the discovery that
a number of genes (referred to herein as CSC-associated genes) are
deregulated in cancer stem cells. In some aspects, the invention
relates to diagnostic arrays and methods for detecting cancer in an
individual based on the expression of CSC-associated genes. In
other aspects, the invention relates to methods useful for treating
individuals having melanoma based on modulating the expression
and/or activity of CSC-associated genes. Compositions and kits that
are useful for the foregoing methods are also disclosed.
[0006] The invention, in some aspects, provides methods for
diagnosing cancer in an individual. In some aspects, the methods
involve determining an expression level of a cancer stem cell
(CSC)-associated gene in Table 5 in a test sample from the
individual and comparing the expression level of the CSC-associated
gene to a reference value, wherein results of the comparison are
diagnostic of cancer. In some embodiments, the cancer is melanoma,
breast cancer, prostate cancer, colon cancer or renal cancer. In
some embodiments, the test sample is a tissue biopsy. In some
embodiments, the test sample is a skin biopsy. In some embodiments,
the test sample is a sample of the cancer, such as a tumor biopsy.
In some embodiments, the methods involve updating a patient record
for the individual to indicate the diagnostic result of the
comparison. In some embodiments, determining comprises detecting in
the test sample a mRNA that is encoded by the CSC-associated gene.
In some embodiments, determining comprises detecting in the test
sample a polypeptide that is encoded by the CSC-associated gene. In
certain embodiments, detecting comprises nucleic acid hybridization
or nucleic acid amplification. In specific embodiments, the nucleic
acid amplification is real-time RT-PCR or RT-PCR. In one
embodiment, the nucleic acid hybridization is performed using a
nucleic acid array. In certain other embodiments, detecting
comprises immunodetection of the polypeptide. In one embodiment,
the immunodetection comprises an Enzyme-Linked Immunosorbent Assay
(ELISA). In one embodiment, the immunodetection comprises an
antibody array. In one embodiment, the immunodetection comprises
immunohistochemistry.
[0007] In some embodiments of the methods, the reference value is
the expression level of the CSC-associated gene in a non-cancer
reference sample, and if the expression level of the CSC-associated
gene in the test sample is about equal to the expression level of
the CSC-associated gene in the non-cancer reference sample, then
the comparison does not indicate cancer.
[0008] In some embodiments of the methods, the reference value is
the expression level of the CSC-associated gene in a cancer
reference sample, and if the expression level of the CSC-associated
gene is about equal to the expression level of the CSC-associated
gene in the cancer reference sample, then the comparison indicates
cancer.
[0009] In some embodiments of the methods, the CSC-associated gene
is in Table 1 or 8 and the reference value is the expression level
of the CSC-associated gene in a non-cancer reference sample, and if
the expression level of the CSC-associated gene in the test sample
is significantly higher than the expression level of the
CSC-associated gene in the non-cancer reference sample, the
comparison indicates cancer.
[0010] In some embodiments of the methods, the CSC-associated gene
is in Table 1 or 8 and the reference value is the expression level
of the CSC-associated gene in a cancer reference sample, and if the
expression level of the CSC-associated gene in the test sample is
significantly lower than the expression level of the CSC-associated
gene in the cancer reference sample, the comparison does not
indicate cancer.
[0011] In some embodiments of the methods, the CSC-associated gene
is in Table 1 or 8 and the reference value is the expression level
of the CSC-associated gene in a non-cancer reference sample, and if
the expression level of the CSC-associated gene in the test sample
is at least 10% higher than the expression level of the
CSC-associated gene in the non-cancer reference sample, the
comparison indicates cancer.
[0012] In some embodiments of the methods, the CSC-associated gene
is in Table 2 or 7 and the reference value is the expression level
of the CSC-associated gene in a non-cancer reference sample, and if
the expression level of the CSC-associated gene in the test sample
is significantly lower than the expression level of the
CSC-associated gene in the non-cancer reference sample, the
comparison indicates cancer.
[0013] In some embodiments of the methods, the CSC-associated gene
is in Table 2 or 7 and the reference value is the expression level
of the CSC-associated gene in a cancer reference sample, and if the
expression level of the CSC-associated gene in the test sample is
significantly higher than the expression level of the
CSC-associated gene in the cancer reference sample, the comparison
does not indicate cancer.
[0014] In some embodiments of the methods, the CSC-associated gene
is in Table 2 or 7 and the reference value is the expression level
of the CSC-associated gene in a non-cancer reference sample, and if
the expression level of the CSC-associated gene in the test sample
is at least 10% lower than the expression level of the
CSC-associated gene in the non-cancer reference sample, the
comparison indicates cancer.
[0015] The invention, in some aspects, provides methods for
isolating a cancer stem cell. In some aspects, the methods involve
contacting a sample with an agent that binds a polypeptide, which
is encoded by a CSC-associated gene in Table 4 and expressed on the
surface of the cancer stem cell, and isolating the agent from the
sample. If the sample contains the cancer stem cell, the agent
binds to the polypeptide on the surface of the cancer stem cell
such that isolation of the agent from the sample results in
isolation of the cancer stem cell. In some embodiments, the
CSC-associated gene is selected from the group consisting of: ANK2,
NCKAP1L, PTPRE, PTPRS, SBF1, SCN3A, SGCA, SGCB, SLC2A11, SLC2A8,
SLC4A1, STX3, and TBC1D8. In some embodiments, the agent is an
isolated peptide that specifically binds the polypeptide on the
surface of the cancer stem cell. In certain embodiments, the
isolated peptide is an antibody or antigen-binding fragment. In
specific embodiments, the antibody or antigen-binding fragment is a
monoclonal antibody, polyclonal antibody, human antibody, chimeric
antibody, humanized antibody, single-chain antibody, F(ab').sub.2,
Fab, Fd, Fv, or single-chain Fv fragment. In some embodiments, the
isolated peptide is bound to a solid support. In some embodiments,
the isolated peptide is conjugated to a detectable label. In some
embodiments, the detectable label is a fluorophore which may be
selected from: FITC, TRITC, Cy3, Cy5, Alexa Fluorescent Dyes, and
Quantum Dots. In some embodiments, the isolating comprises
performing fluorescent activated cell sorting to isolate a cancer
stem cell bound to a detectable label. In some embodiments, the
cancer stem cell is from a melanoma, breast cancer, prostate
cancer, colon cancer or renal cancer.
[0016] The invention, in some aspects, provides methods for
treating an individual having, or at risk of having, cancer. In
some aspects, the methods involve administering a therapeutically
effective amount of a composition that induces the expression of a
CSC-associated gene selected from the group set forth in Table 2 or
7. In some embodiments, the cancer is melanoma, breast cancer,
prostate cancer, colon cancer or renal cancer.
[0017] In some embodiments, the composition that induces the
expression of a CSC-associated gene comprises an isolated plasmid
that expresses the CSC-associated gene. In some embodiments, the
isolated plasmid is in a virus capable of infecting the individual.
In certain embodiments, the virus is selected from adenovirus,
retrovirus, lentivirus, and adeno-associated virus. In some
embodiments, the isolated plasmid comprises a cancer specific
promoter operably linked to the CSC-associated gene.
[0018] The invention, in other aspects, provides methods for
treating an individual having, or at risk of having, cancer that
involve administering a therapeutically effective amount of a
composition that targets a product of a CSC-associated gene
selected from the group set forth in Table 1 or 8. In some
embodiments, the cancer is melanoma, breast cancer, prostate
cancer, colon cancer or renal cancer. In some embodiments, the
CSC-associated gene is selected from the group set forth in Table
4. In certain embodiments, the CSC-associated gene is selected from
the group consisting of: ANK2, NCKAP1L, PTPRE, PTPRS, SBF1, SCN3A,
SGCA, SGCB, SLC2A11, SLC2A8, SLC4A1, STX3, and TBC1D8.
[0019] In some embodiments, the composition that targets a product
of a CSC-associated gene comprises a small interfering nucleic acid
that inhibits expression of the CSC-associated gene. In some
embodiments, the composition comprises an isolated plasmid that
expresses the small interfering nucleic acid. In certain
embodiments, the plasmid is in a virus. In specific embodiments,
the virus is selected from adenovirus, retrovirus, lentivirus, and
adeno-associated virus. In certain embodiments, the isolated
plasmid comprises a cancer-specific promoter operably linked to a
gene encoding the small interfering nucleic acid.
[0020] In some embodiments, the composition that targets a product
(e.g., protein or RNA) of a CSC-associated gene comprises an
isolated molecule that selectively binds to a polypeptide encoded
by the CSC-associated gene. In certain embodiments, the isolated
molecule is conjugated to a therapeutic agent. In specific
embodiments, the isolated molecule is an antibody or
antigen-binding fragment. In particular embodiments, the antibody
or antigen-binding fragment is a monoclonal antibody, polyclonal
antibody, human antibody, chimeric antibody, humanized antibody, a
single-chain antibody, F(ab').sub.2, Fab, Fd, Fv, or single-chain
Fv fragment. In specific embodiments, the therapeutic agent is
selected from: a toxin, a small-interfering nucleic acid, and a
chemotherapeutic agent. In one embodiment, the toxin is a
radioisotope. In particular embodiments, the radioisotope is
selected from the group consisting of: .sup.225Ac, .sup.211At,
.sup.212Bi, .sup.213Bi, .sup.186Rh, .sup.188Rh, .sup.177Lu,
.sup.90Y, .sup.131I, .sup.67Cu, .sup.125I, .sup.123I, .sup.77Br,
.sup.153Sm, .sup.166Bo, .sup.64Cu, .sup.212Pb, .sup.224Ra and
.sup.223Ra. In some embodiments, the therapeutic agent is a small
interfering nucleic acid that inhibits expression of a
CSC-associated gene. In some embodiments, the isolated molecule
binds to the polypeptide and enters an intracellular compartment of
a cancer stem cell of the cancer.
[0021] In some embodiments, the treatment methods involve
determining the expression level of the CSC-associated gene in the
individual. In certain embodiments, the methods involve comparing
the expression level of the CSC-associated gene to a reference
value, wherein results of the comparison are diagnostic of cancer
in the individual. In specific embodiments, if the comparison
results in a diagnosis of cancer in the individual, the
administering is performed. In one embodiment, the determining and
the comparing are repeated at one or more intervals after the
administering. In some embodiments, the administering is orally,
intravenously, intrapleurally, intranasally, intramuscularly,
subcutaneously, intraperitoneally, or as an aerosol.
[0022] The invention, in some aspects, provides methods of
delivering a therapeutic agent to a cancer stem cell that involve
contacting a cancer stem cell with an isolated molecule, which
selectively binds to a polypeptide encoded by a CSC-associated gene
selected from the group set forth in Table 4 and which is
conjugated to a therapeutic agent, in an effective amount to
deliver the therapeutic agent to the cancer stem cell. In some
embodiments, the CSC-associated gene is selected from the group
consisting of: ANK2, NCKAP1L, PTPRE, PTPRS, SBF1, SCN3A, SGCA,
SGCB, SLC2A11, SLC2A8, SLC4A1, STX3, and TBC1D8. In some
embodiments, the isolated molecule is an antibody or
antigen-binding fragment that selectively binds the polypeptide. In
some embodiments, the therapeutic agent is selected from: a toxin,
a small-interfering nucleic acid, and a chemotherapeutic agent. In
one embodiment, the toxin is a radioisotope. In particular
embodiments, the radioisotope is selected from the group consisting
of: .sup.225Ac, .sup.211At, .sup.212Bi, .sup.213Bi, .sup.186Rh,
.sup.188Rh, .sup.177Lu, .sup.90Y, .sup.131I, .sup.67Cu, .sup.125I,
.sup.123I, .sup.77Br, .sup.153Sm, .sup.166Bo, .sup.64Cu,
.sup.212Pb, .sup.224Ra and .sup.223Ra. In some embodiments, the
therapeutic agent is a small interfering nucleic acid that inhibits
expression of a CSC-associated gene. In some embodiments, the
cancer stem cell is in vitro. In other embodiments, the cancer stem
cell is in vivo.
[0023] In some aspects, the invention provides nucleic acid arrays
consisting essentially of at least 2, at least 5, at least 10, at
least 20, at least 50, at least 100, at least 200, at least 300, or
more CSC-associated genes set forth in Table 5.
[0024] In some aspects, the invention provides polypeptide arrays
consisting essentially of at least 2, at least 5, at least 10, at
least 20, at least 50, at least 100, or more polypeptides or
immunogenic fragments thereof encoded by CSC-associated genes set
forth in Table 1 or 8. In some aspects, the invention provides
antibody arrays consisting essentially of at least 2 or more
different antibodies or antigen-binding fragments that selectively
bind polypeptides encoded by CSC-associated genes set forth in
Table 1 or 8.
[0025] In some aspects, the invention provides methods for
stratifying a population comprising individuals having cancer. The
methods involve determining expression levels of at least 2, at
least 5, at least 10, at least 20, at least 50, at least 100, at
least 200, at least 300, or more CSC-associated genes set forth in
Table 5 and stratifying the population based on the expression
levels.
[0026] In some aspects, the invention provides an isolated molecule
that selectively binds to a polypeptide encoded by a CSC-associated
gene set forth in Table 4, and that is conjugated to a therapeutic
agent. In some embodiments, the CSC-associated gene is selected
from the group consisting of: ANK2, NCKAP1L, PTPRE, PTPRS, SBF1,
SCN3A, SGCA, SGCB, SLC2A11, SLC2A8, SLC4A1, STX3, and TBC1D8. In
some embodiments, the therapeutic agent is selected from: a toxin,
a small-interfering nucleic acid, and a chemotherapeutic agent.
[0027] In certain embodiments, the isolated molecule is an antibody
or antigen-binding fragment. In certain embodiments, the antibody
or antigen-binding fragment is a monoclonal antibody, polyclonal
antibody, human antibody, chimeric antibody, humanized antibody,
single-chain antibody, a F(ab').sub.2, Fab, Fd, or Fv fragment. In
certain embodiments, the isolated molecule is an isolated receptor
ligand of the polypeptide.
[0028] The invention, in some aspects, provides compositions
comprising any of the foregoing isolated molecules. In some
embodiments, the compositions include a pharmaceutically acceptable
carrier.
[0029] The invention, in some aspects, provides pharmaceutical kits
that include a container housing any of the foregoing compositions
and instructions for administering the composition to an individual
having cancer.
[0030] Use of a composition of the invention for treating cancer is
also provided as an aspect of the invention.
[0031] A method for manufacturing a medicament of a composition of
the invention for treating cancer is also provided.
[0032] Each of the limitations of the invention can encompass
various embodiments of the invention. It is, therefore, anticipated
that each of the limitations of the invention involving any one
element or combinations of elements can be included in each aspect
of the invention. This invention is not limited in its application
to the details of construction and the arrangement of components
set forth in the following description or illustrated in the
drawings. The invention is capable of other embodiments and of
being practiced or of being carried out in various ways. Also, the
phraseology and terminology used herein is for the purpose of
description and should not be regarded as limiting. The use of
"including," "comprising," or "having," "containing," "involving,"
and variations thereof herein, is meant to encompass the items
listed thereafter and equivalents thereof as well as additional
items.
BRIEF DESCRIPTION OF DRAWINGS
[0033] FIGS. 1A-1I depict an analysis of vasculogenic/angiogenic
pathways in human melanoma. FIG. 1a. is a graphical representation
of pathway activation across ABCB5.sup.+ MMIC. Genes represented by
nodes (dark gray circles, TRIO, MET, FLT1, PSEN1, NRP2, RHOA, PTK2,
PIP5K3, KIAA1267, MLL, GABPA, ETS1, and CHD8) are overexpressed in
ABCB5.sup.+ relative to ABCB5.sup.- human melanoma cells and those
represented by black nodes are expressed at lower levels,
respectively. Black lines between genes show known interactions.
Known gene functions in vasculogenesis and angiogenesis, and genes
known as relevant drug targets are annotated (dark gray lines).
Gene relationships and figure layout are based on Ingenuity Pathway
Analysis and references are provided elsewhere in the text. FIG.
1b. shows detection of vasculogenic/angiogenic pathway members by
RT-PCR in ABCB5.sup.+ MMIC. FIG. 1c. shows FLT1 (VEGFR-1) protein
expression on ABCB5.sup.+ MMIC (top) and ABCB5.sup.- melanoma cells
(bottom) as determined by dual color flow cytometry using ABCB5
phenotype-specific cell gating, with mean percentages
(mean.+-.s.e.m., n=6 replicate experiments) shown on the right.
FIG. 1d. depicts representative immunofluorescence staining for
CD144 expression (Texas red staining) by ABCB5.sup.+ MMIC or
ABCB5.sup.- melanoma cell subpopulations prior to (t=0 h) and upon
48 h of culture (t=48 h) in the presence of 100 ng/ml VEGF.sup.11,
with nuclei counterstained with DAPI. Mean percentages
(mean.+-.s.e.m., n=3 replicate experiments) of cells staining
positively for CD144 in each sample are shown on the right. FIG.
1e. shows representative immunofluorescence staining for CD144
expression (Texas red staining) by melanoma cells cultured for 48 h
(t=48 h) in the presence of 100 ng/ml VEGF as in above, but in the
presence or absence of anti-FLT1 (VEGFR-1) blocking mAb or isotype
control mAb. Nuclei are counterstained with DAPI. Mean percentages
(mean.+-.s.e.m., n=3 replicate experiments) of cells staining
positively for CD144 in each sample are shown in the far right
panel. FIG. 1f. shows tube formation detected by phase contrast
light microscopy of melanoma cells cultured for 24 h (t=24 h) in
the presence of 100 ng/ml VEGF and the presence or absence of
anti-FLT1 (VEGFR-1) blocking mAb or isotype control mAb. Number of
tubes/microscopy field (mean.+-.s.e.m., n=3 replicate experiments)
and tube length (.mu.m) (mean.+-.s.e.m., n=3 replicate experiments)
are illustrated for the different experimental conditions on the
far right panels, respectively. FIG. 1g. shows the adipogenic
differentiation potential of ABCB5.sup.+ and ABCB5.sup.- human
melanoma cells (Oil Red O staining, nuclei are counterstained with
hematoxylin). FIG. 1h. shows the osteogenic differentiation
potential of ABCB5.sup.+ and ABCB5.sup.- human melanoma cells
(Alizarin Red staining). FIG. 1i shows the myogenic differentiation
potential of ABCB5.sup.+ and ABCB5.sup.- human melanoma cells.
Absence of myogenin staining (FITC, green) is detected in
ABCB5.sup.+ or ABCB5.sup.- human melanoma cells (nuclei are
counterstained with DAPI).
[0034] FIGS. 2A-2K depict an analysis of MMIC-driven in vivo
vasculogenesis. FIG. 2a. shows conventionally-stained (H&E)
sections of human melanoma growing at melanoma cell injection site
within human dermis of skin xenograft to NOD/SCID mouse. FIG. 2b.
shows immunohistochemistry for human CD31 indicating angiogenic
response at perimeter of melanoma within human xenograft; broken
line represents interface of tumour nodule with dermal connective
tissue. FIG. 2c. shows PAS (with diastase) immunochemical staining
of CD31-negative interior regions of melanoma xenograft revealing
numerous anastomosing channels (inset is laminin
immunohistochemistry indicating identical pattern). FIG. 2d. shows
transmission electron micrographs of interior regions of melanoma
xenograft; lumenal spaces containing blood products (erythrocytes)
are lined by melanoma cells and associated basement membrane-like
extracellular matrix. FIG. 2e. shows the interior zone of melanoma
xenograft derived from cells expressing GFP transgene and
immunohistochemically stained for endothelial marker CD144 (FAST
RED Chromogen (SIGNET) from Covance Research Products, Inc); CD144
expression is confined to cells forming lumen-like spaces lined by
cells that co-express GFP and CD144 (indicated by dual staining).
FIGS. 2f and g. show low (f) and high (g) magnifications of
immunohistochemistry for ABCB5 protein; reactivity is restricted to
anastomosing channels identical to those seen in panel c. The inset
in panel f depicts similar formation of ABCB5-reactive channels in
a patient-derived melanoma biopsy. FIG. 2h. depicts in situ
hybridization for ABCB5 mRNA revealing a channel pattern
corresponding to that of ABCB5 protein expression (compare with
panel f; inset is sense control). FIG. 2i. shows the detection of
anti-ABCB5 mAb using anti-mouse Ig immunohistochemistry in melanoma
xenografts after intravenous administration in vivo; note
localization to channels (inset represents anti-mouse Ig staining
after intravenous administration of irrelevant isotype-matched
control mAb). FIG. 2j. shows dual-labeling immunofluorescence
microscopy for ABCB5 (left panel), CD144 (middle panel), and ABCB5
& CD144 (right panel). FIG. 2k shows dual-labeling
immunofluorescence microscopy for ABCB5 (left panel), TIE-1 (middle
panel), and ABCB5 & TIE-1 (right panel).
[0035] FIGS. 3A-3F depict the interdependency of MMIC-driven
vasculogenesis and tumourigenesis. FIG. 3a. shows representative
flow cytometric ABCB5 expression or control staining (FITC, F11)
plotted against forward scatter (FSC) for human A375, MUM-2B, and
MUM-2C melanoma cell inocula. FIG. 3b. shows representative
histologic sections of melanomas that developed from three
unsegregated and ABCB5-depleted melanoma cell lines injected
intradermally into human skin xenografts. FIG. 3c. shows
histologically determined tumour formation rate (%) 3 weeks
following intradermal transplantation of unsegregated vs.
ABCB5.sup.+-depleted human A375, MUM-2B or MUM-2C melanoma cells
(2.times.10.sup.6/inoculum) into human skin/Rag2.sup.-/- chimeric
mice (n=5, respectively). FIG. 2d. shows histological tumour
volumes (mean.+-.s.e.m.) 3 weeks following intradermal
transplantation of unsegregated vs. ABCB5.sup.+-depleted human
A375, MUM-2B or MUM-2C melanoma cells (2.times.10.sup.6/inoculum)
into human skin/Rag2.sup.-/- chimeric mice. FIG. 3e shows
immunohistochemistry for laminin revealing extent of channel
formation in melanomas that developed from unsegregated or
ABCB5.sup.+-depleted melanoma cell inocula derived from A375,
MUM-2B or MUM-2C lines injected intradermally into human skin
xenografts (arrows=necrosis). FIG. 3f depicts image analysis of
laminin immunoreactivity for melanomas derived from unsegregated
and ABCB5.sup.+-depleted cell inocula; y-axis is percent of
pixelated area with reactivity (mean.+-.s.e.m.); solid bar
represents tumours derived from unsegregated melanoma cells, open
bars represent tumours derived from ABCB5.sup.+-depleted cells
(A375, P<0.0032; MUM-2B, P<0.0005; MUM-2C, P<0.0059).
[0036] FIGS. 4A and 4B depict an analysis of the correlation of
ABCB5 protein and mRNA expression across human melanoma cell lines.
FIG. 4a. shows western blots of ABCB5 and tubulin expression of a
panel of human melanoma cell lines. FIG. 4b shows relative ABCB5
mRNA expression (log 2) in a panel of human melanoma cell lines
plotted against ABCB5 protein expression as determined by ratios of
ABCB5 89 kD western blot band intensity and tubulin western blot
band intensity for each human melanoma cell line. Data points in
FIG. 4b are: 1, SK-MEL-2; 2, SK-MEL-5; 3, SK-MEL-28; 4, MDA-MB-435;
5, UACC-62; 6, UACC-257; 7, M14; 8, MALME-3M. r, Spearman Rank
Correlation r (corrected for ties).
DETAILED DESCRIPTION
[0037] The present invention relates in part to the discovery that
numerous CSC-associated genes have altered expression or function
in cancer stem cells, e.g., melanoma stem cells. In some aspects,
the invention relates to diagnostic arrays and methods for
detecting cancer, e.g., melanoma, in an individual based on the
expression of CSC-associated genes. In other aspects, the invention
relates to compositions, kits, and methods useful for treating
individuals having cancer. In some embodiments, the treatment
methods involve modulating e.g., inducing or inhibiting, the
activity of CSC-associated genes. The CSC-associated genes can be
modulated by any one of a number of ways known in the art and
described herein e.g., overexpression, RNAi-based inhibition, etc.
In some cases, the CSC-associated genes encode cell surface
proteins which, when upregulated in cancer stem cells, may be
selectively targeted for isolating, e.g., by flow cytometry,
identifying, e.g., by immunolabeling, and killing of cancer stem
cells, e.g., melanoma stem cells.
[0038] The mechanism by which CSCs cause tumor formation and growth
and the potential role of CSC-specific differentiation plasticity
in tumorigenicity are currently unknown. It has been demonstrated
according to the invention that CSC play an important role in
providing nutritional support to growing tumors. For instance we
have shown herein (Examples) a selective capacity of ABCB5.sup.+
malignant melanoma initiating cells (MMIC).sup.3 to undergo
vasculogenic differentiation and to generate blood-perfused
vessel-like channels in vivo. A repertoire of genes differentially
expressed in MMIC compared to tumour bulk populations were
identified by microarray analyses on purified ABCB5.sup.+ and
ABCB5.sup.- cell subsets derived from the established human
melanoma cell lines and from three separate patient-derived
melanoma specimens. Using this approach, 399 genes were identified
that were differentially expressed between ABCB5.+-.MMIC and
ABCB5.sup.- melanoma bulk populations. The genes, which are
outlined in Tables 1-8, are referred to herein as CSC-associated
genes. Of the CSC-associated genes, 265 were upregulated (Table 1;
Table 1 includes Table 1.1 and Table 1.2) and 150 were
downregulated (Table 2). For certain CSC-associated genes,
subcellular location, e.g., plasma membrane, nucleus, etc., gene
type, e.g., enzyme, complex, transporter, etc., and drugs that
affect, e.g., target, their activity are identified (Table 3). A
summary of those annotations and networks is provide in Table 3.
Genes that function share a common pathway have a common "network")
designation in Table 3. Some CSC-associated genes, e.g., those
which have "plasma membrane" annotations, encode proteins that are
associated with the cell surface. Such cell surface proteins are
useful in a variety ways. For example, cell surface proteins that
are upregulated in cancer stem cells, may be selectively targeted,
e.g., using the methods disclosed herein, for isolating,
identifying, and killing of cancer stem cells. A listing of
exemplary cell surface proteins encoded by CSC-associated genes is
provided in Table 4.
TABLE-US-00001 TABLE 1.1 Upregulated CSC-associated genes (p <
0.05) GENESYMBOL ID Fold Change HECW1 237295_at 11.843
RP11-139H14.4 1569124_at 11.472 CDC16 242359_at 6.261 ANK2
202921_s_at 4.162 LOC146325 1553826_a_at 3.943 UGT1A6 206094_x_at
3.86 C12ORF51 1557529_at 3.632 SNRPA1 242146_at 3.54 PDE4B
215671_at 3.457 PAPD4 222282_at 3.39 ZNF536 233890_at 3.303 KSR2
230551_at 3.211 BUB1 233445_at 3.209 ZNF292 236435_at 3.201 CABIN1
1557581_x_at 3.052 SDAD1 242190_at 3.009 ASCC3L1 214982_at 3.009
ZNF224 216983_s_at 2.986 KIDINS220 1557246_at 2.97 WIPF2 216006_at
2.916 C12ORF51 230216_at 2.874 VPS37B 236889_at 2.85 NARG1
1556381_at 2.827 LOC145757 1558649_at 2.779 SDCCAG8 243963_at 2.67
ZNF154 242170_at 2.667 ZFR 238970_at 2.655 TRPV1 1556229_at 2.636
ANAPC5 235926_at 2.631 CUL4A 232466_at 2.607 TRIO 240773_at 2.607
LOC283888 1559443_s_at 2.56 RAB11FIP3 228613_at 2.546 PTK2
234211_at 2.539 MYO10 243159_x_at 2.528 NAT8B 206964_at 2.513
CDC14B 234605_at 2.512 TRIM33 239716_at 2.496 SF1 210172_at 2.452
SGCA 1562729_at 2.395 LOC285147 236166_at 2.377 N4BP2L2 242576_x_at
2.349 HNRPH1 213472_at 2.332 FLJ10357 241627_x_at 2.31 PHF20L1
219606_at 2.3 ANKRD28 241063_at 2.297 TRNT1 243236_at 2.295 GOLGA8A
213650_at 2.289 KIAA1618 231956_at 2.27 RBM5 209936_at 2.249
LOC645513 239556_at 2.24 LOC729397 236899_at 2.231 PABPN1 213046_at
2.228 SVIL 215279_at 2.228 PIP5K3 1557719_at 2.227 STRAP 1558002_at
2.189 KIAA2013 1555933_at 2.18 NUPL1 241425_at 2.179 IFNGR1
242903_at 2.171 AKAP9 215483_at 2.168 LOC254128 1557059_at 2.164
IRS2 236338_at 2.162 RHOA 240337_at 2.143 JARID2 232835_at 2.139
GPD2 243598_at 2.13 RADIL 223693_s_at 2.126 CROP 242389_at 2.121
EXT1 242126_at 2.116 XRCC5 232633_at 2.106 PDXDC1 1560014_s_at
2.105 MEF2C 236395_at 2.104 ZNF567 242429_at 2.103 ZNF337
1565614_at 2.096 TTLL4 1557611_at 2.092 FUBP1 240307_at 2.087 NPTN
228723_at 2.086 TPM4 235094_at 2.079 NCKAP1L 209734_at 2.071
KRTAP19-1 1556410_a_at 2.07 SLC30A9 237051_at 2.063 HDAC3 240482_at
2.062 C10ORF18 244165_at 2.046 SMA4 238446_at 2.035 GBF1 233114_at
2.03 GABPA 243498_at 2.03 SFRS15 243759_at 2.028 CREB3L2 237952_at
2.013 SLC2A8 239426_at 2.012 N4BP2L1 213375_s_at 2.01 IDS
1559136_s_at 2.001 COBRA1 1556434_at 1.985 TXNL1 243664_at 1.98
LOC388135 230475_at 1.979 MTUS1 239576_at 1.975 TAF15 227891_s_at
1.971 HNRPD 241702_at 1.962 TRIM46 238147_at 1.96 NBR1 1568856_at
1.957 WDR68 233782_at 1.924 HNRPD 235999_at 1.92 BLID 239672_at
1.91 LOC145786 229178_at 1.907 HOXD3 206601_s_at 1.897 AOC3
204894_s_at 1.894 PRPF38B 230270_at 1.888 SLC20A1 230494_at 1.884
SEC16B 1552880_at 1.877 FLT1 232809_s_at 1.861 HUWE1 214673_s_at
1.858 BUB1 216277_at 1.856 GPR135 241085_at 1.851 PSEN1 242875_at
1.851 KIAA0907 230028_at 1.83 POLR2J2 1552622_s_at 1.828 SFRS15
222311_s_at 1.818 CBS 240517_at 1.818 ETS1 241435_at 1.797 LRRFIP1
239379_at 1.796 OCIAD1 235537_at 1.794 LRCH3 229387_at 1.793 CCDC14
240884_at 1.771 HNRNPC 235500_at 1.769 DCUN1D2 240478_at 1.76 NPAS2
1557690_x_at 1.76 POFUT2 207448_at 1.759 CHD2 244443_at 1.757
TMEM165 1560622_at 1.756 FLJ31306 239432_at 1.753 HPS1 239382_at
1.749 WTAP 1560274_at 1.747 TNPO1 1556116_s_at 1.739 ZFHX3
215828_at 1.737 AKR1CL2 1559982_s_at 1.732 C20ORF4 234654_at 1.731
CCDC57 214818_at 1.703 MALAT1 224568_x_at 1.699 EWSR1 229966_at
1.686 MYO10 244350_at 1.677 MALAT1 223940_x_at 1.659 ATXN2L
207798_s_at 1.656 PDK1 239798_at 1.654 POLR2J2 1552621_at 1.652
CENPJ 220885_s_at 1.64 PDSS1 236298_at 1.64 UNK 1562434_at 1.637
BDP1 224227_s_at 1.632 N4BP2L2 235547_at 1.631 MDM4 235589_s_at
1.629 SNORA28 241843_at 1.628 ZFX 207920_x_at 1.625 NAPA 239362_at
1.624 PRO1073 228582_x_at 1.607 MLL 212079_s_at 1.599 SGOL2
235425_at 1.591 RBM25 1557081_at 1.57 BARD1 205345_at 1.559
LOC388969 232145_at 1.555 GGT1 211417_x_at 1.555 FAM62C 239770_at
1.551 TTC9C 1569189_at 1.55 TCAG7.907 238678_at 1.546 OSGEP
242930_at 1.541 RHOBTB2 1556645_s_at 1.538 C5ORF24 229098_s_at
1.531 RBM4 213718_at 1.53 SLC2A11 232167_at 1.529 DDX17 213998_s_at
1.528 C22ORF30 216555_at 1.521 C9ORF85 244160_at 1.52 DNM1L
236032_at 1.503 SQLE 213577_at 1.502 CRIPAK 228318_s_at 1.486
ZNF800 227101_at 1.484 RAD54L 204558_at 1.483 TAF1B 239046_at 1.468
THRAP3 217847_s_at 1.464 CNIH3 232758_s_at 1.451 UQCC 229672_at
1.451 HOXA2 228642_at 1.44 RBM26 229433_at 1.43 RFT1 240281_at
1.426 MTERFD3 225341_at 1.422 LOC641298 208118_x_at 1.419 ZNF326
241720_at 1.418 NBPF16 201104_x_at 1.411 ASPM 232238_at 1.411 RNF43
228826_at 1.401 IPW 213447_at 1.399 TTC3 208664_s_at 1.396 USP36
224979_s_at 1.393 KIAA0841 36888_at 1.389 NEK1 213328_at 1.381 AMZ2
227567_at 1.377 TBC1D8 204526_s_at 1.373 STK36 231806_s_at 1.362
SF3B1 214305_s_at 1.359 HELLS 242890_at 1.359 SYNE2 202761_s_at
1.356 KIAA1267 224489_at 1.355 C14ORF135 1563259_at 1.353 SF3B1
201070_x_at 1.35 CLN8 229958_at 1.344 STK36 234005_x_at 1.335
ZNF226 219603_s_at 1.332 COQ4 218328_at 1.328 DTX3 49051_g_at 1.32
WFS1 1555270_a_at 1.315 ZNF251 226754_at 1.313 ARS2 201679_at 1.307
ATAD2 235266_at 1.304 CCDC73 239848_at 1.294 BCL9L 227616_at 1.291
MET 213816_s_at 1.283 NFATC2IP 217527_s_at 1.272 CHD8 212571_at
1.27 TNRC6A 234734_s_at 1.268 OSBPL5 233734_s_at 1.261 COIL
203653_s_at 1.259 CPEB2 226939_at 1.251 TBC1D8 221592_at 1.246
RUNX3 204198_s_at 1.233 LBA1 213261_at 1.225 CENPJ 234023_s_at 1.22
MARCH6 201737_s_at 1.219 ANKRD44 226641_at 1.218 NAPE-PLD
242635_s_at 1.216 C12ORF48 220060_s_at 1.216 CCDC93 219774_at 1.208
ZUFSP 228330_at 1.205 SMC6 218781_at 1.203 TAOK3 220761_s_at 1.195
JARID1A 226367_at 1.192 DCLRE1C 242927_at 1.187 TTC26 233999_s_at
1.184 EIF4G3 201935_s_at 1.174 ORMDL1 223187_s_at 1.171 TCOF1
202385_s_at 1.169 CCDC52 234995_at 1.166 PMS2L3 214473_x_at 1.159
HERC5 219863_at 1.156 CASC5 228323_at 1.144 SON 201085_s_at 1.144
APBB2 40148_at 1.139 LOC338799 226369_at 1.137 PHC1 218338_at
1.123
DEPDC1 232278_s_at 1.119 NRP2 210841_s_at 1.106 ZMYND8 209049_s_at
1.102 CEP55 218542_at 1.096
TABLE-US-00002 TABLE 1.2 Highly upregulated genes as detected by
RT-PCR ABCB5+/ ABCB5- Description Gname Fold change
Angiopoietin-like 3 ANGPT5 3.0596 Brain-specific angiogenesis
inhibitor FLJ41988 3.0596 1 Cadherin 5, type 2, VE-cadherin
7B4/CD144 3.0596 (vascular epithelium) Epidermal growth factor
(beta- HOMG4/URG 187.8365 urogastrone) C-fos induced growth factor
VEGF-D/VEGFD 3.5884 (vascular endothelial growth factor D)
Hepatocyte growth factor F-TCF/HGFB 4.542 (hepapoietin A; scatter
factor) Heparanase HPA/HPR1 286.6871 Insulin-like growth factor 1
IGFI 4.7022 (somatomedin C) Jagged 1 (Alagille syndrome) AGS/AHD
1566.5046 Laminin, alpha 5 KIAA1907 3.8727 Platelet/endothelial
cell adhesion CD31/PECAM-1 11.9037 molecule (CD31 antigen) Plexin
domain containing 1 DKFZp686F0937/ 3.4184 TEM3 Stabilin 1
CLEVER-1/FEEL-1 4.357 Transforming growth factor, alpha TFGA
3549.3357 Tumor necrosis factor (TNF DIF/TNF-alpha 4.0652
superfamily, member 2) Vascular endothelial growth factor C
Flt4-L/VRP 446.7529
TABLE-US-00003 TABLE 2 Downregulated CSC-associated genes (p <
0.05) GENESYMBOL ID Fold Change ECHDC1 233124_s_at 0.943 DARS
201624_at 0.928 GALNT1 201722_s_at 0.926 CGGBP1 224600_at 0.913
CSE1L 201112_s_at 0.911 GMFB 202544_at 0.904 RPL7L1 225515_s_at
0.899 SKP1 200718_s_at 0.898 IGHMBP2 215980_s_at 0.893 LOC137886
212934_at 0.886 CSE1L 210766_s_at 0.885 ERRFI1 224657_at 0.881
MAP2K4 203266_s_at 0.881 TNFAIP1 201207_at 0.88 TBXA2R 207554_x_at
0.877 SEPHS1 208940_at 0.875 IPO7 200993_at 0.875 C16ORF63
225087_at 0.872 INSIG2 209566_at 0.872 TFB1M 228075_x_at 0.87 PAK1
226507_at 0.869 C14ORF156 221434_s_at 0.867 SMYD2 212922_s_at 0.867
ENTPD5 231676_s_at 0.867 PPP3CA 202457_s_at 0.867 MBNL1 201152_s_at
0.867 MRPL42 217919_s_at 0.866 SUPT7L 201838_s_at 0.865 PMP22
210139_s_at 0.865 GABARAPL2 209046_s_at 0.863 PITPNA 201190_s_at
0.863 C2ORF30 224630_at 0.851 TXNDC12 223017_at 0.849 POP4
202868_s_at 0.847 MRPL51 224334_s_at 0.846 AK3 224655_at 0.845
GPR107 211979_at 0.843 TMEM126B 221622_s_at 0.843 PSMA2 201316_at
0.839 KIAA1737 225623_at 0.837 TRAPPC2L 218354_at 0.837 RLBP1L1
224996_at 0.835 CCDC127 226515_at 0.835 CPNE3 202119_s_at 0.833
HIAT1 225222_at 0.832 MECR 218664_at 0.832 ACBD6 225317_at 0.83
SLC16A1 202235_at 0.83 ANXA4 201302_at 0.83 DNAJC21 230893_at 0.829
C22ORF28 200042_at 0.829 SPOPL 225659_at 0.828 PDHB 211023_at 0.827
EIF2S1 201144_s_at 0.824 LOC645166 228158_at 0.823 CAMK2D 225019_at
0.823 LIMS1 212687_at 0.822 VTI1B 209452_s_at 0.821 YY1 224711_at
0.821 TRAPPC2 219351_at 0.821 LOC126917 225615_at 0.819 STX8
204690_at 0.819 NANP 228073_at 0.817 NDFIP1 217800_s_at 0.815 UBE3C
1560739_a_at 0.815 KPNA6 226976_at 0.814 C19ORF42 219097_x_at 0.813
DHX40 218277_s_at 0.812 NUCB2 203675_at 0.812 RAB1A 213440_at 0.81
USP8 229501_s_at 0.808 MAP1LC3B 208785_s_at 0.808 PDHB 208911_s_at
0.807 SH2B3 203320_at 0.806 PPP1R3D 204554_at 0.805 DEGS1 209250_at
0.804 HSDL2 209513_s_at 0.803 LOC203547 225556_at 0.802 CANX
238034_at 0.8 PSMA3 201532_at 0.798 PIGY 224660_at 0.793 CYB5R3
1554574_a_at 0.793 BRI3 223376_s_at 0.792 CREB1 204313_s_at 0.791
LOC389203 225014_at 0.79 WDR41 218055_s_at 0.789 C9ORF78 218116_at
0.789 GNPDA1 202382_s_at 0.787 RPE 225039_at 0.787 HSPA4L 205543_at
0.786 SEPT11 201307_at 0.784 HEATR2 241352_at 0.784 ENAH 222433_at
0.783 MED19 226300_at 0.782 TBC1D5 201814_at 0.782 EMP2 225079_at
0.781 STX11 235670_at 0.778 ANKH 229176_at 0.776 ENDOD1 212573_at
0.775 IL13RA1 201887_at 0.775 RAB14 200927_s_at 0.772 TMEM30A
232591_s_at 0.771 DDX52 212834_at 0.771 PTPMT1 229535_at 0.769
SRPRB 218140_x_at 0.767 FAM98A 212333_at 0.767 SRP72 208803_s_at
0.766 RPE 221770_at 0.766 HOXB9 216417_x_at 0.766 MAEA 207922_s_at
0.765 GHITM 1554510_s_at 0.764 CAPZB 201949_x_at 0.764 ANKRD52
228257_at 0.762 MOBKL1B 214812_s_at 0.762 MIA3 1569057_s_at 0.759
UBE2E3 210024_s_at 0.758 CAMK2D 228555_at 0.758 UBXD7 212840_at
0.754 C18ORF10 213617_s_at 0.754 HSD17B1 228595_at 0.753 PDLIM5
212412_at 0.752 SRP72 208801_at 0.751 ZNF618 226590_at 0.75 TSPAN31
203227_s_at 0.744 MAP3K15 200979_at 0.741 C18ORF10 212055_at 0.737
ATP5I 207335_x_at 0.737 TOX4 201685_s_at 0.73 TBXA2R 336_at 0.73
COL4A2 211966_at 0.729 TIMM23 218119_at 0.723 NDUFAF2 228355_s_at
0.722 FOXN3 218031_s_at 0.721 EIF2S1 201142_at 0.717 NDUFB6
203613_s_at 0.712 TM6SF1 1558102_at 0.704 ELOVL2 213712_at 0.699
PPP1R7 201213_at 0.698 BAT3 230513_at 0.697 ZNF668 219047_s_at
0.691 ERBB3 1563253_s_at 0.691 C12ORF45 226349_at 0.688 PGRMC2
213227_at 0.686 NUDT4 212183_at 0.685 AABHD7 239579_at 0.661 CEP27
228744_at 0.651 RAB11FIP3 216043_x_at 0.551 FHL3 218818_at 0.546
NAALAD2 1554506_x_at 0.464 LOC219731 1557208_at 0.419
TABLE-US-00004 TABLE 3 CSC-genes annotations Entrez Gene ID for
Fold Name Human Affymetrix Change Networks Location Type Drugs
Actin -- 1 Unknown group ADA 100 -- 8 Cytoplasm enzyme pentostatin,
vidarabine Adaptor protein 2 -- 8 Unknown complex AFP 174 -- 5
Extracellular transporter Space AGT 183 -- 8 Extracellular other
Space AHR 196 -- 7 Nucleus ligand- dependent nuclear receptor AKAP9
10142 215483_at 2.168 1 Cytoplasm other Akt -- 2 Unknown group
amino acids -- 6 Unknown chemical - endogenous mammalian AMPH 273
-- 8 Plasma other Membrane AMZ2 51321 227567_at 1.377 8 Unknown
other ANAPC1 64682 -- 4 Nucleus other ANAPC10 10393 -- 4 Nucleus
enzyme ANAPC11 51529 -- 4 Unknown enzyme ANAPC13 25847 -- 4 Unknown
other ANAPC2 29882 -- 4 Nucleus enzyme ANAPC4 29945 -- 4 Unknown
enzyme ANAPC5 51433 235926_at 2.631 4 Nucleus enzyme ANAPC7 51434
-- 4 Unknown other ANK2 287 202921_s_at 4.162 4 Plasma other
Membrane ANKRD28 23243 241063_at 2.297 13 Unknown other AOC3 8639
204894_s_at 1.894 2 Plasma enzyme Membrane AP2A2 161 -- 8 Cytoplasm
transporter APBB2 323 40148_at 1.139 9 Cytoplasm other APP 351 -- 9
Plasma other AAB-001 Membrane ARD1A 8260 -- 8 Nucleus enzyme Arf --
8 Unknown group ARF5 381 -- 8 Cytoplasm transporter ARHGDIB 397 --
7 Cytoplasm other ASCC3L1 23020 214982_at 3.009 9 Nucleus enzyme
(includes EG: 23020) ASCL1 429 -- 9 Nucleus transcription regulator
ASPM 259266 232238_at 1.411 3 Nucleus other ATAD2 29028 235266_at
1.304 7 Unknown other ATP -- 9 Unknown chemical - endogenous
mammalian ATXN2L 11273 207798_s_at 1.656 9 Unknown other BARD1 580
205345_at 1.559 1 Nucleus transcription regulator BCL2 596 -- 6
Cytoplasm other oblimersen, (-)-gossypol BCL9L 283149 227616_at
1.291 6 Cytoplasm other BDP1 55814 224227_s_at 1.632 9 Nucleus
transcription regulator beta-estradiol -- 3 Unknown chemical -
endogenous mammalian BRF1 2972 -- 9 Nucleus transcription regulator
BUB1 (includes 699 233445_at 3.209 5 Nucleus kinase EG: 699) BUB1B
701 -- 4 Nucleus kinase C12ORF48 55010 220060_s_at 1.216 Unknown
other C12ORF51 283450 1557529_at 3.632 4 Unknown other CABIN1 23523
1557581_x_at 3.052 1 Nucleus other Calmodulin -- 1 Unknown group
CASC5 57082 228323_at 1.144 3 Nucleus other CASP3 836 -- 4
Cytoplasm peptidase IDN-6556 CASP6 839 -- 9 Cytoplasm peptidase CBS
875 240517_at 1.818 1 Cytoplasm enzyme CD151 977 -- 7 Plasma other
Membrane CDC14B 8555 234605_at 2.512 5 Nucleus phosphatase CDC16
8881 242359_at 6.261 4 Nucleus other CDC20 991 -- 3 Nucleus other
CDC23 (includes 8697 -- 4 Nucleus enzyme EG: 8697) CDC26 246184 --
4 Nucleus other CDC27 996 -- 4 Nucleus other CDC5L 988 222179_at
1.292 9 Nucleus other CDK2 1017 -- 7 Nucleus kinase BMS-387032,
flavopiridol CDKN1A 1026 -- 7 Nucleus kinase CDT1 81620 -- 7
Nucleus other CDX1 1044 -- 9 Nucleus transcription regulator CENPJ
55835 220885_s_at 1.64 4 Nucleus transcription regulator CEP55
55165 218542_at 1.096 5 Unknown other CHD8 57680 212571_at 1.27 1
Nucleus enzyme CHEK2 11200 -- 5 Nucleus kinase CHRM3 1131 -- 8
Plasma G-protein fesoterodine, Membrane coupled ABT-089, receptor
atropine/edrophonium, cyclopentolate/ phenylephrine,
ipratropium/albuterol, trihexyphenidyl, carbamylcholine,
darifenacin, methacholine, diphenhydramine, quinidine,
procyclidine, trospium, atropine sulfate/benzoic acid/hyoscyamine/
methenamine/methylene blue/phenyl salicylate, homatropine,
dicyclomine, methantheline, orphenadrine, fluoxetine/olanzapine,
doxacurium, aspirin/caffeine/ orphenadrine, propantheline,
tridihexethyl, biperiden, anisotropine methylbromide,
glycopyrrolate, diphenhydramine/8- chlorotheophylline, atropine/
hyoscyamine/ phenobarbital/ scopolamine, atropine
sulfate/diphenoxylate hydrochloride, pipecuronium, flavoxate,
chlorpheniramine/ methscopolamine/ phenylephrine, mepenzolic acid,
atropine sulfate/difenoxin hydrochloride, homatropine
methylbromide, hydroxyamphetamine/ tropicamide, cisatracurium,
hyoscyamine/ phenobarbital, bethanechol, olanzapine, oxybutynin,
tropicamide, solifenacin, cyclopentolate, tolterodine, cevimeline,
acetylcholine, ipratropium, atropine, pilocarpine, benztropine,
hyoscyamine, arecoline, scopolamine, N- methylscopolamine,
tiotropium, carbinoxamine, buclizine, diphenhydramine/
phenylephrine, brompheniramine CIB1 10519 -- 7 Nucleus other Ck2 --
1 Unknown complex CKM 1158 -- 5 Cytoplasm kinase CLIC1 1192 -- 9
Nucleus ion channel CLIC4 25932 -- 6 Cytoplasm ion channel CLIC5
53405 -- 1 Cytoplasm ion channel CLN8 2055 229958_at 1.344
Cytoplasm other COIL 8161 203653_s_at 1.259 6 Nucleus other COL4A1
1282 -- 5 Extracellular other collagenase Space COPB1 1315 -- 8
Cytoplasm transporter Creb -- 2 Unknown group CREB3L2 64764
237952_at 2.013 3 Unknown other CRIPAK 285464 228318_s_at 1.486
Cytoplasm other CROP 51747 242389_at 2.121 7 Nucleus other CRY1
1407 -- 7 Nucleus enzyme CTNNA1 1495 -- 6 Plasma other Membrane
CTNNAL1 8727 -- 6 Plasma other Membrane CTNNB1 1499 -- 6 Nucleus
transcription regulator CUL4A 8451 232466_at 2.607 1 Nucleus other
DAPK1 1612 -- 6 Cytoplasm kinase DCLRE1C 64421 242927_at 1.187
Nucleus enzyme DDX17 10521 213998_s_at 1.528 6 Nucleus enzyme
DENND4A 10260 230607_at 2.368 1 Nucleus other DMD 1756 -- 8 Plasma
other Membrane DNM1L 10059 236032_at 1.503 2 Cytoplasm enzyme DSN1
79980 -- 3 Nucleus other DTX -- 3 Unknown group DTX1 1840 -- 3
Nucleus transcription regulator DTX2 113878 -- 3 Nucleus other DTX3
196403 49051_g_at 1.32 3 Cytoplasm other DUB -- 18 Unknown group
DVL1 1855 -- 6 Cytoplasm other DVL2 1856 -- 6 Cytoplasm other
Dynamin -- 2 Unknown group EGFR 1956 -- 7 Plasma kinase cetuximab,
AEE Membrane 788, panitumumab, BMS-599626, ARRY-334543, XL647,
canertinib, gefitinib, HKI-272, PD 153035, lapatinib, vandetanib,
erlotinib EIF4G3 8672 201935_s_at 1.174 4 Cytoplasm translation
regulator EPOR 2057 -- 9 Plasma transmembrane erythropoietin,
Membrane receptor darbepoetin alfa, continuous erythropoietin
receptor activator ERBB2 2064 -- 3 Plasma kinase trastuzumab, BMS-
Membrane 599626, ARRY- 334543, XL647, CP- 724, 714, HKI-272,
lapatinib, erlotinib ETS1 2113 241435_at 1.797 2 Nucleus
transcription regulator EWSR1 2130 229966_at 1.686 1 Nucleus other
EXT1 2131 242126_at 2.116 4 Cytoplasm enzyme FLOT1 10211 -- 3
Plasma other Membrane FLT1 2321 232809_s_at 1.861 2 Plasma kinase
sunitinib, axitinib,
Membrane CEP 7055 FMR1 2332 -- 7 Nucleus other FRK 2444 -- 9
Nucleus kinase FUBP1 8880 240307_at 2.087 1 Nucleus transcription
regulator FZR1 51343 -- 4 Nucleus other GABPA 2551 243498_at 2.03 2
Nucleus transcription regulator GBF1 8729 233114_at 2.03 8
Cytoplasm other GGT1 2678 211417_x_at 1.555 6 Cytoplasm enzyme GPD2
2820 243598_at 2.13 3 Cytoplasm enzyme HDAC3 8841 240482_at 2.062 1
Nucleus transcription tributyrin, PXD101, regulator pyroxamide,
MGCD0103, vorinostat, FR 901228 HECW1 23072 237295_at 11.843 6
Cytoplasm enzyme HELLS 3070 242890_at 1.359 3 Nucleus enzyme HERC5
51191 219863_at 1.156 6 Cytoplasm enzyme Histone h3 -- 1 Unknown
group HNRNPC 3183 235500_at 1.769 1 Nucleus other HNRPD 3184
241702_at 1.962 4 Nucleus transcription regulator HNRPH1 3187
213472_at 2.332 8 Nucleus other HOXA2 3199 228642_at 1.44 8 Nucleus
transcription regulator HOXD3 3232 206601_s_at 1.897 7 Nucleus
transcription regulator HPS1 3257 239382_at 1.749 14 Cytoplasm
other HPS4 89781 -- 14 Cytoplasm other HSPA5 3309 -- 3 Cytoplasm
other HUWE1 10075 214673_s_at 1.858 6 Nucleus transcription
regulator IFNG 3458 -- 9 Extracellular cytokine Space IFNGR1 3459
242903_at 2.171 4 Plasma transmembrane interferon Membrane receptor
gamma-1b IL1B 3553 -- 4 Extracellular cytokine IL-1 trap Space
Insulin -- 2 Unknown group IRS2 8660 236338_at 2.162 2 Cytoplasm
other ITGB3 3690 -- 7 Plasma transmembrane TP 9201, Membrane
receptor EMD121974, tirofiban ITPR1 3708 -- 4 Cytoplasm ion channel
JARID1A 5927 226367_at 1.192 9 Nucleus transcription regulator
JARID2 3720 232835_at 2.139 4 Nucleus transcription regulator Jnk
-- 2 Unknown group KIAA1267 284058 224489_at 1.355 1 Nucleus other
KIDINS220 57498 1557246_at 2.97 6 Nucleus transcription regulator
KIR2DL3 3804 -- 9 Plasma other Membrane KITLG (includes 4254 -- 9
Extracellular growth factor EG: 4254) Space KLF6 1316 -- 5, 9
Nucleus transcription regulator LCN2 3934 -- 9 Extracellular
transporter Space LMO2 4005 -- 9 Nucleus other LOC388135 388135
230475_at 1.979 5 Unknown other LRRFIP1 9208 239379_at 1.796 3
Nucleus transcription regulator MALAT1 378938 224568_x_at 1.699
Unknown other Mapk -- 2 Unknown group MEF2C 4208 236395_at 2.104 2
Nucleus transcription regulator MET 4233 213816_s_at 1.283 2 Plasma
kinase Membrane mGluR -- 8 Unknown group MIS12 79003 -- 3 Nucleus
other MLL 4297 212079_s_at 1.599 1 Nucleus transcription regulator
MPL 4352 -- 9 Plasma transmembrane SB-497115 Membrane receptor
MTUS1 57509 239576_at 1.975 1 Unknown other MYC 4609 -- 6 Nucleus
transcription regulator MYF6 4618 -- 5 Nucleus transcription
regulator MYO10 4651 243159_x_at 2.528 3 Cytoplasm other MYOD1 4654
-- 5 Nucleus transcription regulator N4BP2L1 90634 213375_s_at 2.01
Unknown other Nap125 -- 16 Unknown group NAPA 8775 239362_at 1.624
2 Cytoplasm transporter NAPE-PLD 222236 242635_s_at 1.216 8
Cytoplasm enzyme NARG1 80155 1556381_at 2.827 8 Nucleus
transcription regulator NAT13 80218 -- 8 Cytoplasm enzyme NBPF15
284565 201104_x_at 1.411 1 Unknown other NBR1 4077 1568856_at 1.957
5 Unknown other NCKAP1L 3071 209734_at 2.071 16 Plasma other
Membrane NCOA3 8202 -- 7 Nucleus transcription regulator NEK1 4750
213328_at 1.381 6 Nucleus kinase NES 10763 -- 5 Cytoplasm other
NFATC2IP 84901 217527_s_at 1.272 1 Nucleus other NFkB -- 2 Unknown
complex NFKBIE (includes 4794 -- 13 Nucleus transcription EG: 4794)
regulator NMB 4828 -- 8 Extracellular other Space NPAS2 4862
1557690_x_at 1.76 7 Nucleus transcription regulator NPTN 27020
228723_at 2.086 1 Plasma other Membrane NRP2 8828 210841_s_at 1.106
2, 3 Plasma kinase Membrane NUPL1 9818 241425_at 2.179 17 Nucleus
transporter OGG1 4968 -- 9 Nucleus enzyme OSBPL5 114879 233734_s_at
1.261 3 Cytoplasm other OSGEP 55644 242930_at 1.541 3 Unknown
peptidase P38 MAPK -- 2 Unknown group PABPN1 8106 213046_at 2.228 5
Nucleus other PAX3 5077 -- 7 Nucleus transcription regulator PCBP1
(includes 5093 -- 6 Nucleus translation EG: 5093) regulator PDE4B
5142 215671_at 3.457 2 Cytoplasm enzyme dyphylline, nitroglycerin,
arofylline, tetomilast, L 869298, aminophylline, anagrelide,
cilomilast, milrinone, rolipram, dipyridamole, L- 826, 141,
roflumilast, tolbutamide, theophylline, pentoxifylline, caffeine
PDE5A 8654 239556_at 2.24 4 Cytoplasm enzyme dyphylline,
nitroglycerin, DA- 8159, aminophylline, sildenafil, dipyridamole,
aspirin/dipyridamole, vardenafil, tolbutamide, tadalafil,
theophylline, pentoxifylline PDGF BB -- 2 Unknown complex PDK1 5163
239798_at 1.654 1 Cytoplasm kinase PDSS1 23590 236298_at 1.64 15
Unknown enzyme PDXDC1 23042 1560014_s_at 2.105 8 Unknown other PHC1
1911 218338_at 1.123 5 Nucleus other PI3K -- 2 Unknown complex
PIP5K1C 23396 -- 7 Plasma kinase Membrane PIP5K3 200576 1557719_at
2.227 2 Cytoplasm kinase Pka -- 1 Unknown complex Pkc(s) -- 2
Unknown group PLAA 9373 -- 4 Cytoplasm other PLC gamma -- 2 Unknown
group Pld -- 8 Unknown group PLK1 5347 -- 7 Nucleus kinase BI 2536
PMS2L3 5387 214473_x_at 1.159 3 Unknown other POLR2J2 246721
1552622_s_at 1.828 1 Nucleus transcription regulator POU4F2 5458 --
6 Nucleus transcription regulator PP2A -- 6 Unknown complex PRDM5
11107 -- 5 Nucleus other PRKCB1 5579 -- 7 Cytoplasm kinase
enzastaurin, ruboxistaurin progesterone -- 8 Unknown chemical -
endogenous mammalian PSEN1 5663 242875_at 1.851 2 Plasma peptidase
(R)-flurbiprofen Membrane PTEN 5728 -- 3 Cytoplasm phosphatase PTK2
5747 234211_at 2.539 2 Cytoplasm kinase PTPN12 5782 -- 7 Cytoplasm
phosphatase PTPN14 5784 -- 6 Cytoplasm phosphatase PTPRA 5786 -- 7
Plasma phosphatase Membrane PTPRD 5789 -- 6 Plasma phosphatase
Membrane PTPRE 5791 -- 7 Plasma phosphatase Membrane PTPRS
(includes 5802 1556116_s_at 1.739 7 Plasma phosphatase EG: 5802)
Membrane RAB11FIP3 9727 228613_at 2.546 8 Cytoplasm other RAB11FIP4
84440 -- 8 Cytoplasm other Rac -- 2 Unknown group RAD50 10111 -- 5
Nucleus enzyme RAD54L 8438 204558_at 1.483 5 Nucleus enzyme RB1
5925 -- 9 Nucleus transcription regulator RBM25 58517 1557081_at
1.57 7 Nucleus other RBM4 5936 213718_at 1.53 7 Nucleus other RBM5
10181 209936_at 2.249 6 Nucleus other RDBP 7936 -- 3 Nucleus other
RHOA 387 240337_at 2.143 2 Cytoplasm enzyme RHOBTB2 23221
1556645_s_at 1.538 Unknown enzyme RNA polymerase II -- 1 Unknown
complex RNU1A 6060 -- 1 Unknown other RP13-122B23.3 25920
1556434_at 1.985 3 Nucleus other RPL10 6134 -- 6 Cytoplasm other
RUNX3 864 204198_s_at 1.233 7 Nucleus transcription regulator SBF1
6305 -- 3 Plasma phosphatase Membrane SCMH1 22955 -- 5 Nucleus
transcription regulator SCN3A 6328 -- 4 Plasma ion channel riluzole
Membrane SEC16A 9919 -- 10 Cytoplasm phosphatase SEC16B 89866
1552880_at 1.877 10 Nucleus other Secretase gamma -- 9 Unknown
complex SF1 7536 210172_at 2.452 1, 4 Nucleus transcription
regulator SF3B1 23451 214305_s_at 1.359 1 Nucleus other SFRS15
57466 243759_at 2.028 Nucleus other SGCA 6442 1562729_at 2.395 8
Plasma other Membrane SGCB 6443 -- 8 Plasma other Membrane SGCD
6444 -- 8 Cytoplasm other SGCG 6445 -- 8 Plasma other Membrane
SH2D1A (includes 4068 -- 5 Cytoplasm other EG: 4068) SKIL 6498 -- 4
Nucleus transcription regulator SLC29A1 2030 -- 9 Plasma
transporter Membrane SLC2A11 66035 232167_at 1.529 9 Plasma other
Membrane SLC2A8 29988 239426_at 2.012 Plasma transporter Membrane
SLC30A9 10463 237051_at 2.063 7 Nucleus transporter SLC4A1 6521 --
9 Plasma transporter Membrane SMAD4 4089 -- 6 Nucleus transcription
regulator SMARCA5 8467 -- 9 Nucleus transcription regulator SMC5
23137 -- 12 Nucleus other SMC6 79677 218781_at 1.203 12 Nucleus
other SMN1 6606 -- 6 Nucleus other SNRPA1 6627 242146_at 3.54 8
Nucleus other SNW1 22938 -- 5 Nucleus transcription regulator SON
6651 201085_s_at 1.144 5 Nucleus other
SP4 6671 -- 3 Nucleus transcription regulator sphingomyelin -- 9
Unknown chemical - endogenous mammalian SPN 6693 -- 3 Plasma
transmembran Membrane e receptor SPTBN1 6711 -- 4, 6, 8 Plasma
other Membrane SQLE 6713 213577_at 1.502 3 Cytoplasm enzyme SQSTM1
8878 -- 5 Cytoplasm transcription regulator SRC 6714 -- 6 Cytoplasm
kinase dasatinib, AZM-475271 STK36 27148 231806_s_at 1.362 6
Unknown kinase STRAP 11171 1558002_at 2.189 2 Plasma other Membrane
STX3 6809 -- 7 Plasma transporter Membrane SUMO1 7341 -- 8 Nucleus
enzyme SUMO2 6613 -- 9 Nucleus other SVIL 6840 215279_at 2.228 4
Plasma other Membrane SYNE2 23224 202761_s_at 1.356 1 Nucleus other
TAF15 8148 227891_s_at 1.971 1 Nucleus transcription regulator
TAF1A 9015 -- 5 Nucleus transcription regulator TAF1B 9014
239046_at 1.468 5 Nucleus transcription regulator TAF1C 9013 -- 5
Nucleus transcription regulator TAOK3 51347 220761_s_at 1.195 2
Cytoplasm kinase Tap -- 17 Unknown complex TBC1D8 11138 204526_s_at
1.373 3 Plasma other Membrane TCERG1 10915 -- 8 Nucleus
transcription regulator TCF7L2 6934 -- 6 Nucleus transcription
regulator TCOF1 (includes 6949 202385_s_at 1.169 1 Nucleus
transporter EG: 6949) TCR -- 2 Unknown complex TERF2 7014 -- 5
Nucleus other TH1L 51497 -- 3 Nucleus other THAP7 80764 -- 1
Nucleus other THRAP3 9967 217847_s_at 1.464 1 Nucleus transcription
regulator TIMP1 7076 -- 9 Extracellular other Space TNF 7124 -- 4
Extracellular cytokine adalimumab, Space etanercept, infliximab,
CDP870, golimumab, thalidomide TNRC6A 27327 234734_s_at 1.268 9
Nucleus other TP53 7157 -- 5 Nucleus transcription regulator
TP53BP1 7158 -- 5 Nucleus transcription regulator TPM4 7171
235094_at 2.079 8 Cytoplasm other Trans- -- 15 Unknown group
hexaprenyl- transtransferase TRIM33 51592 239716_at 2.496 6 Nucleus
transcription regulator TRIO 7204 240773_at 2.607 2 Plasma kinase
Membrane tRNA -- 19 Unknown group adenylyl- transferase tRNA -- 19
Unknown group cytidylyl- transferase TRNT1 51095 243236_at 2.295 19
Cytoplasm enzyme TRPV1 7442 1556229_at 2.636 2 Plasma ion channel
SB-705498, Membrane capsaicin TSG101 7251 -- 5, 7 Nucleus
transcription regulator TSPAN7 7102 -- 7 Plasma other Membrane TTC3
7267 208664_s_at 1.396 7 Cytoplasm other TXNL1 9352 243664_at 1.98
9 Cytoplasm enzyme Ubiquitin -- 1 Unknown group UGT -- 7 Unknown
group UGT1A6 54578 206094_x_at 3.86 7 Cytoplasm enzyme USP36 57602
224979_s_at 1.393 18 Nucleus peptidase Vegf -- 2 Unknown group
VEGFA 7422 -- 3 Extracellular growth factor bevacizumab, Space
ranibizumab, pegaptanib VEGFB (includes 7423 -- 3 Extracellular
growth factor EG: 7423) Space VPS28 51160 -- 5 Cytoplasm
transporter VPS37B 79720 236889_at 2.85 5 Nucleus other WAS 7454 --
11 Cytoplasm other WDR68 10238 233782_at 1.924 4 Cytoplasm other
WFS1 7466 1555270_a_at 1.315 3 Cytoplasm enzyme WIPF2 147179
216006_at 2.916 11 Unknown other WT1 7490 -- 6 Nucleus
transcription regulator WTAP 9589 1560274_at 1.747 2 Nucleus other
XRCC5 7520 232633_at 2.106 5 Nucleus enzyme YWHAG 7532 -- 4
Cytoplasm other ZEB1 6935 -- 5 Nucleus transcription regulator
ZFHX3 463 215828_at 1.737 5 Nucleus transcription regulator ZFR
51663 238970_at 2.655 Nucleus other ZFX 7543 207920_x_at 1.625 9
Nucleus transcription regulator ZMYND8 23613 209049_s_at 1.102 7
Nucleus transcription regulator ZNF224 7767 216983_s_at 2.986 6
Nucleus other ZNF226 7769 219603_s_at 1.332 8 Nucleus transcription
regulator ZNF326 284695 241720_at 1.418 Nucleus transcription
regulator ZNF536 9745 233890_at 3.303 Unknown other ZWINT (includes
11130 -- 3 Nucleus other EG: 11130)
TABLE-US-00005 TABLE 4 Cell Surface Genes Entrez Gene ID for Human
Name Location 7204 TRIO Plasma Membrane 1956 EGFR Plasma Membrane
7102 TSPAN7 Plasma Membrane 977 CD151 Plasma Membrane 2064 ERBB2
Plasma Membrane 2321 FLT1 Plasma Membrane 2030 SLC29A1 Plasma
Membrane 11171 STRAP Plasma Membrane 8828 NRP2 Plasma Membrane 4233
MET Plasma Membrane 273 AMPH Plasma Membrane 351 APP Plasma
Membrane 1756 DMD Plasma Membrane 1495 CTNNA1 Plasma Membrane 8727
CTNNAL1 Plasma Membrane 10211 FLOT1 Plasma Membrane 3459 IFNGR1
Plasma Membrane 23396 PIP5K1C Plasma Membrane 5663 PSEN1 Plasma
Membrane 6445 SGCG Plasma Membrane 6693 SPN Plasma Membrane 6711
SPTBN1 Plasma Membrane 6840 SVIL Plasma Membrane 2057 EPOR Plasma
Membrane 5789 PTPRD Plasma Membrane 4352 MPL Plasma Membrane 5786
PTPRA Plasma Membrane 27020 NPTN Plasma Membrane 3690 ITGB3 Plasma
Membrane 7442 TRPV1 Plasma Membrane 8639 AOC3 Plasma Membrane 1131
CHRM3 Plasma Membrane 3804 KIR2DL3 Plasma Membrane 287 ANK2 Plasma
Membrane 3071 NCKAP1L Plasma Membrane 5791 PTPRE Plasma Membrane
5802 PTPRS Plasma Membrane 6305 SBF1 Plasma Membrane 6328 SCN3A
Plasma Membrane 6442 SGCA Plasma Membrane 6443 SGCB Plasma Membrane
66035 SLC2A11 Plasma Membrane 29988 SLC2A8 Plasma Membrane 6521
SLC4A1 Plasma Membrane 6809 STX3 Plasma Membrane 11138 TBC1D8
Plasma Membrane
[0039] A used herein "CSC-associated gene" refers to a gene whose
expression or function is altered in cancer stem cells.
CSC-associated genes include genes whose expression is signficantly
altered, e.g., significantly upregulated or significantly
downregulated, in cancer stem cells compared with non-cancer stem
cells, e.g., cancer cells that are not stem cells, normal cells,
etc. In some embodiments, genes that have significantly altered
expression levels in cancer stem cells are identified by using an
appropriate statistical test for establishing the significance of
differences between expression levels in a cancer stem cell and a
non-cancer stem cell. Tests for statistical significance are well
known in the art and are exemplified in Applied Statistics for
Engineers and Scientists by Petruccelli, Chen and Nandram 1999
Reprint Ed. The magnitude of up-, or down-, regulated expression of
a CSC-associated gene in a cancer stem cell compared with a
non-cancer stem cell may vary. In some embodiments, the expression
level of a CSC-associated gene is at least 10%, at least 25%, at
least 50%, at least 100%, at least 250%, at least 500%, or at least
1000% higher, or lower, than its expression level in a non-cancer
stem cell. In other embodiments, the expression level of a
CSC-associated gene is at least 2-fold, at least 3-fold, at least
4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least
8-fold, at least 9-fold, at least 10-fold, at least 20-fold, at
least 30-fold, at least 40-fold, at least 50-fold, at least
100-fold, or more higher, or lower, than its expression level a
non-cancer stem cell.
[0040] CSC-associated genes are not limited to genes which are
upregulated or downregulated in cancer stem cells. In some
embodiments, a CSC-associated gene is a gene that may or may not
have altered expression in a cancer stem cell, but that
nevertheless functions in a pathway that is deregulated in cancer
stem cells. Typically, deregulated pathways in cancer stem cells
involve the product(s) of one or more genes whose expression is
upregulated or downregulated and/or the product(s) of one or more
genes with altered functionality, e.g., due to a mutation, thereby
resulting in altered function of the pathway, e.g., overactivity or
underactivity of the pathway.
[0041] In some embodiments, CSC-associated genes are identified in
cancer stem cells of a breast cancer, prostate cancer, colon
cancer, lung cancer, renal cancer or melanoma. In some instances,
CSC-associated genes are identified in cancer stem cells of a
melanoma, which are also referred to as malignant melanoma
initiating cells (MMIC). Other cancer stem cells (e.g., non-ABCB5
CSCs) are known in the art.
[0042] Exemplary CSC-associated genes are disclosed in Tables 1-8.
In some embodiments, a CSC-associated gene is selected from the
group consisting of: ANK2, NCKAP1L, PTPRE, PTPRS, SBF1, SCN3A,
SGCA, SGCB, SLC2A11, SLC2A8, SLC4A1, STX3, and TBC1D8. In some
embodiments, the CSC-associated gene is one that is not a gene of
the group consisting of EGFR, CD151, ERBB2, FLT1, SLC29A1, NRP2,
MET, AMPH, APP, DMD, and ITGB3. In some embodiments, the
CSC-associated gene is one that is not a gene of the group
consisting of: TRIO, TSPAN7, STRAP, CTNNA1, CTNNAL1, FLOT1, IFNGR1,
PIP5K1C, PSEN1, SGCG, SPN, SPTBN1, SVIL, EPOR, PTPRD, MPL, PTPRA,
NPTN, TRPV1, AOC3, CHRM3, and KIR2DL3. In some embodiments, the
CSC-associated gene is one that is not a gene that has previously
been indicated as a tumor suppressor or oncogene. In some
embodiments, the CSC-associated gene is one that is not a gene of
the group consisting of: EWSR1, TP53, EGFR, ITPR1, NBR1, MLL, PTK2,
PTPN14, RB1, JARID1A, SKIL, TNF, TP53BP1, TRIO, SF1, TAF15, NCOA3,
RAD54L, CUL4A, SMARCA5, RAD50, AKAP9, DENND4A, DDX17, HECW1,
ZMYND8, ANAPC13, ANAPC5, TH1L, TRIM33, and CHD8. In some
embodiments, the CSC-associated gene is one that is not a gene of
the group consisting of: BARD1, BCL2, CBS, CTNNB1, ERBB2, EWSR1,
HPS1, IFNG, IL1B, PTEN, TP53, VEGFA, CHEK2, and HPS4.
[0043] In part, the disclosure relates to CSC-associated genes as
well as the RNAs and polypeptides (CSC-associated RNA and
polypeptides) that they encode and antibodies and antigen-binding
fragments that specifically bind them. The CSC-associated genes,
RNAs and polypeptides, encompass variants, homologues, and
fragments. Variants may result from alternative splicing or allelic
variation of certain genes provided in Tables 5. In general,
homologues and alleles typically will share at least 90% nucleotide
identity and/or at least 95% amino acid identity to the sequences
of the cancer antigen nucleic acids and polypeptides, respectively,
in some instances will share at least 95% nucleotide identity
and/or at least 97% amino acid identity, in other instances will
share at least 97% nucleotide identity and/or at least 98% amino
acid identity, in other instances will share at least 99%
nucleotide identity and/or at least 99% amino acid identity, and in
other instances will share at least 99.5% nucleotide identity
and/or at least 99.5% amino acid identity. Homology can be
calculated using various, publicly available software tools known
in the art, such as those developed by NCBI (Bethesda, Md.) that
are available through the internet. Exemplary tools include the
BLAST system (e.g., using the default nucleic acid (Blastn) or
protein (Blastp) search parameters) available from the website of
the National Center for Biotechnology Information (NCBI) at the
National Institutes of Health.
[0044] The CSC-associated genes are, among other things, useful for
diagnosing cancer, such as breast cancer, prostate cancer, colon
cancer, lung cancer, renal cancer or melanoma. Because
CSC-associated gene expression is altered in cancer (e.g.,
upregulated or downregulated), the expression level of
CSC-associated gene(s), e.g., a gene listed in Table 5 or 7, in an
individual is diagnostic of cancer in that individual. Accordingly,
the diagnostic methods disclosed herein can involve determining the
CSC-associated RNA or protein (polypeptide) levels.
[0045] The term "individual" as used herein means any mammalian
individual or subject, including, e.g., humans and non-human
mammals, such as primates, rodents, and dogs. Individuals
specifically intended for diagnosis and treatment using the methods
described herein are preferably humans.
[0046] The expression level of CSC-associated gene(s) may be
determined by using any of a number of methods known in the art. In
some embodiments, the expression levels are determined from a
biological sample (e.g., a test sample) obtained from a individual
(e.g., a human). Exemplary, biological samples include an isolated
cell, an isolated tissue, saliva, gingival secretions,
cerebrospinal fluid (spinal fluid), gastrointestinal fluid, mucus,
urogenital secretions, synovial fluid, blood, serum, plasma, urine,
cystic fluid, lymph fluid, ascites, pleural effusion, interstitial
fluid, intracellular fluid, ocular fluids, seminal fluid, mammary
secretions, vitreal fluid, and nasal secretions. However,
biological samples are not so limited and other exemplary
biological specimens will be readily apparent to one of ordinary
skill in the art. For the purposes of diagnosing melanoma, for
example, the biological sample is preferably a skin tissue sample,
e.g., a skin biopsy containing a suspicious lesion.
[0047] Expression levels of CSC-associated genes may be determined
for diagnostic purposes using nucleic acid hybridization or nucleic
acid amplification to detect the mRNAs that they encode. Methods
for nucleic acid hybridization or amplification are well known in
the art. In some embodiments, the nucleic acid amplification is
real-time RT-PCR or RT-PCR. Other methods known to one of ordinary
skill in the art could be employed to analyze mRNA levels, for
example nucleic acid arrays, cDNA analysis, Northern analysis, and
RNase Protection Assays. Nucleic acid arrays may be used to assay
(e.g., for diagnostic purposes) the expression levels of multiple
CSC-associated genes in parallel. Other suitable nucleic acid
detection methods will be apparent to the skilled artisan.
[0048] Expression levels of CSC-associated genes may be determined
for diagnostic purposes by detecting the polypeptides that they
encode. Methods for detecting polypeptides are well known in the
art. Exemplary polypeptide detection methods include, but are not
limited to, Enzyme Linked Immunosorbent Assays (ELISA),
radioimmunoassays (RIA), sandwich immunometric assays, flow
cytometry, western blot assays, immunoprecipitation assays,
immunohistochemistry, immunomicroscopy, lateral flow
immuno-chromatographic assays, BIACORE technology, and proteomics
methods, such as mass spectroscopy. Antibody arrays may be used to
assay (e.g., for diagnostic purposes) the expression levels of
multiple CSC-associated genes in parallel. Other suitable
polypeptide detection methods will be apparent to the skilled
artisan.
[0049] In some embodiments, e.g., where polypeptide, antibody or
nucleic acid arrays are used, expression levels of up to 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56,
57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105,
106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118,
119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131,
132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144,
145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157,
158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170,
171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183,
184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196,
197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209,
210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222,
223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235,
236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248,
249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261,
262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274,
275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287,
288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300,
301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313,
314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326,
327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339,
340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352,
353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365,
366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378,
379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391,
392, 393, 394, 395, 396, 397, 398, 399, or more CSC-associated
genes may be tested in parallel.
[0050] The diagnostic methods of the invention involve a comparison
between expression levels of CSC-associated genes in a test sample
and a reference value. The results of the comparison are diagnostic
of cancer, e.g., melanoma. In some embodiments, the reference value
is the expression level of the gene in a reference sample. A
reference value may be a predetermined value and may also be
determined from reference samples (e.g., control biological
samples) tested in parallel with the test samples. A reference
value may be a positive or negative control level. A reference
value can be a single cut-off value, such as a median or mean or a
range of values, such as a confidence interval. Reference values
can be established for various subgroups of individuals, such as
individuals predisposed to cancer, individuals having early or late
stage cancer, male and/or female individuals, or individuals
undergoing cancer therapy. The level of the reference value will
depend upon the particular population or subgroup selected. For
example, an apparently healthy population will have a different
"normal" value than will a population which has cancer, or a
population that has a predisposition for cancer. Appropriate ranges
and categories for reference values can be selected with no more
than routine experimentation by those of ordinary skill in the
art.
[0051] The reference sample can be any of a variety of biological
samples against which a diagnostic assessment may be made. Examples
of reference samples include biological samples from control
populations or control samples. Reference samples may be generated
through manufacture to be supplied for testing in parallel with the
test samples, e.g., reference sample may be supplied in diagnostic
kits. When the reference sample is from a cancer, e.g., tumor
tissue, the expression level of the reference sample (the reference
value) is the expression level of the CSC-associated gene in the
cancer. Similarly, when the reference sample is a normal sample,
e.g., non-tumor tissue, the expression level of the reference
sample (the reference value) is the expression level of the
CSC-associated gene in the non-tumor tissue. Similarly, when the
reference sample is a cancer stem cell sample, the expression level
of the reference sample (the reference value) is the expression
level of the CSC-associated gene in the cancer stem cell sample. In
some embodiments, the reference sample is of a melanoma and the
expression level of the reference sample is the expression level of
the CSC-associated gene in melanoma. In some embodiments, the
reference sample is of a non-melanoma tissue and the expression
level of the reference sample is the expression level of the
CSC-associated gene in non-melanoma tissue. Other appropriate
reference samples will be apparent to the skilled artisan.
[0052] The diagnostic methods are based in part on a comparison of
expression levels of CSC-associated genes between test samples and
reference sample. In some embodiments, if the expression level of
the CSC-associated gene in the test sample is about equal to the
expression level of the CSC-associated gene in the reference
sample, then the test sample and reference sample are likely of a
similar origin, category or class. For example, if expression
levels in a test sample and reference sample are about the same
(e.g., not statistically significantly different), and the
reference sample is from a normal tissue, then the test sample is
likely a normal tissue sample, and a normal diagnosis could be
indicated. Alternatively, if expression levels in a test sample and
reference sample are about the same, and the reference sample is
from a cancer tissue, then the test sample is likely a cancer
sample, and a diagnosis of cancer could be indicated. In certain
embodiments, if the expression level in a test sample and reference
sample are about the same, and the reference sample is from a
melanoma, then the test sample is likely a melanoma sample, and a
diagnosis of melanoma could be indicated.
[0053] In some cases, depending on factors such as the particular
CSC-associated gene(s) being evaluated, the condition being
diagnosed, and the type of reference sample, an expression level of
a CSC-associated gene in a test sample that is statistically
significantly higher or statistically significantly lower than its
expression level in a reference sample indicates a diagnosis. For
example, when the CSC-associated gene is among those listed in
Table 1 or 8 and the reference value is the expression level of the
CSC-associated gene in a normal (e.g., non-cancerous) reference
sample, if the expression level of the CSC-associated gene in the
test sample is significantly higher than the expression level of
the CSC-associated gene in the normal reference sample, the
comparison indicates cancer, e.g., melanoma. Similarly, when the
CSC-associated gene is among those listed in Table 1 or 8 and the
reference value is the expression level of the CSC-associated gene
in a cancer, e.g., melanoma, reference sample, if the expression
level of the CSC-associated gene in the test sample is
significantly lower than the expression level of the CSC-associated
gene in the cancer reference sample, the comparison does not
indicate cancer. Alternatively, when the CSC-associated gene is
among those listed in Table 2 or 7 and the reference value is the
expression level of the CSC-associated gene in a normal reference
sample, if the expression level of the CSC-associated gene in the
test sample is significantly lower than the expression level of the
CSC-associated gene in the normal reference sample, the comparison
indicates cancer. Similarly, when the CSC-associated gene is in
Table 2 or 7 and the reference value is the expression level of the
CSC-associated gene in a cancer, e.g., melanoma, reference sample,
if the expression level of the CSC-associated gene in the test
sample is significantly higher than the expression level of the
CSC-associated gene in the cancer reference sample, the comparison
does not indicate melanoma. Appropriate combinations of particular
CSC-associated gene(s), conditions to be diagnosed, and types of
reference samples, can be selected with no more than routine
experimentation by those of ordinary skill in the art for use in
the diagnostic methods disclosed herein.
[0054] The magnitude of the difference between the test sample and
reference sample that is sufficient to indicate a diagnosis will
depend on a variety of factors such as the particular
CSC-associated gene(s) being evaluated, the condition being
diagnosed, heterogeneity in healthy or disease populations from
which samples are drawn, the type of reference sample, the
magnitude of expression level of a CSC-associated gene, the assay
being used, etc. It is well within the purview of the skilled
artisan to determine the appropriate magnitude of difference
between the test sample and reference sample that is sufficient to
indicate a diagnosis. In some embodiments, the expression level of
the CSC-associated gene in the test sample is at least 10%, at
least 20%, at least 50%, at least 100%, at least 200%, at least
500%, at least 1000% or more higher than the expression level of
the gene in the reference sample. In other embodiments, the
expression level of the CSC-associated gene in the test sample is
at least 10%, at least 20%, at least 50%, at least 100%, at least
200%, at least 500%, at least 1000% or more lower than the
expression level of the gene in the reference sample.
[0055] Some CSC-associated genes that are normally produced in very
low quantities but whose production is dramatically increased in
tumor cells, e.g., a CSC-associated gene in Table 1 or 8, can
trigger an immune response. Thus, in some instances, specific
immunoreactivity against a CSC-associated polypeptide, e.g., a
polypeptide encoded by a gene listed in Table 1 or 8, in a
individual may be diagnostic of cancer in the individual.
Immunoreactivity against CSC-associated polypeptides may be humoral
or cellular, and is associated with a specific immune response to a
CSC-associated polypeptide that is upregulated in a cancer stem
cell in an individual. In the case of a humoral response the
diagnostic methods may involve detecting the presence of one or
more antibodies in an individual that specifically bind
CSC-associated polypeptides. Methods for detecting antibodies are
disclosed herein (e.g., ELISA, peptide arrays, etc.) and are well
known in the art. In some cases, the presence of CSC-polypeptide
specific effector cells is diagnostic of an immune response
specific to that CSC-polypeptide.
[0056] T Lymphocytes recognize complexes of peptide ligands (e.g.,
CSC-associated polypeptides) and Major Histocompatibility Complex
(MHC) molecules presented at the surface of Antigen Presenting
Cells (APC). Class I tetramers bind to a distinct set of T cell
receptors (TCRs) on a subset of CD8+ T cells, and Class II
tetramers bind to a distinct population of CD4+ T cells. Methods
for detecting antigen-specific T cells using MHC tetramers are well
known in the art (e.g., New Microarray Detects Antigen-Specific T
Cells and Immune Responses. PLoS Biol 1(3): e76 2003) and can be
used to detect CSC-polypeptide specific T cells which may be
diagnostic of cancer in an individual. ITAG reagents, for example,
from Beckman Coulter provide a convenient way to measure the
cellular response directed toward a single CSC-associated peptide
using MHC tetramers.
[0057] The methods for evaluating expression of CSC-associated
genes, e.g., diagnostic methods, disclosed herein may be combined
with methods for treating an individual having or suspected of
having cancer. The treatment may comprise a step of determining the
expression level of the CSC-associated gene in the individual. The
treatment may also comprise a step of comparing the expression
level of the CSC-associated gene to a reference value, such that
the results of the comparison are diagnostic of cancer in the
individual. In certain cases, if the comparison results in a
diagnosis of cancer in the individual, the administering step is
performed. In some cases, after a diagnosis is made using the
methods disclosed herein, a treatment plan is selected. For
example, if a diagnostic assay reveals that the expression of a
particular CSC-associated gene is altered, e.g., increased or
decreased, compared to a normal reference sample, then a treatment
directed at that particular CSC-associated gene may be implemented.
The diagnostic methods can also be used to evaluate the response to
a treatment. For example, the determining and the comparing may be
repeated at one or more intervals after the administering step to
evaluate the response to the treatment.
[0058] CSC-associated polypeptide arrays and arrays of antibodies
that bind CSC-associated polypeptides may be constructed by
immobilizing large numbers of isolated CSC associated polypeptides
or antibodies, or antigen binding fragments, to a solid support.
Methods for producing polypeptide and antibody arrays are well
known in the art. The methods typically involve production of
proteins (CSC-associated polypeptides or antibodies) from an
expression library, cloned into E. coli, yeast, or mammalian cells,
or similar system, e.g., hybridomas etc., from which the expressed
proteins are then purified, for example via His, GST tag, or
Protein A/G affinity purification. Cell free protein
transcription/translation is an alternative for synthesis of
proteins which do not express well in bacterial or other in vivo
systems. The purified isolated CSC associated polypeptides or
antibodies are immobilized on the array surface (solid support
surface) using art known methods. For example, proteins can be
immobilized by adsorption, covalent (e.g., aldehydes) and
non-covalent (e.g., biotin-streptavidin) interactions. Other
methods of conjugation will be readily apparent to one of ordinary
skill in the art. In some embodiments, the polypeptide arrays of
the invention consist essentially of at least 2, at least 5, at
least 10, at least 20, at least 50, at least 100, or more
polypeptides or immunogenic fragments thereof encoded by a
CSC-associated gene set forth in Table 1, 5, 7, or 8. In some
embodiments, the antibody arrays of the invention consist
essentially of at least 2, at least 5, at least 10, at least 20, at
least 50, at least 100, or more different antibodies or
antigen-binding fragments that specifically bind polypeptides
(CSC-associated polypeptides) encoded by a CSC-associated gene set
forth in Table 1, 5, 7, or 8.
[0059] Methods for producing nucleic acid arrays are well known in
the art. Nucleic acid arrays may be constructed by, e.g.,
immobilizing to a solid support large numbers oligonucleotides,
polynucleotides, or cDNAs having sequences complementary to
CSC-associated mRNAs. The skilled artisan is also referred to
Chapter 22 "Nucleic Acid Arrays" of Current Protocols In Molecular
Biology (Eds. Ausubel et al. John Wiley and #38; Sons NY, 2000),
International Publication WO00/58516, U.S. Pat. Nos. 5,677,195 and
5,445,934 which provide exemplary methods relating to nucleic acid
array construction and use in detection of nucleic acids of
interest. In some embodiments, the nucleic acid arrays consist
essentially of at least 2, at least 5, at least 10, at least 20, at
least 50, at least 100, at least 200, at least 300, or more of the
CSC-associated genes set forth in Table 1, 5, 7, or 8.
[0060] In some embodiments, the expression levels of multiple
CSC-associated genes may be combined to produce an expression
profile. As used herein, "expression profile" refers to a set of
expression levels of a plurality (e.g., 2 or more) of
CSC-associated genes. Expression profiles have a variety of uses.
For example, expression profiles may be used to classify (or
sub-classify) a sample, preferably a clinical sample. In some
embodiments, reference samples, for which a classification, e.g., a
disease category, e.g., breast cancer, prostate cancer, melanoma,
etc., has already been ascertained, are used to produce known
expression profiles. In some embodiments, the similarity of an
expression profile of a test sample and a known expression profile,
is assessed by comparing the level of the same CSC-associated gene
in the test and known expression profiles (i.e., expression level
pairs). In some cases, a test expression profile is compared with
one or more members of a plurality of known expression profiles,
and a known expression profile that most closely resembles (i.e.,
is most similar to) the test profile is identified. In certain
cases, the classification of a known expression profile that is
identified as similar to a test expression profile is assigned to
the test expression profile, thereby classifying the clinical
sample associated with the test expression profile. The methods are
useful for classifying samples across a range of phenotypes, e.g.,
disease status, risk status, etc., based on expression profiles. In
some embodiments, a classification model (e.g., discriminant
function, naive bayes, support vector machine, logistic regression,
and others known in the art) may be built based on the reference
expression profiles from various samples from individuals known to
have different disorders (e.g., cancers) and/or from healthy
individuals, and used to classify subsequently obtained samples
(e.g., clinical samples).
[0061] The invention also provides methods for stratifying a
population comprising individuals having cancer. In some
embodiments, methods involve determining expression levels of at
least 2, at least 5, at least 10, at least 20, at least 50, at
least 100, at least 200, at least 300, or more of the
CSC-associated genes set forth in Table 5, 7, or 8, for example, by
using the arrays of the invention, and stratifying the population
based on the expression levels. The stratification methods are
useful in epidemiological studies, for example, to identify
subpopulations of individuals at risk of cancer. The methods are
also useful in clinical studies to identify patient subpopulations
that respond better or worse to a particular treatment.
[0062] In some aspects, CSC-associated genes provide a basis for
identifying, isolating, cloning, propagating, and expanding CSC
populations in vitro. The present invention contemplates any
suitable method of employing agents, e.g., isolated peptides, e.g.,
antibodies, that bind to CSC-associated polypeptides to separate
CSCs from other cells. Accordingly, included in the present
invention is a method of producing a population of isolated CSCs.
The methods involve contacting a sample, e.g., a cell suspension,
with one or a combination of agents, e.g., antibodies or antigen
binding fragments or ligands, which recognize and bind to an
epitope, e.g., a cell surface protein, including CSC-associated
polypeptides (e.g., polypeptides encoded by the genes listed in
Table 4), on the CSC and separating and recovering from the sample
the cells bound by the agents. The CSC-associated polypeptide may
be encoded by a CSC-associated gene that is selected from the group
consisting of: ANK2, NCKAP1L, PTPRE, PTPRS, SBF1, SCN3A, SGCA,
SGCB, SLC2A11, SLC2A8, SLC4A1, STX3, and TBC1D8.
[0063] In some instances, commerically available antibodies or
antibody fragments that bind CSC-associated polypeptides may be
used in the methods disclosed herein. For example, antibodies
against ANK2 include, e.g., rabbit anti-human Ankyrin brain
polyclonal antibody from Abcam; mouse anti-human ANK2 monoclonal
antibody clone 2.2 from Genway Biotech, Inc.; and mouse anti-human
Ankyrin, brain variant 2 (ANK2) monoclonal, clone 2.20 and rabbit
anti-human ankyrin, brain variant 2 (ank2) polyclonal from Lifespan
Biosciences. Antibodies against NCKAP1L include, e.g., rabbit
anti-human HEM1 polyclonal antibody from Proteintech Group, Inc.
and are described in Weiner O D, et al., (2006) Hem-1 Complexes Are
Essential for Rac Activation, Actin Polymerization, and Myosin
Regulation during Neutrophil Chemotaxis. PLoS Biol 4(2): e38.
Antibodies against PTPRE include, e.g., rabbit anti-PTPepsilon
C-term RB0551-0552 polyclonal antibody from Abgent, mouse
anti-human PTPRE polyclonal antibody from Abnova Corporation; mouse
anti-PTPRE monoclonal antibody Clone 2D10 from Abnova Corporation;
chicken anti-human PTPRE polyclonal antibody from Thermo
Scientific; and Rabbit Anti-Protein Tyrosine phosphatase epsilon
(PTPRE) antibody from Acris Antibodies GmbH. Antibodies against
PTPRS include, e.g., mouse anti-PTPRS monoclonal antibody from
Abcam; mouse anti-human PTPRS monoclonal antibody Clone 1H6 from
Abnova Corporation; chicken anti-human PTPRS polyclonal antibody
from ABR-Affinity Bioreagents, now sold as Thermo Scientific;
chicken anti-human PTPRS polyclonal antibody from GeneTex; and
mouse anti-human PTPRS monoclonal antibody, Clone 1H6 from GeneTex.
Antibodies against SCN3A include, e.g., rabbit anti-SCN3A
polyclonal antibody from Abcam; mouse anti-human SCN3A monoclonal
antibody Clone 3F3 from Abnova Corporation; and mouse Anti-human
SCN3A monoclonal antibody Clone 3F3 from GeneTex. Antibodies
against SCNB include, e.g., mouse anti-beta Sarcoglycan Monoclonal
Antibody from Abcam; mouse anti-human SGCB monoclonal antibody
Clone 1C10 from Abnova Corporation; mouse anti-human SGCB
monoclonal antibody Clone 1C10 from GeneTex; and rabbit anti-human
Beta-sarcoglycan (SGCB) Polyclonal from Lifespan Biosciences.
Antibodies against SLC2A8 include, e.g., rabbit anti-human Glucose
Transporter 8 Polyclonal Antibody from Abcam; goat
anti-GLUT8/SLC2A8 polyclonal antibody from Everest Biotech; rabbit
anti-GLUCOSE TRANSPORTER 8 Polyclonal Antibody from GenWay Biotech,
Inc.; rabbit Anti-Human GLUCOSE TRANSPORTER 5, C Terminus
Polyclonal Antibody from GenWay Biotech, Inc.; goat anti-SLC2A8
polyclonal antibody from IMGENEX; and rabbit anti-Human Solute
Carrier Family 2 (Facilitated Glucose Transporter) Member 8
(Slc2a8) polyclonal from Lifespan Biosciences. Antibodies against
SBF1 include, e.g., rabbit Anti-MTMRS C-term RB0717 polyclonal
antibody from Abgent. Antibodies against SGCA include, e.g., mouse
Anti-SGCA monoclonal antibody Clone 3C4 from Abnova Corporation;
rabbit Anti-Human SGCA polyclonal antibody from Atlas Antibodies;
mouse Anti-SGCA monoclonal antibody clone 3C4 from Novus
Biologicals; rabbit Anti-Human SGCA PRESTIGE ANTIBODIES from
Sigma-Aldrich. Antibodies against SLC2A11 include, e.g., rabbit
anti-human Solute Carrier Family 2 (Facilitated Glucose
Transporter), Member 11 (Slc2a11) polyclonal from Lifespan
Biosciences. Antibodies against SLC4A1 include, e.g., rabbit
anti-human Band 3, N Terminus polyclonal antibody from Abcam; mouse
anti-human SLC4A1 MaxPab.RTM. polyclonal antibody from Abnova
Corporation; rabbit anti-human SLC4A1 polyclonal antibody from
Aviva Systems Biology; mouse anti-Band 3 Monoclonal Antibody Clone
BIII 136 from GenWay Biotech, Inc.; and mouse anti-human Solute
Carrier Family 4, Anion Exchanger, Member 1 (SLC4A1) monoclonal
Clone 3 h3 from Lifespan Biosciences. Antibodies against STX3
include, e.g., rabbit anti-human STX3 Polyclonal Antibody from
Atlas Antibodies and rabbit anti-human STX3 from Sigma-Aldrich.
Antibodies against TBC1D8 include, e.g., mouse anti-human TBC1D8
monoclonal antibody Clone 1A12 from Abnova Corporation; mouse
anti-human TBC1D8 monoclonal antibody Clone 1A12 from GeneTex;
mouse anti-human TBC1D8 monoclonal antibody Clone SS-18 from Santa
Cruz Biotechnology, Inc.; and rabbit anti-human TBC1D8, aa 132-231
polyclonal antibody from Strategic Diagnostics, Inc.
[0064] Agents may be linked to a solid-phase and utilized to
capture CSCs from a sample. The bound cells may then be separated
from the solid phase by known methods depending on the nature of
the agent, e.g., antibody, and solid phase. Alternatively, the
agents may be conjugated to a detectable label, e.g., a
fluorophore, that can be utilized to separate cells in a liquid
phase, such as by fluorescent activated cell sorting. Exemplary
fluorophores are well known in the art (e.g., Invitrogen's
MOLECULAR PROBES technologies) and include FITC, TRITC, Cy3, Cy5,
Alexa Fluorescent Dyes, and Quantum Dots.
[0065] Systems appropriate for preparing the desired cell
population include magnetic bead/paramagnetic particle column
utilizing isolated peptides that bind CSC-associated polypeptides
for either positive or negative selection; separation based on
biotin or streptavidin affinity; and high speed flow cytometric
sorting of immunofluorescent-stained CSCs mixed in a suspension of
other cells. Thus, the methods of the present invention include the
isolation of a population of CSCs.
[0066] Isolated CSCs may be prepared as substantially pure
preparations. The term "substantially pure" means that a
preparation is substantially free of other cells. For example, an
isolated CSC should constitute at least 70 percent of the total
cells present with greater percentages, e.g., at least 85, 90, 95
or 99 percent, being preferred. The cells may be packaged in a
finished container such as a cryovial along with any other
components that may be desired, e.g., agents for preserving cells,
or reducing bacterial growth. The CSCs are useful for a variety of
purposes. The isolated cells may be used in basic research setting
and in screening assays to identify compounds or compositions that
affect growth of CSCs.
[0067] Isolated CSCs, prepared according to the methods disclosed
herein, may be useful in a drug discovery context for lead compound
identification and optimization in cell-based screens. For example,
the effect of a compound on the growth and/or survival of a CSC may
be determined in a cell-based screen that uses an assay selected
from: a cell counting assay, a replication labeling assay, a cell
membrane integrity assay, a cellular ATP-based viability assay, a
mitochondrial reductase activity assay, a caspase activity assay,
an Annexin V staining assay, a DNA content assay, a DNA degradation
assay, and a nuclear fragmentation assay. Other exemplary assays
include BrdU, EdU, or H3-Thymidine incorporation assays; DNA
content assays using a nucleic acid dye, such as Hoechst Dye, DAPI,
Actinomycin D, 7-aminoactinomycin D or Propidium Iodide; Cellular
metabolism assays such as AlamarBlue, MTT, XTT, and CellTitre Glo;
Nuclear Fragmentation Assays; Cytoplasmic Histone Associated DNA
Fragmentation Assay; PARP Cleavage Assay; TUNEL staining; and
Annexin staining.
[0068] In some aspects, the agents for isolating CSCs are antibody
or antigen-binding fragments. The antibodies and antigen binding
fragments of the invention include monoclonal antibodies,
polyclonal antibodies, human antibodies, chimeric antibodies,
humanized antibodies, single-chain antibodies, F(ab').sub.2, Fab,
Fd, Fv, or single-chain Fv fragments.
[0069] Other aspects of the invention relate to treatment methods.
In some embodiments, the methods involve modulating, e.g., inducing
or inhibiting, the activity of CSC-associated genes (RNA or
protein) and, thereby, inhibiting the growth and survival of cancer
stem cells. In some embodiments, the treatment methods involve
selective delivery, e.g., by antibodies or antigen-binding
fragments, of therapeutic agents to cancer stem cells. The methods
are useful for inhibiting the proliferation and/or survival of
cancer stem cells and, therefore, are useful for treating cancer,
e.g., melanoma. The level of modulation, e.g., inducing or
inhibiting, of the activity of a CSC-associated gene that is
sufficient to affect the growth and/or survival of a cancer stem
cell compared with a control level depends on a variety of factors,
including the particular CSC-associated gene being modulated, the
cancer stem cell within which the modulation occurs, and the level
of expression in the control sample. It is well within the purview
of the skilled artisan to determine the appropriate level of
modulation that is sufficient to sufficient to inhibit the growth
and/or survival of a cancer stem cell.
[0070] The term "inhibiting" refers to any decrease in expression
level or activity. As used herein, "inhibit", "suppress", or
"reduce" may, or may not, be complete. For example, cell
proliferation, may, or may not, be decreased to a state of complete
arrest for an effect to be considered one of suppression,
inhibition or reduction of cell proliferation. Moreover,
"suppress", "inhibit", or "reduce" may comprise the maintenance of
an existing state and the process of effecting a change in state.
For example, inhibition of cell proliferation may refer to the
prevention of proliferation of a non-proliferating cell
(maintenance of a non-proliferating state) and the process of
inhibiting the proliferation of a proliferating cell (process of
affecting a proliferation state change). Similarly, inhibition of
cell survival may refer to killing of a cell, or cells, such as by
necrosis or apoptosis, and the process of rendering a cell
susceptible to death, such as by inhibiting the expression or
activity of an anti-apoptotic regulatory factor. The suppression,
inhibition, or reduction may be at least about 5%, 10%, 15%, 20%,
25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,
90%, 95%, 99% of control level (e.g., an untreated state). In some
cases, the level of modulation (e.g., suppression, inhibition, or
reduction) compared with a control level is statistically
significant. "Statistically signficant" is a term well known in the
art and, for example, may refer to a p-value of less than 0.05,
e.g., a p-value of less than 0.025 or a p-value of less than 0.01,
using an appropriate statistical test (e.g., ANOVA, MANOVA, t-test,
multiple comparison test, etc.).
[0071] The methods involve treating an individual having, or at
risk of having, cancer. As used herein an "individual at risk of
having cancer" is an individual, e.g., a human, with an increased
likelihood of having cancer compared with a control population,
e.g., a general population. Any one of a number of risk factors
known in the art may be evaluated to determine whether or not an
individual is at risk of having cancer. For example, factors that
render an individual at risk of having melanoma include, for
example, UV exposure, family history of melanoma, personal history
of melanoma, fair skin, freckles, high numbers of nevi (moles),
light hair, age, gender, and Xeroderma pigmento sum.
[0072] The treatment methods disclosed herein may involve
administering a therapeutically effective amount of a composition
that induces the expression of a CSC-associated gene which is
downregulated in cancer (e.g., a gene in Table 2 or 7). In some
instances, the composition that induces expression of a
CSC-associated gene comprises a vector, such as an isolated
plasmid, that expresses the CSC-associated gene.
[0073] As used herein, a "vector" may be any of a number of nucleic
acid molecules into which a desired sequence may be inserted by
restriction and ligation for transport between different genetic
environments or for expression in a host cell. Vectors are
typically composed of DNA although RNA vectors are also available.
Vectors include, but are not limited to, plasmids, phagemids and
virus genomes or portions thereof.
[0074] An expression vector is one into which a desired sequence
may be inserted, e.g., by restriction and ligation such that it is
operably joined to regulatory sequences and may be expressed as an
RNA transcript. Vectors may further contain one or more marker
sequences suitable for use in the identification of cells that have
or have not been transformed or transfected with the vector.
Markers include, for example, genes encoding proteins that increase
or decrease either resistance or sensitivity to antibiotics or
other compounds, genes that encode enzymes whose activities are
detectable by standard assays known in the art (e.g.,
.beta.-galactosidase or alkaline phosphatase), and genes that
visibly affect the phenotype of transformed or transfected cells,
hosts, colonies or plaques (e.g., green fluorescent protein).
[0075] Methods for identifying and obtaining coding sequences for
use in the methods disclosed herein are routine in the art. For
example, the skilled artisan may search Entrez Gene database using
a GeneID or GeneAlias of a CSC-associated gene, e.g., a GeneID
listed in Table 5, 7 or 8, to identify transcripts associated with
CSC-associated genes. In most cases, links to commercial suppliers
(e.g., Open Biosystems) of cDNA's containing the transcripts are
provided in the Entrez Gene webinterface, which can be utilized to
procure a copy cDNA clone. In other cases, commerical sources
(e.g., Sigma Aldrich) can be contacted directly.
[0076] As used herein, a coding sequence and regulatory sequences
are said to be "operably" joined when they are covalently linked in
such a way as to place the expression or transcription of the
coding sequence under the influence or control of the regulatory
sequences. If it is desired that the coding sequences be translated
into a functional protein, two DNA sequences are said to be
operably joined if induction of a promoter in the 5' regulatory
sequences results in the transcription of the coding sequence and
if the nature of the linkage between the two DNA sequences does not
(1) result in the introduction of a frame-shift mutation, (2)
interfere with the ability of the promoter region to direct the
transcription of the coding sequences, or (3) interfere with the
ability of the corresponding RNA transcript to be translated into a
protein. Thus, a promoter region would be operably joined to a
coding sequence if the promoter region were capable of effecting
transcription of that DNA sequence such that the resulting
transcript might be translated into the desired protein or
polypeptide. It will be appreciated that a coding sequence need not
encode a protein but may instead, for example, encode a functional
RNA such as an shRNA.
[0077] The precise nature of the regulatory sequences needed for
gene expression may vary between species or cell types, but shall
in general include, as necessary, 5' non-transcribed and 5'
non-translated sequences involved with the initiation of
transcription and translation respectively, such as a TATA box,
capping sequence, CAAT sequence, and the like. Such 5'
non-transcribed regulatory sequences will include a promoter region
that includes a promoter sequence for transcriptional control of
the operably joined gene. Regulatory sequences may also include
enhancer sequences or upstream activator sequences as desired. The
vectors of the invention may optionally include 5' leader or signal
sequences. The choice and design of an appropriate vector is within
the ability and discretion of one of ordinary skill in the art. One
of skill in the art will be aware of appropriate regulatory
sequences for expression of interfering RNA, e.g., shRNA, miRNA,
etc.
[0078] In some embodiments, a virus vector for delivering a nucleic
acid molecule, an isolated plasmid, is selected from the group
consisting of adenoviruses, adeno-associated viruses, poxviruses
including vaccinia viruses and attenuated poxviruses, Semliki
Forest virus, Venezuelan equine encephalitis virus, retroviruses,
Sindbis virus, and Ty virus-like particle. Examples of viruses and
virus-like particles which have been used to deliver exogenous
nucleic acids include: replication-defective adenoviruses (e.g.,
Xiang et al., Virology 219:220-227, 1996; Eloit et al., J. Virol.
7:5375-5381, 1997; Chengalvala et al., Vaccine 15:335-339, 1997), a
modified retrovirus (Townsend et al., J. Virol. 71:3365-3374,
1997), a nonreplicating retrovirus (Irwin et al., J. Virol.
68:5036-5044, 1994), a replication defective Semliki Forest virus
(Zhao et al., Proc. Natl. Acad. Sci. USA 92:3009-3013, 1995),
canarypox virus and highly attenuated vaccinia virus derivative
(Paoletti, Proc. Natl. Acad. Sci. USA 93:11349-11353, 1996),
non-replicative vaccinia virus (Moss, Proc. Natl. Acad. Sci. USA
93:11341-11348, 1996), replicative vaccinia virus (Moss, Dev. Biol.
Stand. 82:55-63, 1994), Venzuelan equine encephalitis virus (Davis
et al., J. Virol. 70:3781-3787, 1996), Sindbis virus (Pugachev et
al., Virology 212:587-594, 1995), lentiviral vectors (Naldini L, et
al., Proc Natl Acad Sci USA. 1996 Oct. 15; 93(21):11382-8) and Ty
virus-like particle (Allsopp et al., Eur. J. Immunol 26:1951-1959,
1996).
[0079] Another virus useful for certain applications is the
adeno-associated virus, a double-stranded DNA virus. The
adeno-associated virus is capable of infecting a wide range of cell
types and species and can be engineered to be
replication-deficient. It further has advantages, such as heat and
lipid solvent stability, high transduction frequencies in cells of
diverse lineages, including hematopoietic cells, and lack of
superinfection inhibition thus allowing multiple series of
transductions. The adeno-associated virus can integrate into human
cellular DNA in a site-specific manner, thereby minimizing the
possibility of insertional mutagenesis and variability of inserted
gene expression. In addition, wild-type adeno-associated virus
infections have been followed in tissue culture for greater than
100 passages in the absence of selective pressure, implying that
the adeno-associated virus genomic integration is a relatively
stable event. The adeno-associated virus can also function in an
extrachromosomal fashion.
[0080] Other useful viral vectors are based on non-cytopathic
eukaryotic viruses in which non-essential genes have been replaced
with the gene of interest. Non-cytopathic viruses include certain
retroviruses, the life cycle of which involves reverse
transcription of genomic viral RNA into DNA with subsequent
proviral integration into host cellular DNA. In general, the
retroviruses are replication-deficient (i.e., capable of directing
synthesis of the desired transcripts, but incapable of
manufacturing an infectious particle). Such genetically altered
retroviral expression vectors have general utility for the
high-efficiency transduction of genes in vivo. Standard protocols
for producing replication-deficient retroviruses (including the
steps of incorporation of exogenous genetic material into a
plasmid, transfection of a packaging cell lined with plasmid,
production of recombinant retroviruses by the packaging cell line,
collection of viral particles from tissue culture media, and
infection of the target cells with viral particles) are provided in
Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual,"
W.H. Freeman Co., New York (1990) and Murry, E. J. Ed. "Methods in
Molecular Biology," vol. 7, Humana Press, Inc., Clifton, N.J.
(1991).
[0081] In some embodiments, isolated plasmid vectors comprises a
tumor-specific, e.g., melanoma-specific, e.g., a tyrosinase
promoter, operably linked to the CSC-associated gene (See, e.g.,
Lillehammer, T. et al., Cancer Gene Therapy (2005) 12, 864-872).
Other exemplary tumor-specific promoters are known in the art and
will be apparent to the skilled artisan.
[0082] The treatment methods may involve administering a
therapeutically effective amount of a composition that targets a
product of a CSC-associated gene (i.e., Table 1), which are
CSC-associated genes that upregulated in cancer stem cells. The
composition may target a product of a CSC-associated gene selected
from the group set forth in Table 4, which are upregulated in
cancer stem cells and are associated with the cell surface.
[0083] The product, e.g., mRNA or protein, of a CSC-associated gene
can be targeted by any one of a number of methods known in the art.
For example, the composition may comprise a gene knockdown reagent,
e.g., siRNA, that is complementary to a CSC-associated mRNA and
inhibits its expression. In other embodiments, the composition may
comprise an isolated molecule, e.g., antibody or antigen binding
fragment, that is conjugated to a siRNA and that specifically binds
to a CSC-associated polypeptide. Such antibody conjugated siRNAs
(or similar gene suppression agents) may target a CSC-associated
mRNA such as any of those encoded by the genes set forth in Table
1.
[0084] The CSC-associated gene may be selected from the following
group ANK2, NCKAP1L, PTPRE, PTPRS, SBF1, SCN3A, SGCA, SGCB,
SLC2A11, SLC2A8, SLC4A1, STX3, and TBC1D8 which are upregulated in
cancer stem cells and associated with the cell surface. The siRNA
may target another gene in the cell that is useful for inhibiting
the growth and/or survival of the cell, for example an oncogene.
For example, oncogenes that may be targeted include FOS, JUN MYB,
RAS, and ABU Other exemplary oncogenes are well known in the art
and several such examples are described in, for example. The
Genetic Basis of Human Cancer (Vogelstein, B. and Kinzler, K. W.
eds. McGraw-Hill, New York. N. Y., 1998). Other upregulated genes
include Epidermal growth factor (beta-urogastrone, HOMG4/URG);
Heparanase (HPA/HPR1); Jagged 1 (Alagille syndrome, AGS/AHD);
Platelet/endothelial cell adhesion molecule (CD31 antigen,
CD31/PECAM-1); Transforming growth factor, alpha (TFGA); and
Vascular endothelial growth factor C (Flt4-L/VRP). Homologues of
such genes can also be used.
[0085] Various strategies for gene knockdown known in the art can
be used to inhibit gene expression (e.g., expression of
CSC-associated genes). For example, gene knockdown strategies may
be used that make use of RNA interference (RNAi) and/or microRNA
(miRNA) pathways including small interfering RNA (siRNA), short
hairpin RNA (shRNA), double-stranded RNA (dsRNA), miRNAs, and other
small interfering nucleic acid-based molecules known in the art. In
one embodiment, vector-based RNAi modalities (e.g., shRNA or
shRNA-mir expression constructs) are used to reduce expression of a
gene (e.g., a CSC-associated) in a cell. In some embodiments,
therapeutic compositions of the invention comprise an isolated
plasmid vector (e.g., any isolated plasmid vector known in the art
or disclosed herein) that expresses a small interfering nucleic
acid such as an shRNA. The isolated plasmid may comprise a
tumor-specific, e.g., melanoma-specific, promoter operably linked
to a gene encoding the small interfering nucleic acid, e.g., an
shRNA. In some cases, the isolated plasmid vector is packaged in a
virus capable of infecting the individual. Exemplary viruses
include adenovirus, retrovirus, lentivirus, adeno-associated virus,
and others that are known in the art and disclosed herein.
[0086] A broad range of RNAi-based modalities could be employed to
inhibit expression of a gene in a cell, such as siRNA-based
oligonucleotides and/or altered siRNA-based oligonucleotides.
Altered siRNA based oligonucleotides are those modified to alter
potency, target affinity, safety profile and/or stability, for
example, to render them resistant or partially resistant to
intracellular degradation. Modifications, such as
phosphorothioates, for example, can be made to oligonucleotides to
increase resistance to nuclease degradation, binding affinity
and/or uptake. In addition, hydrophobization and bioconjugation
enhances siRNA delivery and targeting (De Paula et al., RNA.
13(4):431-56, 2007) and siRNAs with ribo-difluorotoluyl nucleotides
maintain gene silencing activity (Xia et al., ASC Chem. Biol.
1(3):176-83, (2006)). siRNAs with amide-linked oligoribonucleosides
have been generated that are more resistant to S1 nuclease
degradation than unmodified siRNAs (Iwase R et al. 2006 Nucleic
Acids Symp Ser 50: 175-176). In addition, modification of siRNAs at
the 2'-sugar position and phosphodiester linkage confers improved
serum stability without loss of efficacy (Choung et al., Biochem.
Biophys. Res. Commun. 342(3):919-26, 2006). Other molecules that
can be used to inhibit expression of a gene (e.g., a CSC-associated
gene) include sense and antisense nucleic acids (single or double
stranded), ribozymes, peptides, DNAzymes, peptide nucleic acids
(PNAs), triple helix forming oligonucleotides, antibodies, and
aptamers and modified form(s) thereof directed to sequences in
gene(s), RNA transcripts, or proteins. Antisense and ribozyme
suppression strategies have led to the reversal of a tumor
phenotype by reducing expression of a gene product or by cleaving a
mutant transcript at the site of the mutation (Carter and Lemoine
Br. J. Cancer. 67(5):869-76, 1993; Lange et al., Leukemia.
6(11):1786-94, 1993; Valera et al., J. Biol. Chem. 269(46):28543-6,
1994; Dosaka-Akita et al., Am. J. Clin. Pathol. 102(5):660-4, 1994;
Feng et al., Cancer Res. 55(10):2024-8, 1995; Quattrone et al.,
Cancer Res. 55(1):90-5, 1995; Lewin et al., Nat Med. 4(8):967-71,
1998). Ribozymes have also been proposed as a means of both
inhibiting gene expression of a mutant gene and of correcting the
mutant by targeted trans-splicing (Sullenger and Cech Nature
371(6498):619-22, 1994; Jones et al., Nat. Med. 2(6):643-8, 1996).
Ribozyme activity may be augmented by the use of, for example,
non-specific nucleic acid binding proteins or facilitator
oligonucleotides (Herschlag et al., Embo J. 13(12):2913-24, 1994;
Jankowsky and Schwenzer Nucleic Acids Res. 24(3):423-9, 1996).
Multitarget ribozymes (connected or shotgun) have been suggested as
a means of improving efficiency of ribozymes for gene suppression
(Ohkawa et al., Nucleic Acids Symp Ser. (29):121-2, 1993).
[0087] Triple helix approaches have also been investigated for
sequence-specific gene suppression. Triple helix forming
oligonucleotides have been found in some cases to bind in a
sequence-specific manner (Postel et al., Proc. Natl. Acad. Sci.
U.S.A. 88(18):8227-31, 1991; Duval-Valentin et al., Proc. Natl.
Acad. Sci. U.S.A. 89(2):504-8, 1992; Hardenbol and Van Dyke Proc.
Natl. Acad. Sci. U.S.A. 93(7):2811-6, 1996; Porumb et al., Cancer
Res. 56(3):515-22, 1996). Similarly, peptide nucleic acids have
been shown to inhibit gene expression (Hanvey et al., Antisense
Res. Dev. 1(4):307-17, 1991; Knudsen and Nielson Nucleic Acids Res.
24(3):494-500, 1996; Taylor et al., Arch. Surg. 132(11):1177-83,
1997). Minor-groove binding polyamides can bind in a
sequence-specific manner to DNA targets and hence may represent
useful small molecules for suppression at the DNA level (Trauger et
al., Chem. Biol. 3(5):369-77, 1996). In addition, suppression has
been obtained by interference at the protein level using dominant
negative mutant peptides and antibodies (Herskowitz Nature
329(6136):219-22, 1987; Rimsky et al., Nature 341(6241):453-6,
1989; Wright et al., Proc. Natl. Acad. Sci. U.S.A. 86(9):3199-203,
1989). In some cases suppression strategies have led to a reduction
in RNA levels without a concomitant reduction in proteins, whereas
in others, reductions in RNA have been mirrored by reductions in
protein. The diverse array of suppression strategies that can be
employed includes the use of DNA and/or RNA aptamers that can be
selected to target a protein of interest (e.g, a CSC-associated
polypeptide).
[0088] Methods of delivering a therapeutic agent to a cancer stem
cell are also provided. The methods involve a step of contacting a
cancer stem cell with an isolated molecule that selectively binds
to a cell surface polypeptide encoded by a CSC-associated gene,
such as those selected from the group set forth in Table 4. The
CSC-associated gene may be selected from the group consisting of:
ANK2, NCKAP1L, PTPRE, PTPRS, SBF1, SCN3A, SGCA, SGCB, SLC2A11,
SLC2A8, SLC4A1, STX3, and TBC1D8. The cancer stem cell may be in
vivo or in vitro. Isolated molecules that bind to CSC-associated
polypeptides on the surface of a cancer stem cell may be taken up
into an intracellular compartment of the cancer stem cell.
[0089] Cancer stem cells include stem cells of a colon carcinoma, a
pancreatic cancer, a breast cancer, an ovarian cancer, a prostate
cancer, a squamous cell carcinoma, a cervical cancer, a lung
carcinoma, a small cell lung carcinoma, a bladder carcinoma, a
squamous cell carcinoma, a basal cell carcinoma, an adenocarcinoma,
a sweat gland carcinoma, a sebaceous gland carcinoma, a papillary
carcinoma, a papillary adenocarcinoma, a cystadenocarcinoma, a
medullary carcinoma, a bronchogenic carcinoma, a renal cancer,
e.g., renal cell carcinoma, a hepatocellular carcinoma, a bile duct
carcinoma, a choriocarcinoma, a seminoma, a embryonal carcinoma, a
Wilms' tumor, or a testicular tumor. In specific embodiments, the
cancer stem cells are stem cells of melanoma. Cancer stem cells
include ABCB5.sup.+ cells and ABCB5.sup.- cells. Stem cells of
other cancers will be known to one of ordinary skill in the
art.
[0090] The treatment methods of the invention involve administering
compositions that comprise isolated molecules, or combinations of
different isolated molecules, that specifically bind to
CSC-associated polypeptides (polypeptides encoded by the
CSC-associated gene) to treat cancer, e.g., melanoma, in an
individual. When the CSC-associated polypeptide is associated with
the extracellular surface of a cell, e.g., a cancer stem cell,
e.g., a melanoma stem cell, the isolated molecule can bind the
CSC-associated polypeptide and, for example, serve as an vehicle
for specifically targeting therapeutic agents (therapeutic
molecules) to the cell. In some embodiments, isolated molecules
that binds to a CSC-associated polypeptide on the surface of a cell
are taken up into an intracellular compartment of the cell bind to
a secreted molecule, such as a growth factor that may assist the
tumor (such as those listed in Table 1.2). The isolated molecules
that interact with unregulated proteins may be used alone as
therapeutics or in combination with other therapeutics.
[0091] As used herein treatment of or treating cancer includes
preventing the development of a cancer, reducing the symptoms of a
cancer and/or inhibiting, slowing the growth of or preventing
further growth of an existing cancer. Treatment may include
amelioration, cure, and/or maintenance of a cure (i.e., prevention
or delay of relapse) of a disorder, e.g., cancer. Treatment after a
disorder has started aims to reduce, ameliorate or altogether
eliminate the disorder, and/or its associated symptoms, to prevent
it from becoming worse, to slow the rate of progression, or to
prevent the disorder from re-occurring once it has been initially
eliminated (i.e., to prevent a relapse).
[0092] Cancers include for instance a colon carcinoma, a pancreatic
cancer, a breast cancer, an ovarian cancer, a prostate cancer, a
squamous cell carcinoma, a cervical cancer, a lung carcinoma, a
small cell lung carcinoma, a bladder carcinoma, a squamous cell
carcinoma, a basal cell carcinoma, an adenocarcinoma, a sweat gland
carcinoma, a sebaceous gland carcinoma, a papillary carcinoma, a
papillary adenocarcinoma, a cystadenocarcinoma, a medullary
carcinoma, a bronchogenic carcinoma, a renal cell carcinoma, a
hepatocellular carcinoma, a bile duct carcinoma, a choriocarcinoma,
a seminoma, an embryonal carcinoma, a Wilms' tumor, or a testicular
tumor. In certain embodiments, the cancer is melanoma.
[0093] The invention, in some aspects, relates to an isolated
molecule that selectively binds to a polypeptide encoded by a
CSC-associated gene set forth in Table 4 and that is conjugated to
a therapeutic agent. In some instances, the CSC-associated gene is
selected from the group consisting of: ANK2, NCKAP1L, PTPRE, PTPRS,
SBF1, SCN3A, SGCA, SGCB, SLC2A11, SLC2A8, SLC4A1, STX3, and TBC1D8.
Compositions comprising the foregoing isolated molecules are also
disclosed.
[0094] As used herein an "isolated molecule" is a molecule such as
a polypeptide, nucleic acid, polysaccharide, drug, nucleoprotein,
lipoprotein, glycoprotein, steroid, and lipid that is isolated from
its natural environment or produced synthetically. In some
embodiments, the isolated molecule is a ligand of a CSC-associated
polypeptide. In other embodiments, the isolated molecule is an
antibody or antigen-binding fragment. As disclosed herein, antibody
or antigen-binding fragments include monoclonal antibodies,
polyclonal antibodies, human antibodies, chimeric antibodies,
humanized antibodies, single-chain antibodies, F(ab').sub.2, Fab,
Fd, Fv, or single-chain Fv fragments. In some embodiments, an
isolated molecule may have therapeutic utility alone and need not
be conjugated to a therapeutic agent. For example, an isolated
molecule may bind to a cell surface receptor that is a
CSC-associated polypeptide and function as an antagonist or
competitive inhibitor of the receptor (e.g., to inhibit a signaling
pathway).
[0095] In some embodiments, isolated molecules are conjugated to
therapeutic agents. As used herein, a "therapeutic agent" is a
molecule such as a polypeptide, nucleic acid, polysaccharide, drug,
nucleoprotein, lipoprotein, glycoprotein, steroid, and lipid that
is capable of altering the state of a cell (e.g., killing a cell,
inhibiting growth of a cell) for therapeutic purposes. A
therapeutic agent may be, for instance, a toxin, a
small-interfering nucleic acid, or a chemotherapeutic agent.
Alternatively the therapeutic may be administered in conjunction
with the molecule. In conjunction refers to delivery to the same
subject. The actual administration may be at the same or a
different time or in the same or a different delivery vehicle.
[0096] Toxins include for example, radioisotopes such as
.sup.225Ac, .sup.211At, .sup.212Bi, .sup.213Bi, .sup.186Rh,
.sup.188Rh, .sup.177Lu, .sup.90Y, .sup.131I, .sup.67Cu, .sup.125I,
.sup.123I, .sup.77Br, .sup.153Sm, .sup.166Bo, .sup.64Cu,
.sup.212Pb, .sup.224Ra and .sup.223Ra, and others known in the art.
Suitable chemical toxins include members of the enediyne family of
molecules, such as calicheamicin and esperamicin as well as
poisonous lectins, plant toxins such as ricin, abrin, modeccin,
botulina and diphtheria toxins. Of course, combinations of the
various toxins could also be coupled to one isolated molecule,
e.g., an antibody, thereby accommodating variable cytotoxicity. The
coupling of one or more toxin molecules to the isolated molecule,
e.g., antibody, is envisioned to include many chemical mechanisms,
for instance covalent binding, affinity binding, intercalation,
coordinate binding, and complexation.
[0097] Chemotherapeutic agents include the following compounds or
classes of compounds: Acivicin; Aclarubicin; Acodazole
Hydrochloride; Acronine; Adozelesin; Adriamycin; Aldesleukin;
Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide;
Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin;
Azacitidine; Azetepa; Azotomycin; Batimastat; Buniodepa;
Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate;
Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine;
Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer;
Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin;
Cedefingol; Chlorombucil; Cirolemycin; Cisplatin; Cladribine;
Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; DACA
(N-[2-(Dimethyl-amino)ethyl]acridine-4-carboxamide); Dactinomycin;
Daunorubicin Hydrochloride; Daunomycin; Decitabine; Dexormaplatin;
Dezaguanine; Dezaguanine Ifesylate; Diaziquone; Docetaxel;
Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene
Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate;
Eflornithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate;
Epipropidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin
Hydrochloride; Estramustine; Estramustine Phosphate Sodium;
Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate;
Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide;
Floxuridine; Fludarabine Phosphate; Fluorouracil; 5-FdUMP;
Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine;
Gemcitabine Hydrochloride; Gold Au 198; Hydroxyurea; Idarubicin
Hydrochloride; Ifosfamide; Ilmofosine; Interferon Alfa-2a;
Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3;
Interferon Beta-1a; Interferon Gamma-1b; Iproplatin; Irinotecan
Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate;
Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone
Hydrochloride; Masoprocol; Maytansine; Mechlorethamine
Hydrochloride; Megestrol Acetate; Melengestrol Acetate; Melphalan;
Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium;
Metoprine; Meturedepa; Mitindomide; Mitocarcin; Mitocromin;
Mitogillin; Mitomalcin; Mitomycin, Mitosper; Mitotane; Mitoxantrone
Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin;
Ormaplatin; Oxisuran; Paclitaxel Pegaspargase; Peliomycin;
Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman;
Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane;
Porfimer Sodium; Porfiromycin; Prednimustine; Procarbazine
Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin;
Riboprine; Rogletimide; Safingol; Safingol Hydrochloride;
Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin;
Spirogermanium Hydrochloride; Spiromustine; Spiroplatin;
Streptonigrin; Streptozocin; Strontium Chloride Sr 89; Sulofenur;
Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur;
Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxirone;
Testolactone; Thiamiprine; Thioguanine; Thiotepa; Thymitaq;
Tiazofurin; Tirapazamine; Tomudex; TOP-53; Topotecan Hydrochloride;
Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate;
Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole
Hydrochloride; Uracil Mustard; Uredepa; Vapreotide; Verteporfin;
Vinblastine; Vinblastine Sulfate; Vincristine; Vincristine Sulfate,
Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate
Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine
Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin;
Zorubicin Hydrochloride; 2-Chlorodeoxyadenosine; 2'-Deoxyformycin;
9-aminocamptothecin; raltitrexed; N-propargyl-5, 8-dideazafolic
acid, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine;
2-chloro-2'-deoxyadenosine; anisomycin; trichostatin A; hPRL-G129R;
CEP-751; linomide; Piritrexim Isethionate; Sitogluside; Tamsulosin
Hydrochloride and Pentomone.
[0098] The invention, in some aspects, provides kits comprising one
or more containers housing one or more of the compositions of the
invention. The kit may be designed to facilitate use of the methods
described herein by researchers and can take many forms. Each of
the compositions of the kit, where applicable, may be provided in
liquid form (e.g., in solution), or in solid form, (e.g., a dry
powder). In certain cases, some of the compositions may be
constitutable or otherwise processable (e.g., to an active form),
for example, by the addition of a suitable solvent or other species
(for example, water or a cell culture medium), which may or may not
be provided with the kit. The kits may also include reference
samples. As used herein, "instructions" can define a component of
instruction and/or promotion, and typically involve written
instructions on or associated with packaging of the invention.
Instructions also can include any oral or electronic instructions
provided in any manner such that a user will clearly recognize that
the instructions are to be associated with the kit, for example,
audiovisual (e.g., videotape, DVD, etc.), Internet, and/or
web-based communications, etc. The written instructions may be in a
form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceuticals or biological products,
which instructions can also reflects approval by the agency of
manufacture, use or sale for animal administration.
[0099] The kit may contain any one or more of the components
described herein in one or more containers. As an example, in one
embodiment, the kit may include instructions for mixing one or more
components of the kit and/or isolating and mixing a sample and
applying to a individual. The kit may include a container housing
agents described herein. The agents may be in the form of a liquid,
gel or solid (powder). The agents may be prepared sterilely,
packaged in syringe and shipped refrigerated. Alternatively it may
be housed in a vial or other container for storage. A second
container may have other agents prepared sterilely. Alternatively
the kit may include the active agents premixed and shipped in a
syringe, vial, tube, or other container. The kit may have one or
more or all of the components required to administer the agents to
an animal, such as a syringe, topical application devices, or iv
needle tubing and bag, particularly in the case of the kits for
treating individuals with cancer.
[0100] The compositions and therapeutic agents may be administered
simultaneously or sequentially. When the other therapeutic agents
are administered simultaneously they can be administered in the
same or separate formulations, but are administered at the same
time. The other therapeutic agents are administered sequentially
with one another and with the modulators, when the administration
of the other therapeutic agents and the modulators is temporally
separated. The separation in time between the administration of
these compounds may be a matter of minutes or it may be longer.
[0101] The compositions of the present invention preferably contain
a pharmaceutically acceptable carrier or excipient suitable for
rendering the compound or mixture administrable orally as a tablet,
capsule or pill, or parenterally, intravenously, intradermally,
intramuscularly or subcutaneously, or transdermally. The active
ingredients may be admixed or compounded with any conventional,
pharmaceutically acceptable carrier or excipient. The compositions
may be sterile.
[0102] As used herein, the term "pharmaceutically acceptable
carrier" includes any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic agents, absorption
delaying agents, and the like. The use of such media and agents for
pharmaceutically active substances is well known in the art. Except
insofar as any conventional media or agent is incompatible with the
compositions of this invention, its use in the therapeutic
formulation is contemplated. Supplementary active ingredients can
also be incorporated into the pharmaceutical formulations. A
composition is said to be a "pharmaceutically acceptable carrier"
if its administration can be tolerated by a recipient patient.
Sterile phosphate-buffered saline is one example of a
pharmaceutically acceptable carrier. Other suitable carriers are
well-known in the art.
[0103] It will be understood by those skilled in the art that any
mode of administration, vehicle or carrier conventionally employed
and which is inert with respect to the active agent may be utilized
for preparing and administering the pharmaceutical compositions of
the present invention. Illustrative of such methods, vehicles and
carriers are those described, for example, in Remington's
Pharmaceutical Sciences, 18th ed. (1990), the disclosure of which
is incorporated herein by reference. Those skilled in the art,
having been exposed to the principles of the invention, will
experience no difficulty in determining suitable and appropriate
vehicles, excipients and carriers or in compounding the active
ingredients therewith to form the pharmaceutical compositions of
the invention.
[0104] An effective amount, also referred to as a therapeutically
effective amount is an amount sufficient to ameliorate at least one
adverse effect associated with expression, or reduced expression,
of a CSC-associated gene in a cell or in an individual in need of
such inhibition or supplementation. The therapeutically effective
amount to be included in pharmaceutical compositions depends, in
each case, upon several factors, e.g., the type, size and condition
of the patient to be treated, the intended mode of administration,
the capacity of the patient to incorporate the intended dosage
form, etc. Generally, an amount of active agent is included in each
dosage form to provide from about 0.1 to about 250 mg/kg, and
preferably from about 0.1 to about 100 mg/kg. One of ordinary skill
in the art would be able to determine empirically an appropriate
therapeutically effective amount.
[0105] Combined with the teachings provided herein, by choosing
among the various active compounds and weighing factors such as
potency, relative bioavailability, patient body weight, severity of
adverse side-effects and preferred mode of administration, an
effective prophylactic or therapeutic treatment regimen can be
planned which does not cause substantial toxicity and yet is
entirely effective to treat the particular individual. The
effective amount for any particular application can vary depending
on such factors as the disease or condition being treated, the
particular therapeutic agent being administered, the size of the
individual, or the severity of the disease or condition. One of
ordinary skill in the art can empirically determine the effective
amount of a particular nucleic acid and/or other therapeutic agent
without necessitating undue experimentation.
[0106] The pharmaceutical compositions can be administered by any
suitable route for administering medications. A variety of
administration routes are available. The particular mode selected
will depend, of course, upon the particular agent or agents
selected, the particular condition being treated, and the dosage
required for therapeutic efficacy. The methods of this invention,
generally speaking, may be practiced using any mode of
administration that is medically acceptable, meaning any mode that
produces effective levels of an immune response without causing
clinically unacceptable adverse effects. Preferred modes of
administration are discussed herein. For use in therapy, an
effective amount of the nucleic acid and/or other therapeutic agent
can be administered to an individual by any mode that delivers the
agent to the desired surface, e.g., mucosal, systemic.
[0107] Administering the pharmaceutical composition of the present
invention may be accomplished by any means known to the skilled
artisan. Routes of administration include but are not limited to
oral, parenteral, intravenous, intramuscular, intraperitoneal,
intranasal, sublingual, intratracheal, inhalation, subcutaneous,
ocular, vaginal, and rectal. Systemic routes include oral and
parenteral. Several types of devices are regularly used for
administration by inhalation. These types of devices include
metered dose inhalers (MDI), breath-actuated MDI, dry powder
inhaler (DPI), spacer/holding chambers in combination with MDI, and
nebulizers.
[0108] In some cases, compounds of the invention are prepared in a
colloidal dispersion system. Colloidal dispersion systems include
lipid-based systems including oil-in-water emulsions, micelles,
mixed micelles, and liposomes. A preferred colloidal system of the
invention is a liposome. Liposomes are artificial membrane vessels
which are useful as a delivery vector in vivo or in vitro. It has
been shown that large unilamellar vesicles (LUVs), which range in
size from 0.2-4.0 .mu.m can encapsulate large macromolecules. RNA,
DNA and intact virions can be encapsulated within the aqueous
interior and be delivered to cells in a biologically active form.
Fraley et al. (1981) Trends Biochem Sci 6:77.
[0109] Liposomes may be targeted to a particular tissue by coupling
the liposome to a specific binding molecule such as one that binds
to a CSC-associated polypeptide. Binding molecules which may be
useful for targeting a liposome to, for example, a cancer stem cell
include, but are not limited to intact or fragments of molecules,
e.g., antibodies or antigen binding fragments, which interact with
CSC-associated polypeptides on the surface of cancer stem cells.
Such binding molecules may easily be identified by binding assays
well known to those of skill in the art.
[0110] Lipid formulations for transfection are commercially
available from QIAGEN, for example, as EFFECTENE.TM. (a
non-liposomal lipid with a special DNA condensing enhancer) and
SUPERFECT.TM. (a novel acting dendrimeric technology).
[0111] Liposomes are commercially available from Gibco BRL, for
example, as LIPOFECTIN.TM. and LIPOFECTACE.TM., which are formed of
cationic lipids such as N-[1-(2, 3 dioleyloxy)-propyl]-N, N,
N-trimethylammonium chloride (DOTMA) and dimethyl
dioctadecylammonium bromide (DDAB). Methods for making liposomes
are well known in the art and have been described in many
publications. Liposomes also have been reviewed by Gregoriadis G
(1985) Trends Biotechnol 3:235-241.
[0112] Certain cationic lipids, including in particular N-[1-(2, 3
dioleoyloxy)-propyl]-N,N,N-trimethylammonium methyl-sulfate
(DOTAP), appear to be especially advantageous when combined with
the modified oligonucleotide analogs of the invention.
[0113] In one embodiment, the vehicle is a biocompatible
microparticle or implant that is suitable for implantation or
administration to the mammalian recipient. Exemplary bioerodible
implants that are useful in accordance with this method are
described in PCT International application no. PCT/US/03307
(Publication No. WO95/24929, entitled "Polymeric Gene Delivery
System". PCT/US/0307 describes a biocompatible, preferably
biodegradable polymeric matrix for containing an exogenous gene
under the control of an appropriate promoter. The polymeric matrix
can be used to achieve sustained release of the therapeutic agent
in the individual.
[0114] The polymeric matrix preferably is in the form of a
microparticle such as a microsphere (e.g., wherein a therapeutic
agent is dispersed throughout a solid polymeric matrix) or a
microcapsule (e.g., wherein a therapeutic agent is stored in the
core of a polymeric shell). Other forms of the polymeric matrix for
containing the therapeutic agent include films, coatings, gels,
implants, and stents. The size and composition of the polymeric
matrix device is selected to result in favorable release kinetics
in the tissue into which the matrix is introduced. The size of the
polymeric matrix further is selected according to the method of
delivery which is to be used, typically injection into a tissue or
administration of a suspension by aerosol into the nasal and/or
pulmonary areas. Preferably when an aerosol route is used the
polymeric matrix and the therapeutic agent are encompassed in a
surfactant vehicle. The polymeric matrix composition can be
selected to have both favorable degradation rates and also to be
formed of a material which is bioadhesive, to further increase the
effectiveness of transfer when the matrix is administered to a
nasal and/or pulmonary surface that has sustained an injury. The
matrix composition also can be selected not to degrade, but rather,
to release by diffusion over an extended period of time.
Biocompatible microspheres that are suitable for delivery, such as
oral or mucosal delivery, are disclosed in Chickering et al. (1996)
Biotech Bioeng 52:96-101 and Mathiowitz E et al. (1997) Nature
386:410-414 and PCT Pat. Application WO97/03702.
[0115] Both non-biodegradable and biodegradable polymeric matrices
can be used to deliver the therapeutic agentsto an individual.
Biodegradable matrices are preferred. Such polymers may be natural
or synthetic polymers. The polymer is selected based on the period
of time over which release is desired, generally in the order of a
few hours to a year or longer. Typically, release over a period
ranging from between a few hours and three to twelve months is most
desirable, particularly for the nucleic acid agents. The polymer
optionally is in the form of a hydrogel that can absorb up to about
90% of its weight in water and further, optionally is cross-linked
with multi-valent ions or other polymers.
[0116] Bioadhesive polymers of particular interest include
bioerodible hydrogels described by H. S. Sawhney, C. P. Pathak and
J. A. Hubell in Macromolecules, (1993) 26:581-587, the teachings of
which are incorporated herein. These include polyhyaluronic acids,
casein, gelatin, glutin, polyanhydrides, polyacrylic acid,
alginate, chitosan, poly(methyl methacrylates), poly(ethyl
methacrylates), poly(butylmethacrylate), poly(isobutyl
methacrylate), poly(hexylmethacrylate), poly(isodecyl
methacrylate), poly(lauryl methacrylate), poly(phenyl
methacrylate), poly(methyl acrylate), poly(isopropyl acrylate),
poly(isobutyl acrylate), and poly(octadecyl acrylate).
[0117] If the therapeutic agent is a nucleic acid, the use of
compaction agents may also be desirable. Compaction agents also can
be used alone, or in combination with, a biological or
chemical/physical vector. A "compaction agent", as used herein,
refers to an agent, such as a histone, that neutralizes the
negative charges on the nucleic acid and thereby permits compaction
of the nucleic acid into a fine granule. Compaction of the nucleic
acid facilitates the uptake of the nucleic acid by the target cell.
The compaction agents can be used alone, i.e., to deliver a nucleic
acid in a form that is more efficiently taken up by the cell or,
more preferably, in combination with one or more of the
above-described vectors.
[0118] Other exemplary compositions that can be used to facilitate
uptake of a nucleic acid include calcium phosphate and other
chemical mediators of intracellular transport, microinjection
compositions, electroporation and homologous recombination
compositions (e.g., for integrating a nucleic acid into a
preselected location within the target cell chromosome).
[0119] The compounds may be administered alone (e.g., in saline or
buffer) or using any delivery vehicle known in the art. For
instance the following delivery vehicles have been described:
cochleates; Emulsomes; ISCOMs; liposomes; live bacterial vectors
(e.g., Salmonella, Escherichia coli, Bacillus Calmette-Guerin,
Shigella, Lactobacillus); live viral vectors (e.g., Vaccinia,
adenovirus, Herpes Simplex); microspheres; nucleic acid vaccines;
polymers (e.g. carboxymethylcellulose, chitosan); polymer rings;
proteosomes; sodium fluoride; transgenic plants; virosomes; and,
virus-like particles.
[0120] The formulations of the invention are administered in
pharmaceutically acceptable solutions, which may routinely contain
pharmaceutically acceptable concentrations of salt, buffering
agents, preservatives, compatible carriers, adjuvants, and
optionally other therapeutic ingredients.
[0121] The term pharmaceutically-acceptable carrier means one or
more compatible solid or liquid filler, diluents or encapsulating
substances which are suitable for administration to a human or
other vertebrate animal. The term carrier denotes an organic or
inorganic ingredient, natural or synthetic, with which the active
ingredient is combined to facilitate the application. The
components of the pharmaceutical compositions also are capable of
being commingled with the compounds of the present invention, and
with each other, in a manner such that there is no interaction
which would substantially impair the desired pharmaceutical
efficiency.
[0122] For oral administration, the compounds can be formulated
readily by combining the active compound(s) with pharmaceutically
acceptable carriers well known in the art. Such carriers enable the
compounds of the invention to be formulated as tablets, pills,
dragees, capsules, liquids, gels, syrups, slurries, suspensions and
the like, for oral ingestion by an individual to be treated.
Pharmaceutical preparations for oral use can be obtained as solid
excipient, optionally grinding a resulting mixture, and processing
the mixture of granules, after adding suitable auxiliaries, if
desired, to obtain tablets or dragee cores. Suitable excipients
are, in particular, fillers such as sugars, including lactose,
sucrose, mannitol, or sorbitol; cellulose preparations such as, for
example, maize starch, wheat starch, rice starch, potato starch,
gelatin, gum tragacanth, methyl cellulose,
hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose,
and/or polyvinylpyrrolidone (PVP). If desired, disintegrating
agents may be added, such as the cross-linked polyvinyl
pyrrolidone, agar, or alginic acid or a salt thereof such as sodium
alginate. Optionally the oral formulations may also be formulated
in saline or buffers for neutralizing internal acid conditions or
may be administered without any carriers.
[0123] Dragee cores are provided with suitable coatings. For this
purpose, concentrated sugar solutions may be used, which may
optionally contain gum arabic, talc, polyvinyl pyrrolidone,
carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer
solutions, and suitable organic solvents or solvent mixtures.
Dyestuffs or pigments may be added to the tablets or dragee
coatings for identification or to characterize different
combinations of active compound doses.
[0124] Pharmaceutical preparations which can be used orally include
push-fit capsules made of gelatin, as well as soft, sealed capsules
made of gelatin and a plasticizer, such as glycerol or sorbitol.
The push-fit capsules can contain the active ingredients in
admixture with filler such as lactose, binders such as starches,
and/or lubricants such as talc or magnesium stearate and,
optionally, stabilizers. In soft capsules, the active compounds may
be dissolved or suspended in suitable liquids, such as fatty oils,
liquid paraffin, or liquid polyethylene glycols. In addition,
stabilizers may be added. Microspheres formulated for oral
administration may also be used. Such microspheres have been well
defined in the art. All formulations for oral administration should
be in dosages suitable for such administration.
[0125] For buccal administration, the compositions may take the
form of tablets or lozenges formulated in conventional manner.
[0126] For administration by inhalation, the compounds for use
according to the present invention may be conveniently delivered in
the form of an aerosol spray presentation from pressurized packs or
a nebulizer, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In
the case of a pressurized aerosol the dosage unit may be determined
by providing a valve to deliver a metered amount. Capsules and
cartridges of e.g. gelatin for use in an inhaler or insufflator may
be formulated containing a powder mix of the compound and a
suitable powder base such as lactose or starch.
[0127] The compounds, when it is desirable to deliver them
systemically, may be formulated for parenteral administration by
injection, e.g., by bolus injection or continuous infusion.
Formulations for injection may be presented in unit dosage form,
e.g., in ampoules or in multi-dose containers, with an added
preservative. The compositions may take such forms as suspensions,
solutions or emulsions in oily or aqueous vehicles, and may contain
formulatory agents such as suspending, stabilizing and/or
dispersing agents.
[0128] Pharmaceutical formulations for parenteral administration
include aqueous solutions of the active compounds in water-soluble
form. Additionally, suspensions of the active compounds may be
prepared as appropriate oily injection suspensions. Suitable
lipophilic solvents or vehicles include fatty oils such as sesame
oil, or synthetic fatty acid esters, such as ethyl oleate or
triglycerides, or liposomes. Aqueous injection suspensions may
contain substances which increase the viscosity of the suspension,
such as sodium carboxymethyl cellulose, sorbitol, or dextran.
Optionally, the suspension may also contain suitable stabilizers or
agents which increase the solubility of the compounds to allow for
the preparation of highly concentrated solutions.
[0129] Alternatively, the active compounds may be in powder form
for constitution with a suitable vehicle, e.g., sterile
pyrogen-free water, before use.
[0130] The compounds may also be formulated in rectal or vaginal
compositions such as suppositories or retention enemas, e.g.,
containing conventional suppository bases such as cocoa butter or
other glycerides.
[0131] In addition to the formulations described previously, the
compounds may also be formulated as a depot preparation. Such
long-acting formulations may be formulated with suitable polymeric
or hydrophobic materials (for example as an emulsion in an
acceptable oil) or ion exchange resins, or as sparingly soluble
derivatives, for example, as a sparingly soluble salt.
[0132] The pharmaceutical compositions also may comprise suitable
solid or gel phase carriers or excipients. Examples of such
carriers or excipients include but are not limited to calcium
carbonate, calcium phosphate, various sugars, starches, cellulose
derivatives, gelatin, and polymers such as polyethylene
glycols.
[0133] Suitable liquid or solid pharmaceutical preparation forms
are, for example, aqueous or saline solutions for inhalation,
microencapsulated, encochleated, coated onto microscopic gold
particles, contained in liposomes, nebulized, aerosols, pellets for
implantation into the skin, or dried onto a sharp object to be
scratched into the skin. The pharmaceutical compositions also
include granules, powders, tablets, coated tablets,
(micro)capsules, suppositories, syrups, emulsions, suspensions,
creams, drops or preparations with protracted release of active
compounds, in whose preparation excipients and additives and/or
auxiliaries such as disintegrants, binders, coating agents,
swelling agents, lubricants, flavorings, sweeteners or solubilizers
are customarily used as described above. The pharmaceutical
compositions are suitable for use in a variety of drug delivery
systems. For a brief review of methods for drug delivery, see
Langer R (1990) Science 249:1527-1533, which is incorporated herein
by reference.
[0134] The compounds may be administered per se (neat) or in the
form of a pharmaceutically acceptable salt. When used in medicine
the salts should be pharmaceutically acceptable, but
non-pharmaceutically acceptable salts may conveniently be used to
prepare pharmaceutically acceptable salts thereof. Such salts
include, but are not limited to, those prepared from the following
acids: hydrochloric, hydrobromic, sulphuric, nitric, phosphoric,
maleic, acetic, salicylic, p-toluene sulphonic, tartaric, citric,
methane sulphonic, formic, malonic, succinic,
naphthalene-2-sulphonic, and benzene sulphonic. Also, such salts
can be prepared as alkaline metal or alkaline earth salts, such as
sodium, potassium or calcium salts of the carboxylic acid
group.
[0135] Suitable buffering agents include: acetic acid and a salt
(1-2% w/v); citric acid and a salt (1-3% w/v); boric acid and a
salt (0.5-2.5% w/v); and phosphoric acid and a salt (0.8-2% w/v).
Suitable preservatives include benzalkonium chloride (0.003-0.03%
w/v); chlorobutanol (0.3-0.9% w/v); parabens (0.01-0.25% w/v) and
thimerosal (0.004-0.02% w/v).
[0136] The compositions may conveniently be presented in unit
dosage form and may be prepared by any of the methods well known in
the art of pharmacy. All methods include the step of bringing the
compounds into association with a carrier which constitutes one or
more accessory ingredients. In general, the compositions are
prepared by uniformly and intimately bringing the compounds into
association with a liquid carrier, a finely divided solid carrier,
or both, and then, if necessary, shaping the product. Liquid dose
units are vials or ampoules. Solid dose units are tablets, capsules
and suppositories.
[0137] Other delivery systems can include time-release, delayed
release or sustained release delivery systems. Such systems can
avoid repeated administrations of the compounds, increasing
convenience to the individual and the physician. Many types of
release delivery systems are available and known to those of
ordinary skill in the art. They include polymer base systems such
as poly(lactide-glycolide), copolyoxalates, polycaprolactones,
polyesteramides, polyorthoesters, polyhydroxybutyric acid, and
polyanhydrides. Microcapsules of the foregoing polymers containing
drugs are described in, for example, U.S. Pat. No. 5,075,109.
Delivery systems also include non-polymer systems that are: lipids
including sterols such as cholesterol, cholesterol esters and fatty
acids or neutral fats such as mono-, di-, and tri-glycerides;
hydrogel release systems; silastic systems; peptide-based systems;
wax coatings; compressed tablets using conventional binders and
excipients; partially fused implants; and the like. Specific
examples include, but are not limited to: (a) erosional systems in
which an agent of the invention is contained in a form within a
matrix such as those described in U.S. Pat. Nos. 4,452,775,
4,675,189, and 5,736,152, and (b) diffusional systems in which an
active component permeates at a controlled rate from a polymer such
as described in U.S. Pat. Nos. 3,854,480, 5,133,974 and 5,407,686.
In addition, pump-based hardware delivery systems can be used, some
of which are adapted for implantation.
EXAMPLES
[0138] Among the numerous CSC-associated genes are genes involved
in vasculogenesis and angiogenesis. For example, global gene
expression analyses validated by mRNA and protein determinations
revealed preferential display of genes for vascular endothelial
growth factor receptor-1 (VEGFR-1) and related members of signaling
cascades involved in vasculogenesis and angiogenesis in ABCB5.sup.+
MMIC. In vitro, vascular endothelial growth factor (VEGF) induced
expression of the endothelial-associated marker CD144 (VE-cadherin)
in VEGFR-1-expressing ABCB5.sup.+ MMIC but not VEGFR-1-negative
ABCB5.sup.- melanoma bulk populations, indicating a unique capacity
of CSC for VEGF/VEGFR-1 signaling-dependent vasculogenic
differentiation. In vivo, tumors initiated from patient-derived
melanoma cells or established melanoma cultures by
xenotransplantation into the murine subcutis or by intradermal
injection into human skin in chimeric murine recipients formed
perfused ABCB5 mRNA- and protein-expressing vessel-like channels
also detected in clinical melanoma specimens that co-expressed
CD144 and the vasculogenic mimicry marker TIE-1.sup.4. Tumour
initiation in human skin by fluorescent transgene-expressing human
melanoma cells confirmed CD144.sup.+ channels to be of melanoma
origin. Moreover, MMIC depletion in tumour grafts to human skin
significantly reduced channel formation and resulted in attenuated
tumour growth. Our results identify melanoma vasculogenesis driven
by ABCB5.sup.+ MMIC as a novel mechanism by which CSC may promote
tumor growth. Furthermore, they suggest that MMIC-dependent
vasculogenesis represents a novel CSC target for
VEGF/VEGFR-1-directed inhibitors of angiogenesis.
Example 1 Materials and Methods
[0139] Melanoma Cells and Culture Methods.
[0140] The established human cutaneous melanoma cell lines G3361,
A375, MALME-3M, SK-MEL-2, SK-MEL-5, SK-MEL-28, UACC-62, UACC-257,
M14 and MDA-MB-435 were cultured as described.sup.3,5,23. Clinical
cutaneous melanoma cells were derived from surgical specimen
according to human subjects research protocols approved by the IRBs
of the University of Wurzburg Medical School or the Wistar
Institute, Philadelphia, Pa. as described previously.sup.3. The
established human uveal melanoma cell lines MUM-2B and MUM-2C were
a gift of Dr. Mary J. Hendrix, Northwestern University, and were
cultured as described.sup.16.
[0141] Cell Isolation.
[0142] ABCB5.sup.+-purified (ABCB5.sup.+) cells were isolated by
positive selection and ABCB5.sup.+-depleted (ABCB5.sup.-) cell
populations were generated by removing ABCB5.sup.+ cells using
anti-ABCB5 mAb (clone 3C2-1D12.sup.23) labeling and magnetic bead
cell sorting as described.sup.3. Briefly, human G3361, A375, MUM-2B
or MUM-2C melanoma cells or single cell suspensions derived from
clinical melanoma samples were labeled with anti-ABCB5 mAb for 30
min at 4.degree. C., washed twice for excess antibody removal,
followed by incubation with secondary anti-mouse IgG mAb-coated
magnetic microbeads for 30 min at 4.degree. C. Subsequently, cells
were washed twice for excess magnetic microbead removal and then
sorted into ABCB5.sup.+ and ABCB5.sup.- cell fractions by
dual-passage cell separation in MidiMACS or MiniMACS separation
columns (depending on cell number) according to the manufacturer's
recommendations (Miltenyi Biotec, Auburn, Calif.). Assessment of
purity of ABCB5.sup.+ and ABCB5.sup.- (ABCB5.sup.+ cell-depleted)
melanoma cell isolates and determination of cell viability
following magnetic cell sorting were performed and yielded similar
results as described previously.sup.3.
[0143] Global Gene Expression Microarray Analyses.
[0144] Microarray analyses were performed on purified ABCB5.sup.+
(n=5) and ABCB5.sup.- (n=5) cell subsets derived from the
established human melanoma cell lines G3361 and A375 and from three
distinct clinical melanoma specimen previously characterized in our
laboratory with regards to ABCB5 expression and MMIC phenotype in
human melanoma xenotransplantation assays.sup.3. Total RNA was
extracted, processed and hybridized as described previously.sup.10
onto Affymetrix human HG-U133Plus2 GeneChip microarrays
(Affymetrix, Santa Clara, Calif.). Statistical analysis of
microarray results was performed as described previously.sup.10.
The expression data set in its entirety will be made available
through GEO (gene expression omnibus). Functional gene networks
were generated using Ingenuity Pathways Analysis (Ingenuity.RTM.
Systems, ingenuity.com), by mapping each gene identifier to its
corresponding gene object in the Ingenuity Pathways Knowledge Base.
These focus genes were overlaid onto a global molecular network
developed from information contained in the Ingenuity Pathways
Knowledge Base. Focus gene networks were then algorithmically
generated based on their connectivity and subsequently analyzed to
identify the biological functions that were most significant to the
genes in the network.
[0145] RNA Extraction and Reverse Transcriptase-PCR.
[0146] Total RNA was isolated from ABCB5.sup.+ and ABCB5.sup.-
human melanoma cells using RNeasy columns (QIAGEN, Valencia,
Calif.). Standard cDNA synthesis reactions were performed using 5
.mu.g RNA and the SuperScript First-Strand Synthesis System for
reverse transcriptase-PCR (Invitrogen, Carlsbad, Calif.) as per the
manufacturer's instructions. For PCR analysis, 5 .mu.l of diluted
first strand product (.about.100 ng of cDNA) was added to 45 .mu.l
of PCR reaction mixture containing 5 units of Superscript II
(Invitrogen) according to the manufacturer's protocol. The
following PCR program was performed: denaturation at 95.degree. C.
for 5 min, then cycled 35 times at 94.degree. C. for 1 min,
53.degree. C. for 30 s, and 72.degree. C. for 30 s, and
subsequently extended at 72.degree. C. for 10 min. The primer
sequences were as follows: PTK2 forward primer,
5'-TGCCTTTTACTTTCGTGTGG-3'(SEQ ID NO:1); PTK2 reverse primer
5'-CCAAATTCCTGTTTTGCTTCA-3'(SEQ ID NO:2); MET forward primer
5'-CCCCACCTTATCCTGACGTA-3'(SEQ ID NO:3); MET reverse primer
5'-CGTGTGTCCACCTCATCATC-3'(SEQ ID NO:4); NRP2 forward primer
5'-GAGGCAGGGGAAAATAGAGG-3'(SEQ ID NO:5); NRP2 reverse primer
5'-TCTCCCGAAAGGTTGAAATG-3'(SEQ ID NO:6); ETS1 forward primer
5'-CGCTTACTCTGTTGGGGTCT-3'(SEQ ID NO:7); ETS1 reverse primer
5'-TCTCCAGCAAAATGATGTGC-3'(SEQ ID NO:8); FLT1 forward primer
5'-TGGCAACTGCTTTTATGTTCTG-3'(SEQ ID NO:9); FLT1 reverse primer
5'-TCCATAGGGTGATGGTCAAA-3'(SEQ ID NO: 10). The reaction products
were resolved on a 1% LE agarose gel (Ambion, Austin, Tex.) and
photographed. .beta.-Actin primers were used as controls to ensure
RNA integrity.
[0147] RNA Extraction and Real Time Quantitative PCR.
[0148] Total RNA was isolated from unsegregated or sorted human
melanoma cells using the RT.sup.2 qPCR Grade RNA isolation kit
(SABiosciences, Frederick, Md.). Standard cDNA synthesis reactions
were performed using 1 .mu.g RNA and the RT.sup.2 First Strand Kit
for reverse transcriptase-PCR (SABiosciences) as per the
manufacturer's instructions. The reverse transcriptase product (1
.mu.l) was amplified by primer pairs specific for ABCB5.sup.5.
.beta.-actin was used as a normalizing control. The primers for
ABCB5 (Genebank accession no. AY234788) detection were
5'-GCTGAGGAATCCACCCAATCT-3' (forward) (SEQ ID NO:11) and
5'-AGCCTGAATGGCCTTTTGTG-3' (reverse) (SEQ ID NO:12). The primers
for .beta.-actin detection were 5'-CCTGGCACCCAGCACAAT-3' (SEQ ID
NO:13) (forward) and 5'-AGTACTCCGTGTGGATCGGC-3' (reverse) (SEQ ID
NO: 14). Samples were assayed using Sybergreen chemistry and
kinetic PCR (ABI 7300 Sequence Detector; Applied Biosystems, Foster
City, Calif.). Samples were amplified using the Sybergreen PCR
reagent kit (Applied Biosystems) according to the manufacturer's
protocol. Sense and antisense primers were used at a final
concentration of 10 nM. The cDNA samples were amplified under
following conditions: 50.degree. C. for 2 min and 95.degree. C. for
10 min, followed by 40 cycles of amplification at 94.degree. C. for
15 s and 60.degree. C. for 1 min. All samples were run in
triplicate. The relative amounts of transcripts were analyzed using
the 2(-Delta Delta C(T)) method as described previously.sup.3,5,10.
Statistical differences between mRNA expression levels were
determined using the nonparametric Mann-Whitney test. A two-sided P
value of P<0.05 was considered significant.
[0149] Western Analysis.
[0150] Total cell lysates were harvested from logarithmically
growing cultures of the human melanoma cell lines MALME-3M,
SK-MEL-2, SK-MEL-5, SK-MEL-28, UACC-62, UACC-257, M14, and
MDA-MB-435 and analyzed by 8% SDS-PAGE and Western assay to detect
relative levels of ABCB5 (mAb 3C2-1D12.sup.23) and alpha-tubulin
(mAb clone DM1A, Sigma-Aldrich, St. Louis, Mo.), using LI-COR
Odyssey IR imaging system densitometry.
[0151] Flow Cytometry.
[0152] G3361, A375, MUM-2B, or MUM-2C melanoma cells were analyzed
for surface ABCB5 expression by incubation with anti-ABCB5 mAb or
isotype control mAb for 30 min at 4.degree. C., followed by
counterstaining with FITC-conjugated goat anti-mouse Ig or with
APC-conjugated donkey anti-mouse IgG secondary Abs and single color
flow cytometry at the Fl1 (FITC) or F14 (APC) emission spectrum on
a Becton Dickinson FACScan as described.sup.3,5,23. Washing was
performed twice between each step. Analysis of coexpression of
ABCB5 with the VEGFR-1 surface marker in G3361 melanoma cells was
performed by dual-color flow cytometry as described.sup.3. Briefly,
melanoma cells were incubated for 30 min at 4.degree. C. with
anti-ABCB5 mAb or isotype control mAb, followed by counterstaining
with APC-conjugated donkey anti-mouse IgG secondary Ab as above.
Subsequently, cells were fixed at 4.degree. C. and then incubated
for 30 min at 4.degree. C. with PE-conjugated anti-VEGFR-1 mAb
(R&D Systems, Minneapolis, Minn.) or PE-conjugated isotype
control mAb (BD PharMingen, San Diego, Calif.). Dual color flow
cytometry was subsequently performed with acquisition of
fluorescence emission at the F14 (APC) and F12 (PE) spectra on a
Becton Dickinson FACScan. Washing was performed twice between each
step. Statistical differences between expression levels of markers
were determined using the nonparametric Mann-Whitney test. A
two-sided P value of P<0.05 was considered significant.
[0153] In Vitro Vasculogenic Differentiation and Tube Formation
Assays.
[0154] VEGF-dependent induction of CD144 expression and formation
of capillary-like tube structures by human G3361 melanoma cells was
assayed on growth factor reduced Matrigel, a basement membrane
matrix preparation (BD Biosciences, San Jose, Calif.). Growth
factor reduced Matrigel was added to eight-chamber polystyrene
vessel tissue culture-treated glass slides and allowed to
gelatinize for 20 min at 37.degree. C. Purified ABCB5.sup.+ or
ABCB5.sup.- or unsegregated human melanoma cells were seeded into
culture slide wells at densities of 5.times.10.sup.4 cells/cm.sup.2
in medium 199 containing 5% FCS.sup.11 in the presence or absence
of VEGF (100 ng/ml). After 48-hour incubation, cells were fixed
with 4% paraformaldehyde/PBS for 20 min at room temperature, and
after extensive washing with PBS the cells were blocked in 5%
donkey serum/0.01% Tween 20/PBS for 1 hr at room temperature. Cells
were then incubated with rabbit anti-CD144 polyclonal Ab (diluted
1:100; Bethyl Laboratories, Montgomery, Tex.) overnight at
4.degree. C. After extensive washing with 0.01% Tween 20/PBS, the
cells were incubated with goat anti-rabbit Texas red-conjugated
secondary Ab (diluted 1:250; Jackson ImmunoResearch Laboratories,
West Grove, Pa.) for 1 hr at room temperature. Following washing
with 1.times.PBS/0.01% Tween 20, cells were then mounted in
Vectashield (Vecta Laboratories, Burlingame, Calif.) supplemented
with 100 ng/ml DAPI to visualize nuclei. Cells were analyzed by
fluorescent microscopy using a Mercury-100 Watts fluorescent light
source (Microvideo Instruments, Avon, Mass.) attached to a Nikon
Eclipse TE 300 microscope (Nikon Instruments, Melville, N.Y.) with
the use of separate filters for each fluorochrome. The images were
obtained using a Spot digital camera (Diagnostic Instruments Inc.,
Sterling Heights, Mich.), and the Spot 3.3.2. software package was
imported into Adobe Photoshop (Adobe Systems, Mountain View,
Calif.). For tube formation assays, unsegregated human melanoma
cells were seeded into culture slide wells at densities of
5.times.10.sup.4 cells/cm.sup.2 in medium 199 containing 5%
FCS.sup.11. Immediately, cells were pretreated with medium alone,
rabbit anti-VEGFR1 Ab (10 .mu.g/ml; Santa Cruz Biotechnology, Santa
Cruz, Calif.) or rabbit isotype control Ab (10 .mu.g/ml; BD
Biosciences) at 37.degree. C. for 2 hrs prior to stimulation with
VEGF (100 ng/ml). Tube formation was detected by phase contrast
microscope (Nikon Eclipse TE 300 microscope) after 24 hrs of
incubation. For quantitative analysis of tube formation and length
and for determination of CD144 expression at 48 hrs, n=3 three
randomly selected microscopy fields were photographed per
experimental condition. Images were acquired as described above and
tube formation was analyzed using Image J software available from
the National Institutes of Health web site as described
previously.sup.24. For quantification of CD144 expression, positive
cells were counted using Neurolucida 8.10 software (MBF Bioscience,
Williston, Vt.). Differences among groups were analyzed by one-way
ANOVA followed by Bonferroni post hoc tests. Differences with P
values<0.05 were considered statistically significant.
[0155] In Vitro Adipogenic, Osteogenic and Myogenic Differentiation
Assays.
[0156] For adipogenic, osteogenic and myogenic differentiation
assays purified ABCB5.sup.+ and ABCB5.sup.- G3361 melanoma cells
were seeded in triplicate at 3.times.10.sup.3 cells/well in 96-well
culture plates. Adipogenic and osteogenic differentiation was
assessed using commercially available differentiation kits and Oil
Red O and Alizarin Red staining, respectively, according to the
manufacturer's instructions (Chemicon International, Temecula,
Calif.). Myogenic differentiation assays were performed as
described previously.sup.10. Briefly, melanoma subpopulations were
incubated in growth medium consisting of DMEM with 4% glucose, 20%
fetal bovine serum (vol/vol), 1% (vol/vol) penicillin-streptomycin
(10,000 UI/ml-10,000 .mu.g/ml, Invitrogen) for 10 days. The medium
was exchanged every 2 days. At day 14, cells were fixed in ice cold
methanol for 3 min on ice and incubated with 1:50 diluted
anti-myogenin mouse monoclonal Ab (Dako, Carpinteria, Calif.)
overnight at 4.degree. C. Plates were then washed, incubated with
goat anti-mouse FITC-conjugated secondary Ab (Jackson
ImmunoResearch Laboratories, diluted 1:100) and then mounted with
Vectashield mounting medium (Vector) supplemented with 100 ng/ml
DAPI to visualize nuclei. Slides were visualized with the 20.times.
and 40.times. objective on a Nikon Eclipse TE2000-S microscope,
photographed using the Spot 7.4 slider camera and images processed
using Spot software version 4.0.9. (Diagnostic Instruments,
Sterling Heights, Mich.). For quantification of differentiation
marker expression, positive cells were manually counted and
statistical differences between expression levels of markers were
determined using the nonparametric Mann-Whitney test. A two-sided P
value of P<0.05 was considered significant.
[0157] Immunohistochemistry and Immunofluorescence Double
Labeling.
[0158] The following primary Abs were used: rat anti-Laminin B2,
(Abcam, Cambridge, Mass.), rabbit anti-CD144, (Cell Signaling,
Beverly, Mass.), goat anti-Tie-1, (Neuromics, Edina, Minn.), and
mouse anti-ABCB5.sup.3,5,23. Isotype matched irrelevant Abs served
as negative control. The secondary Abs were horse anti-mouse
IgG-HRP, horse anti-goat IgG-HRP, goat anti-rabbit IgG-HRP (VECTOR
Laboratories, Burlingame, Calif.) and goat anti-rat IgG-HRP
(Biolegend, San Diego, Calif.), and donkey anti-mouse IgG-AF488,
donkey anti-rabbit IgG-AF594, and donkey anti-goat IgG-AF594
(Invitrogen, Carlsbad, Calif.). Immunohistochemistry was performed
using the 2-step horseradish peroxidase method. Briefly, frozen
tissue sections were fixed with -20.degree. C. acetone for 5 min,
then incubated with primary Ab at 4.degree. C. overnight. After
washing out unbound primary Ab with phosphate-buffered saline
(PBS), the tissue sections were incubated with secondary Ab at room
temperature for 30 min, then washed with PBS 3.times.5 min.
Immunoreactivity was detected using NovaRed peroxidase substrate
(VECTOR Laboratories, Burlingame, Calif.). For immunofluorescence
double labeling, the frozen tissue sections were fixed with
-20.degree. C. acetone for 5 min, then incubated with the mix of 2
primary Abs (for example ABCB5 Ab+CD144 Ab) at 40.degree. C.
overnight. After washing with PBS, the tissue sections were
incubated with the mix of 2 secondary Abs (for example donkey
anti-mouse IgG-AF488+ donkey anti-rabbit IgG-AF594) at room
temperature for 1 hour, then washed with PBS 3.times.5 min, and the
sections were then mounted with ProLong Gold antifade reagent with
DAPI (Invitrogen, Carlsbad, Calif.). The sections were viewed under
a Olympus BX51 System fluorescence microscope (Olympus Corporation,
Tokyo, Japan). For HLA-2A immunohistochemistry of SK-MEL-5 melanoma
xenografts to chimeric mouse/human skin, frozen sections were
incubated with 5 .mu.g/ml mouse anti-human HLA-2A Ab (BD
Pharmingen, San Jose, Calif.) at 4.degree. C. overnight. After
washing out unbound primary Ab with phosphate buffered saline
(PBS), sections were incubated with 1:200 peroxidase-conjugated
horse anti-mouse IgG Ab (Vector Laboratories, Burlingame, Calif.)
at room temperature for 30 min. Unbound secondary Ab was washed out
with PBS. Color was developed using the NovRed peroxidase substrate
kit (Vector Laboratories) and sections were counterstained with
hematoxylin Gill's No.1 (Fisher Scientific, Pittsburgh, Pa.).
[0159] In Situ Hybridization.
[0160] RNA probes were prepared as follows: PCR-derived RNA probe
templates were synthesized by introducing the T7 promoter into the
antisense strand and the SP6 promoter into the sense strand. The
primer pair, AB5T7AS
(5'-TAATACGACTCACTATAGGGATGTCTGGCTTTTTCCCTTCTTGAC-3') (SEQ ID
NO:15) and AB5SP6S
(5'-GATTTAGGTGACACTATAGAAATTCAAGCTGGACGAATGACCCCA-3') (SEQ ID
NO:16), was used to generate the DNA template for antisense and
sense RNA probes spanning 200 base pairs of human ABCB5 cDNA. This
sequence encodes ABCB5 amino acids 499-564 (GI:34539755). The
primer pair CD133T7AS
(5'-TAATACGACTCACTATAGGGAGCAGCCCCAGGACACAGCATA-3') (SEQ ID NO:17)
and CD133SP6S (5'-GATTTAGGTGACACTATAGAGACCCAAGACTCCCATAAAGC-3')
(SEQ ID NO:18) was used to generate the DNA template for antisense
and sense RNA probes spanning 200 base pairs of human CD133 cDNA,
wherein this sequence encodes CD133 amino acid 42-108 (GI:
5174386). The sequence specificities for ABCB5 and CD133 were
confirmed using the Genbank database BLAST program. The RNA probes
were labeled with digoxigenin (DIG) using the DIG RNA labeling kit
(Roche Applied Science, Indianapolis, Ind.). For in situ
hybridization, 8 .mu.M frozen tissue sections were baked at
50.degree. C. for 15 min, then fixed in 4% paraformaldehyde at room
temperature (RT) for 20 min. The sections were treated with 1
.mu.g/ml proteinase K/PBS at 37.degree. C. for 20 min and
inactivated proteinase K with 0.2% glucine/PBS at RT for 5 min.
Upon washes with PBS 2.times.2 min, the tissue sections were fixed
in 4% paraformadehyde at RT for 15 min, washed with PBS 2.times.5
min, and then treated with 0.25% acetic anhydride/0.1M
triethanolamine at RT for 10 min. The tissue sections were placed
in 2.times.SSC and then hybridized with 500 ng/ml antisense or
sense probe in hybridization buffer (0.3M NaCl, 10 mM Tris-HCl pH
7.6, 5 mM EDTA, 1 .times. Denharts, 50% formamide, 100 .mu.g/ml
tRNA and 10% dectran sulphate) at 42.degree. C. overnight. Post
hybridization sections were treated with 0.2.times.SSC at
55.degree. C. for 2.times.20 min, 20 .quadrature.g/ml RNaseA in
0.5M NaCl, 10 mM Tris-HCl pH 7.5 at 37.degree. C. for 30 min, and
0.2.times.SSC at 55.degree. C. for 20 min. The hybridized probes
were immunodetected using the DIG detection kit (Roche) and the
Tyramide Signal Amplification (TSA) kit (PerkinElmer, Boston,
Mass.) as follows: 1.times.DIG block buffer for 30 min, 1:100
anti-DIG Ab peroxidase conjugate at RT for 1 hour, 1.times.DIG wash
3.times.5 min, TSA reagent 10 min at RT, PBS 2.times.5 min, 1:100
streptavidin-horseradish peroxidase 30 min at RT, PBS 3.times.5
min. The labeling was visualized with NovaRed substrate (Vector
Laboratories).
[0161] Animals.
[0162] BALB/c nude mice and NOD/SCID mice were purchased from The
Jackson Laboratory (Bar Harbor, Me.). SCID mice (C.B-17) and BALB/c
Rag2.sup.-/- mice were purchased from Taconic (Germantown, N.Y.).
The animals were housed in autoclaved microisolator cages and were
fed sterilized food and water. Mice were maintained in accordance
with the institutional guidelines of Children's Hospital Boston and
Harvard Medical School and experiments were performed according to
approved experimental protocols.
[0163] Human to Mouse Melanoma Xenotransplantation and Human to
Chimeric Mouse/Human Skin Melanoma Xenotransplantation.
[0164] Human to mouse melanoma xenografts were established by
subcutaneous injection of human G3361, A375, SK-MEL-5 or clinical
patient-derived human melanoma cells in BALB/c nude or NOD/SCID
mice as described previously.sup.3. For human to chimeric
mouse/human skin melanoma xenotransplantation, single donor-derived
split human skin was obtained in accordance with the Partners
HealthCare Research Management Institutional Review Board by
cutting abdominal skin with a 0.016-inch gauge dermatome. Human
skin was subsequently xenografted onto immunodeficient Rag2.sup.-/-
mice as described previously.sup.13, under a protocol approved by
the institutional animal committee. Briefly, two circular graft
beds, each, 1.5 cm.sup.2 were prepared on bilateral dorsa of 4-8
week old Rag2.sup.-/- micetreated with antibiotics (1 tablet of
additional food per week containing Amoxicillin (3 mg), Flagyl
(0.69 mg) and Bismuth (0.185 mg)) to prevent Helicobacter pylorii
infection. Human donor skin was trimmed to conform to the bed and
held in place with staples until 10 days following surgery.
Unsegregated or ABCB5.sup.+-depleted A375, MUM-2B or MUM-2C
melanoma cells (2.times.10.sup.6 in 20 .mu.l PBS) were
intradermally microinjected into grafts after 6 weeks
stabilization. All skin grafts were harvested in their entirety 3
weeks after tumour cell inoculation, fixed in formalin, serially
sectioned and stained with H&E using standard methods for
histological analysis of tumour formation. Sections representing
maximum cross-sectional tumour area and thus best approximating the
size of the generally spherical to ovoid tumour nodules were
evaluated. Tumour volume (TV) was histologically determined and
calculated as described.sup.3. Statistically significant
differences in histological tumour formation were assessed using
the Fisher's Exact test. Differences in tumour volume were
statistically compared using the nonparametric Mann-Whitney Test,
with a two-sided P value of P<0.05 considered significant.
[0165] Stable Green Fluorescence Protein (GFP)-Transfected Melanoma
Xenografts to Human-SCID Chimeras.
[0166] Recombinant lentiviral vectors harboring GFP cDNA were
obtained from Dr. M. Herlyn at the Wistar Institute and used to
infect human A375 melanoma cells by lentiviral gene transfer. Two
days after infection, cells were selected with puromycin (1
.mu.g/ml) for a period of 7 days. Transgene expression was verified
by fluorescence microscopy and flow cytometry. Melanoma xenografts
were generated in human-SCID chimeras according to the protocol
previously described.sup.13. SCID mice (C.B-17) between 4-6 weeks
of age were purchased from Taconic (Germantown, N.Y.). Mice were
anesthetized and prepared for transplantation by shaving the hair
from a 2 cm.sup.2 area on the dorsal torso followed by removal of
full thickness skin down to the fascia. Full thickness human
foreskin grafts of the same size were placed onto the wound beds.
The skin grafts were then covered by Vaseline-saturated gauze and
secured with band aids and 3M sports tapes. After 10 days, the
dressings were removed and the mice allowed to recover for
approximately 4-5 weeks before melanoma inoculation. GFP-labeled
A375 melanoma cells were harvested and suspended in PBS at a
density of 10.sup.8 cells/ml. One hundred .mu.l each of cell
suspension were injected intradermally into the human skin grafts.
The tumour xenografts were then harvested in 3 weeks or when the
tumour reaches 1 cm.sup.3 in size, and processed for frozen
section. For double immunofluorescence, frozen sections (5 .mu.m
thick) of melanoma xenografts were fixed in 4% paraformaldehyde,
blocked with donkey serum, and incubated sequentially with
anti-CD144 (Cell Signaling, Danvers, Mass.), Texas red-conjugated
donkey anti-rabbit (Invitrogen, Carlsbad, Calif.), anti-GFP (Novus
Biologicals, Littleton, Colo.), and FITC-conjugated donkey
anti-goat Abs (Jackson ImmunoResearch, West Grove, Pa.). After
washing in PBS, the sections were coverslipped using an antiquench
mountant containing DAPI (VectaShield, Vector Laboratories,
Burlingame, Calif.). Irrelevant isotype-matched primary Abs were
included as controls.
Example 2
[0167] The mechanisms through which ABCB5.sup.+ MMIC or CSC in
other cancers trigger and promote neoplastic progression are
currently unknown. We hypothesized that ABCB5.sup.+ MMIC possess
vasculogenic differentiation plasticity and selectively drive
melanoma growth through a specific role in providing nutritional
support to growing tumours based on preferential co-expression in
vivo of the vasculogenic differentiation markers CD144
(VE-cadherin) and TIE-1.sup.3 by the ABCB5.sup.+ tumourigenic
minority population.
[0168] To further characterize the repertoire of genes
differentially expressed in MMIC compared to tumour bulk
populations, we first performed microarray analyses on purified
ABCB5.sup.+ (n=5) and ABCB5.sup.- (n=5) cell subsets derived from
the established human melanoma cell lines G3361 and A375 and from
three separate patient-derived melanoma specimens, all previously
characterized in our laboratory with regard to ABCB5 expression and
MMIC phenotype in human melanoma xenotransplantation assays.sup.3.
Using this approach.sup.10, 399 genes were identified that were
differentially expressed (P<0.05) between ABCB5.sup.+ MMIC and
ABCB5.sup.- melanoma bulk populations (Table 5), in addition to
ABCB5 shown overexpressed in ABCB5.sup.+ purified populations by
real-time PCR (P<0.05). One identified functional gene network,
validated by PCR-based gene expression analyses in ABCB5.sup.+
melanoma cell subsets, showed key molecules of vasculogenesis (the
ability to differentiate along endothelial lines), FLT1 (VEGFR-1)
and PTK2 (FAK), and of angiogenesis (the ability to induce ingrowth
and proliferation of mature stromal blood vessels), FLT1 (VEGFR-1),
PTK2 (FAK), MET (HGFR), NRP2, and ETS1, to be specifically
overexpressed in ABCB5.sup.+ MMIC (FIG. 1a,b).
[0169] Another set of genes differentially expressed in ABCB+
melanoma stem cells vs. ABCB5-melanoma bulk population cells was
identified using RT-PCR. The data is shown in Table 6. The
fold-expression levels are shown in the 7.sup.th column and can be
compared to the control values shown in the last few rows of the
table. A positive value indicates that the gene had higher
expression levels in ABCB5+ cells and a negative value indicates
that the gene had higher expression levels in ABCB5- cells. Some of
the genes exhibited a greater than 100-fold and some even greater
1000-fold increase in expression in ABCB5+ versus ABCB5- cells. The
highly expressed genes include factors that are likely secreted by
the stem cells which may act on cells in a tumor either in an
autocrine fashion on tumor stem cells, or in a paracrine fashion
also on bulk population cancer cells. Appropriate therapies can be
designed to treat cancers by inhibiting the expression or activity
of such factors.
[0170] Preferential expression of VEGFR-1 by ABCB5.sup.+ MMIC vs.
ABCB5.sup.- subpopulations was also demonstrated by dual-color flow
cytometry at the protein level (15.6.+-.5.3% vs. 4.4.+-.2.0% of
cells, respectively, mean.+-.s.e.m., n=6, P<0.05) (FIG. 1c). To
determine whether VEGF/VEGFR-1 interaction in MMIC influenced
expression of the vasculogenic differentiation marker CD144, we
evaluated functionally the effects of VEGF signaling in purified
ABCB5.sup.+ MMIC or ABCB5.sup.- melanoma subpopulations. VEGF (100
ng/ml.sup.11) selectively induced expression of CD144 at high
levels in VEGFR-1-expressing ABCB5.sup.+ but not VEGFR-1-negative
ABCB5.sup.- melanoma cells, to 36.2.+-.5.7% vs. 4.8.+-.2.7% of
cells (mean.+-.s.e.m., n=3), respectively (P<0.01) (FIG. 1d).
Preincubation with a blocking monoclonal antibody (mAb) to VEGFR-1
abrogated the ability of VEGF to induce CD144 expression in human
melanoma cells (0.0.+-.0.0% in VEGFR-1 mAb-treated vs. 64.+-.1% or
57.+-.3% in untreated or isotype control mAb-treated cultures,
respectively, mean.+-.s.e.m., n=3, P<0.01) (FIG. 1e). Moreover,
VEGFR-1 mAb strongly inhibited VEGF-induced multicellular
capillary-like tube formation by human melanoma cells in
established in vitro vasculogenic differentiation assays.sup.11,
with significantly reduced numbers of tubes formed/microscopy field
(6.7.+-.0.9 in VEGFR-1 mAb-treated vs. 99.0.+-.24.0 or 76.7.+-.3.3%
in untreated or isotype control mAb-treated cultures, respectively,
mean.+-.s.e.m., n=3, P<0.05), and significantly lower average
tube length (33.2.+-.4.5 .mu.m in VEGFR-1 mAb-treated vs.
92.1.+-.1.6 .mu.m or 86.5.+-.1.7 .mu.m in untreated or isotype
control mAb-treated cultures, respectively, mean.+-.s.e.m., n=3,
P<0.001) (FIG. 1f). In contrast, both ABCB5.sup.+ MMIC and
ABCB5.sup.- melanoma bulk population exhibited similar adipogenic
and osteogenic differentiation capacity previously detected in
human melanoma cells.sup.12 (adipogenesis: 100.0.+-.0.0% vs.
93.2.+-.6.9% of cells Oil Red-positive, respectively;
mean.+-.s.e.m., n=3, NS; osteogenesis: 90.8.+-.9.2% vs.
98.3.+-.1.7% of cells Alizarin Red-positive, respectively;
mean.+-.s.e.m., n=3, NS) (FIG. 1g,h), and neither ABCB5.sup.+ MMIC
nor ABCB5.sup.- melanoma bulk population exhibited capacity for
myogenic differentiation.sup.10 (0.0.+-.0.0% vs. 0.0.+-.0.0% of
cells myogenin-positive, respectively; mean.+-.s.e.m., n=3, NS)
(FIG. 1h). The selective in vitro vasculogenic differentiation
capacity of ABCB5.sup.+ MMIC in response to VEGF/VEGFR-1 signaling
indicated a potential role of this CSC subset in tumour
vasculogenesis.
TABLE-US-00006 TABLE 5 Differentially expressed genes between
ABCB5.sup.+ MMIC and ABCB5.sup.- melanoma bulk populations (P <
0.05). Molecules ID Fold Change AABHD7 239579_at 0.661 ACBD6
225317_at 0.83 AK3 224655_at 0.845 AKAP9 215483_at 2.168 AKR1CL2
1559982_s_at 1.732 AMZ2 227567_at 1.377 ANAPC5 235926_at 2.631 ANK2
202921_s_at 4.162 ANKH 229176_at 0.776 ANKRD28 241063_at 2.297
ANKRD44 226641_at 1.218 ANKRD52 228257_at 0.762 ANXA4 201302_at
0.83 AOC3 204894_s_at 1.894 APBB2 40148_at 1.139 ARS2 201679_at
1.307 ASCC3L1 214982_at 3.009 (includes EG:23020) ASPM 232238_at
1.411 ATAD2 235266_at 1.304 ATP5I 207335_x_at 0.737 ATXN2L
207798_s_at 1.656 BARD1 205345_at 1.559 BAT3 230513_at 0.697 BCL9L
227616_at 1.291 BDP1 224227_s_at 1.632 BLID 239672_at 1.91 BRI3
223376_s_at 0.792 BUB1 216277_at 1.856 (includes EG:699) BUB1
233445_at 3.209 (includes EG:699) C10ORF18 244165_at 2.046 C12ORF45
226349_at 0.688 C12ORF48 220060_s_at 1.216 C12ORF51 230216_at 2.874
C12ORF51 1557529_at 3.632 C14ORF135 1563259_at 1.353 C14ORF156
221434_s_at 0.867 C16ORF63 225087_at 0.872 C18ORF10 213617_s_at
0.754 C18ORF10 212055_at 0.737 C19ORF42 219097_x_at 0.813 C20ORF4
234654_at 1.731 C22ORF28 200042_at 0.829 C22ORF30 216555_at 1.521
C2ORF30 224630_at 0.851 C5ORF24 229098_s_at 1.531 C9ORF78 218116_at
0.789 C9ORF85 244160_at 1.52 CABIN1 1557581_x_at 3.052 CAMK2D
225019_at 0.823 CAMK2D 228555_at 0.758 CANX 238034_at 0.8 CAPZB
201949_x_at 0.764 CASC5 228323_at 1.144 CBS 240517_at 1.818 CCDC127
226515_at 0.835 CCDC14 240884_at 1.771 CCDC52 234995_at 1.166
CCDC57 214818_at 1.703 CCDC73 239848_at 1.294 CCDC93 219774_at
1.208 CDC14B 234605_at 2.512 CDC16 242359_at 6.261 CENPJ
234023_s_at 1.22 CENPJ 220885_s_at 1.64 CEP27 228744_at 0.651 CEP55
218542_at 1.096 CGGBP1 224600_at 0.913 CHD2 244443_at 1.757 CHD8
212571_at 1.27 CLN8 229958_at 1.344 CNIH3 232758_s_at 1.451 COBRA1
1556434_at 1.985 COIL 203653_s_at 1.259 COL4A2 211966_at 0.729 COQ4
218328_at 1.328 CPEB2 226939_at 1.251 CPNE3 202119_s_at 0.833 CREB1
204313_s_at 0.791 CREB3L2 237952_at 2.013 CRIPAK 228318_s_at 1.486
CROP 242389_at 2.121 CSE1L 201112_s_at 0.911 CSE1L 210766_s_at
0.885 CUL4A 232466_at 2.607 CYB5R3 1554574_a_at 0.793 DARS
201624_at 0.928 DCLRE1C 242927_at 1.187 DCUN1D2 240478_at 1.76
DDX17 213998_s_at 1.528 DDX52 212834_at 0.771 DEGS1 209250_at 0.804
DEPDC1 232278_s_at 1.119 DHX40 218277_s_at 0.812 DNAJC21 230893_at
0.829 DNM1L 236032_at 1.503 DTX3 49051_g_at 1.32 ECHDC1 233124_s_at
0.943 EIF2S1 201142_at 0.717 EIF2S1 201144_s_at 0.824 EIF4G3
201935_s_at 1.174 ELOVL2 213712_at 0.699 EMP2 225079_at 0.781 ENAH
222433_at 0.783 ENDOD1 212573_at 0.775 ENTPD5 231676_s_at 0.867
ERBB3 1563253_s_at 0.691 ERRFI1 224657_at 0.881 ETS1 241435_at
1.797 EWSR1 229966_at 1.686 EXT1 242126_at 2.116 FAM62C 239770_at
1.551 FAM98A 212333_at 0.767 FHL3 218818_at 0.546 FLJ10357
241627_x_at 2.31 FLJ31306 239432_at 1.753 FLT1 232809_s_at 1.861
FOXN3 218031_s_at 0.721 FUBP1 240307_at 2.087 GABARAPL2 209046_s_at
0.863 GABPA 243498_at 2.03 GALNT1 201722_s_at 0.926 GBF1 233114_at
2.03 GGT1 211417_x_at 1.555 GHITM 1554510_s_at 0.764 GMFB 202544_at
0.904 GNPDA1 202382_s_at 0.787 GOLGA8A 213650_at 2.289 GPD2
243598_at 2.13 GPR107 211979_at 0.843 GPR135 241085_at 1.851 HDAC3
240482_at 2.062 HEATR2 241352_at 0.784 HECW1 237295_at 11.843 HELLS
242890_at 1.359 HERC5 219863_at 1.156 HIAT1 225222_at 0.832 HNRNPC
235500_at 1.769 HNRPD 235999_at 1.92 HNRPD 241702_at 1.962 HNRPH1
213472_at 2.332 HOXA2 228642_at 1.44 HOXB9 216417_x_at 0.766 HOXD3
206601_s_at 1.897 HPS1 239382_at 1.749 HSD17B1 228595_at 0.753
HSDL2 209513_s_at 0.803 HSPA4L 205543_at 0.786 HUWE1 214673_s_at
1.858 IDS 1559136_s_at 2.001 IFNGR1 242903_at 2.171 IGHMBP2
215980_s_at 0.893 IL13RA1 201887_at 0.775 INSIG2 209566_at 0.872
IPO7 200993_at 0.875 IPW 213447_at 1.399 IRS2 236338_at 2.162
JARID1A 226367_at 1.192 JARID2 232835_at 2.139 KIAA0841 36888_at
1.389 KIAA0907 230028_at 1.83 KIAA1267 224489_at 1.355 KIAA1618
231956_at 2.27 KIAA1737 225623_at 0.837 KIAA2013 1555933_at 2.18
KIDINS220 1557246_at 2.97 KPNA6 226976_at 0.814 KRTAP19-1
1556410_a_at 2.07 KSR2 230551_at 3.211 LBA1 213261_at 1.225 LIMS1
212687_at 0.822 LOC126917 225615_at 0.819 LOC137886 212934_at 0.886
LOC145757 1558649_at 2.779 LOC145786 229178_at 1.907 LOC146325
1553826_a_at 3.943 LOC203547 225556_at 0.802 LOC219731 1557208_at
0.419 LOC254128 1557059_at 2.164 LOC283888 1559443_s_at 2.56
LOC285147 236166_at 2.377 LOC338799 226369_at 1.137 LOC388135
230475_at 1.979 LOC388969 232145_at 1.555 LOC389203 225014_at 0.79
LOC641298 208118_x_at 1.419 LOC645166 228158_at 0.823 LOC645513
239556_at 2.24 LOC729397 236899_at 2.231 LRCH3 229387_at 1.793
LRRFIP1 239379_at 1.796 MAEA 207922_s_at 0.765 MALAT1 224568_x_at
1.699 MALAT1 223940_x_at 1.659 MAP1LC3B 208785_s_at 0.808 MAP2K4
203266_s_at 0.881 MAP3K15 200979_at 0.741 6-Mar 201737_s_at 1.219
MBNL1 201152_s_at 0.867 MDM4 235589_s_at 1.629 MECR 218664_at 0.832
MED19 226300_at 0.782 MEF2C 236395_at 2.104 MET 213816_s_at 1.283
MIA3 1569057_s_at 0.759 MLL 212079_s_at 1.599 MOBKL1B 214812_s_at
0.762 MRPL42 217919_s_at 0.866 (includes EG:28977) MRPL51
224334_s_at 0.846 MTERFD3 225341_at 1.422 MTUS1 239576_at 1.975
MYO10 243159_x_at 2.528 MYO10 244350_at 1.677 N4BP2L1 213375_s_at
2.01 N4BP2L2 235547_at 1.631 N4BP2L2 242576_x_at 2.349 NAALAD2
1554506_x_at 0.464 NANP 228073_at 0.817 NAPA 239362_at 1.624
NAPE-PLD 242635_s_at 1.216 NARG1 1556381_at 2.827 NAT8B 206964_at
2.513 NBPF16 201104_x_at 1.411 NBR1 1568856_at 1.957 NCKAP1L
209734_at 2.071 NDFIP1 217800_s_at 0.815 NDUFAF2 228355_s_at 0.722
NDUFB6 203613_s_at 0.712 NEK1 213328_at 1.381 NFATC2IP 217527_s_at
1.272 NPAS2 1557690_x_at 1.76 NPTN 228723_at 2.086 NRP2 210841_s_at
1.106 NUCB2 203675_at 0.812 NUDT4 212183_at 0.685 NUPL1 241425_at
2.179 OCIAD1 235537_at 1.794 ORMDL1 223187_s_at 1.171 OSBPL5
233734_s_at 1.261 OSGEP 242930_at 1.541 PABPN1 213046_at 2.228
PAK1 226507_at 0.869 PAPD4 222282_at 3.39 PDE4B 215671_at 3.457
PDHB 211023_at 0.827 PDHB 208911_s_at 0.807 PDK1 239798_at 1.654
PDLIM5 212412_at 0.752 PDSS1 236298_at 1.64 PDXDC1 1560014_s_at
2.105 PGRMC2 213227_at 0.686 PHC1 218338_at 1.123 PHF20L1 219606_at
2.3 PIGY 224660_at 0.793 (includes EG:84992) PIP5K3 1557719_at
2.227 PITPNA 201190_s_at 0.863 PMP22 210139_s_at 0.865 PMS2L3
214473_x_at 1.159 POFUT2 207448_at 1.759 POLR2J2 1552622_s_at 1.828
POLR2J2 1552621_at 1.652 POP4 202868_s_at 0.847 PPP1R3D 204554_at
0.805 PPP1R7 201213_at 0.698 PPP3CA 202457_s_at 0.867 PRO1073
228582_x_at 1.607 PRPF38B 230270_at 1.888 PSEN1 242875_at 1.851
PSMA2 201316_at 0.839 PSMA3 201532_at 0.798 PTK2 234211_at 2.539
PTPMT1 229535_at 0.769 RAB11FIP3 228613_at 2.546 RAB11FIP3
216043_x_at 0.551 RAB14 200927_s_at 0.772 RAB1A 213440_at 0.81
RAD54L 204558_at 1.483 RADIL 223693_s_at 2.126 RBM25 1557081_at
1.57 RBM26 229433_at 1.43 RBM4 213718_at 1.53 RBM5 209936_at 2.249
RFT1 240281_at 1.426 RHOA 240337_at 2.143 RHOBTB2 1556645_s_at
1.538 RLBP1L1 224996_at 0.835 RNF43 228826_at 1.401 RP11-139H14.4
1569124_at 11.472 RPE 221770_at 0.766 RPE 225039_at 0.787 RPL7L1
225515_s_at 0.899 RUNX3 204198_s_at 1.233 SDAD1 242190_at 3.009
SDCCAG8 243963_at 2.67 SEC16B 1552880_at 1.877 SEPHS1 208940_at
0.875 11-Sep 201307_at 0.784 SF1 210172_at 2.452 SF3B1 201070_x_at
1.35 SF3B1 214305_s_at 1.359 SFRS15 222311_s_at 1.818 SFRS15
243759_at 2.028 SGCA 1562729_at 2.395 SGOL2 235425_at 1.591 SH2B3
203320_at 0.806 SKP1 200718_s_at 0.898 SLC16A1 202235_at 0.83
SLC20A1 230494_at 1.884 SLC2A11 232167_at 1.529 SLC2A8 239426_at
2.012 SLC30A9 237051_at 2.063 SMA4 238446_at 2.035 SMC6 218781_at
1.203 SMYD2 212922_s_at 0.867 SNORA28 241843_at 1.628 SNRPA1
242146_at 3.54 SON 201085_s_at 1.144 SPOPL 225659_at 0.828 SQLE
213577_at 1.502 SRP72 208801_at 0.751 SRP72 208803_s_at 0.766 SRPRB
218140_x_at 0.767 STK36 234005_x_at 1.335 STK36 231806_s_at 1.362
STRAP 1558002_at 2.189 STX11 235670_at 0.778 STX8 204690_at 0.819
SUPT7L 201838_s_at 0.865 SVIL 215279_at 2.228 SYNE2 202761_s_at
1.356 TAF15 227891_s_at 1.971 TAF1B 239046_at 1.468 TAOK3
220761_s_at 1.195 TBC1D5 201814_at 0.782 TBC1D8 221592_at 1.246
TBC1D8 204526_s_at 1.373 TBXA2R 207554_x_at 0.877 TBXA2R 336_at
0.73 TCAG7.907 238678_at 1.546 TCOF1 202385_s_at 1.169 (includes
EG:6949) TFB1M 228075_x_at 0.87 THRAP3 217847_s_at 1.464 TIMM23
218119_at 0.723 TM6SF1 1558102_at 0.704 TMEM126B 221622_s_at 0.843
TMEM165 1560622_at 1.756 TMEM30A 232591_s_at 0.771 TNFAIP1
201207_at 0.88 TNPO1 1556116_s_at 1.739 TNRC6A 234734_s_at 1.268
TOX4 201685_s_at 0.73 TPM4 235094_at 2.079 TRAPPC2 219351_at 0.821
TRAPPC2L 218354_at 0.837 TRIM33 239716_at 2.496 TRIM46 238147_at
1.96 TRIO 240773_at 2.607 TRNT1 243236_at 2.295 TRPV1 1556229_at
2.636 TSPAN31 203227_s_at 0.744 TTC26 233999_s_at 1.184 TTC3
208664_s_at 1.396 TTC9C 1569189_at 1.55 TTLL4 1557611_at 2.092
TXNDC12 223017_at 0.849 TXNL1 243664_at 1.98 UBE2E3 210024_s_at
0.758 UBE3C 1560739_a_at 0.815 UBXD7 212840_at 0.754 UGT1A6
206094_x_at 3.86 UNK 1562434_at 1.637 UQCC 229672_at 1.451 USP36
224979_s_at 1.393 USP8 229501_s_at 0.808 VPS37B 236889_at 2.85
VTI1B 209452_s_at 0.821 WDR41 218055_s_at 0.789 WDR68 233782_at
1.924 WFS1 1555270_a_at 1.315 WIPF2 216006_at 2.916 WTAP 1560274_at
1.747 XRCC5 232633_at 2.106 YY1 224711_at 0.821 ZFHX3 215828_at
1.737 ZFR 238970_at 2.655 ZFX 207920_x_at 1.625 ZMYND8 209049_s_at
1.102 ZNF154 242170_at 2.667 ZNF224 216983_s_at 2.986 ZNF226
219603_s_at 1.332 ZNF251 226754_at 1.313 ZNF292 236435_at 3.201
ZNF326 241720_at 1.418 ZNF337 1565614_at 2.096 ZNF536 233890_at
3.303 ZNF567 242429_at 2.103 ZNF618 226590_at 0.75 ZNF668
219047_s_at 0.691 ZNF800 227101_at 1.484 ZUFSP 228330_at 1.205
TABLE-US-00007 TABLE 6 Differentially expressed genes between
ABCB5.sup.+ and ABCB5.sup.- cells as detected by RT-PCR. PCR Array
Catalog #: PAHS-024 ABCB5+/ ABCB5- Fold Position Unigene Refseq
Symbol Description Gname change A01 Hs.525622 NM_005163 AKT1 V-akt
murine thymoma AKT/PKB 1.2687 viral oncogene homolog 1 A02
Hs.369675 NM_001146 ANGPT1 Angiopoietin 1 AGP1/AGPT 1.2953 A03
Hs.583870 NM_001147 ANGPT2 Angiopoietin 2 AGPT2/ANG2 2.7007 A04
Hs.209153 NM_014495 ANGPTL3 Angiopoietin-like 3 ANGPT5 3.0596 A05
Hs.9613 NM_001039667 ANGPTL4 Angiopoietin-like 4 ANGPTL2/ARP4
1.6974 A06 Hs.1239 NM_001150 ANPEP Alanyl (membrane) APN/CD13
1.3597 aminopeptidase (aminopeptidase N, aminopeptidase M,
microsomal aminopeptidase, CD13, p150) A07 Hs.194654 NM_001702 BAI1
Brain-specific FLJ41988 3.0596 angiogenesis inhibitor 1 A08
Hs.54460 NM_002986 CCL11 Chemokine (C-C motif) SCYA11 1.8834 ligand
11 A09 Hs.303649 NM_002982 CCL2 Chemokine (C-C motif) GDCF-2/
2.0326 ligand 2 GDCF-2HC11 A10 Hs.76206 NM_001795 CDH5 Cadherin 5,
type 2, VE- 7B4/CD144 3.0596 cadherin (vascular epithelium) A11
Hs.517356 NM_030582 COL18A1 Collagen, type XVIII, KNO 1.9634 alpha
1 A12 Hs.570065 NM_000091 COL4A3 Collagen, type IV, alpha TUMSTATIN
2.1634 3 (Goodpasture antigen) B01 Hs.789 NM_001511 CXCL1 Chemokine
(C-X-C FSP/GRO1 1.2086 motif) ligand 1 (melanoma growth stimulating
activity, alpha) B02 Hs.632586 NM_001565 CXCL10 Chemokine (C-X-C
C7/IFI10 -2.1987 motif) ligand 10 B03 Hs.89690 NM_002090 CXCL3
Chemokine (C-X-C CINC-2b/ 2.061 motif) ligand 3 GRO3 B04 Hs.89714
NM_002994 CXCL5 Chemokine (C-X-C ENA-78/ 1.8834 motif) ligand 5
SCYB5 B05 Hs.164021 NM_002993 CXCL6 Chemokine (C-X-C CKA-3/ 2.1936
motif) ligand 6 GCP-2 (granulocyte chemotactic protein 2) B06
Hs.77367 NM_002416 CXCL9 Chemokine (C-X-C CMK/Humig -1.1225 motif)
ligand 9 B07 Hs.592212 NM_001953 TYMP Thymidine ECGF1/ 1.5837
phosphorylase MNGIE B08 Hs.154210 NM_001400 EDG1 Endothelial
CHEDG1/ 1.0377 differentiation, D1S3362 sphingolipid G-protein-
coupled receptor, 1 B09 Hs.516664 NM_182685 EFNA1 Ephrin-A1
B61/ECKLG 1.4573 B10 Hs.516656 NM_004952 EFNA3 Ephrin-A3 EFL2/EPLG3
1.3692 B11 Hs.149239 NM_004093 EFNB2 Ephrin-B2 EPLG5/HTKL 1.1355
B12 Hs.419815 NM_001963 EGF Epidermal growth factor HOMG4/URG
187.8365 (beta-urogastrone) C01 Hs.76753 NM_000118 ENG Endoglin
(Osler-Rendu- CD105/END 1.1514 Weber syndrome 1) C02 Hs.437008
NM_004444 EPHB4 EPH receptor B4 HTK/MYK1 1.3692 C03 Hs.115263
NM_001432 EREG Epiregulin ER 1.8834 C04 Hs.483635 NM_000800 FGF1
Fibroblast growth factor AFGF/ECGF 1.5511 1 (acidic) C05 Hs.284244
NM_002006 FGF2 Fibroblast growth factor BFGF/FGFB 1.1355 2 (basic)
C06 Hs.1420 NM_000142 FGFR3 Fibroblast growth factor ACH/CD333
1.7092 receptor 3 (achondroplasia, thanatophoric dwarfism) C07
Hs.11392 NM_004469 FIGF C-fos induced growth VEGF-D/VEGFD 3.5884
factor (vascular endothelial growth factor D) C08 Hs.654360
NM_002019 FLT1 Fms-related tyrosine FLT/VEGFR1 2.4172 kinase 1
(vascular endothelial growth factor/vascular permeability factor
receptor) C09 Hs.388245 NM_021973 HAND2 Heart and neural crest
DHAND2/Hed 2.0186 derivatives expressed 2 C10 Hs.396530 NM_000601
HGF Hepatocyte growth factor F-TCF/HGFB 4.542 (hepapoietin A;
scatter factor) C11 Hs.654600 NM_001530 HIF1A Hypoxia-inducible
factor HIF-1alpha/ -1.0918 1, alpha subunit (basic HIF1
helix-loop-helix transcription factor) C12 Hs.44227 NM_006665 HPSE
Heparanase HPA/HPR1 286.6871 D01 Hs.504609 NM_002165 ID1 Inhibitor
of DNA binding ID -1.0329 1, dominant negative helix-loop-helix
protein D02 Hs.76884 NM_002167 ID3 Inhibitor of DNA binding HEIR-1
-1.3535 3, dominant negative helix-loop-helix protein D03 Hs.37026
NM_024013 IFNA1 Interferon, alpha 1 IFL/IFN 1.8834 D04 Hs.93177
NM_002176 IFNB1 Interferon, beta 1, IFB/IFF 1.8834 fibroblast D05
Hs.856 NM_000619 IFNG Interferon, gamma IFG/IFI 1.8834 D06
Hs.160562 NM_000618 IGF1 Insulin-like growth factor IGFI 4.7022 1
(somatomedin C) D07 Hs.126256 NM_000576 IL1B Interleukin 1, beta
IL-1/IL1-BETA 2.0898 D08 Hs.654458 NM_000600 IL6 Interleukin 6
(interferon, BSF2/HGF 1.7331 beta 2) D09 Hs.624 NM_000584 IL8
Interleukin 8 3-10C/AMCF-I 1.1674 D10 Hs.436873 NM_002210 ITGAV
Integrin, alpha V CD51/DKFZ 1.217 (vitronectin receptor, p686A08142
alpha polypeptide, antigen CD51) D11 Hs.218040 NM_000212 ITGB3
Integrin, beta 3 (platelet CD61/GP3A -1.0619 glycoprotein IIIa,
antigen CD61) D12 Hs.224012 NM_000214 JAG1 Jagged 1 (Alagille
AGS/AHD 1566.5046 syndrome) E01 Hs.479756 NM_002253 KDR Kinase
insert domain CD309/FLK1 1.234 receptor (a type III receptor
tyrosine kinase) E02 Hs.473256 NM_005560 LAMA5 Laminin, alpha 5
KIAA1907 3.8727 E03 Hs.421391 NM_007015 LECT1 Leukocyte cell
derived BRICD3/ 1.8834 chemotaxin 1 CHM-I E04 Hs.194236 NM_000230
LEP Leptin OB/OBS 2.1485 E05 Hs.82045 NM_002391 MDK Midkine
(neurite growth- MK/NEGF2 1.4573 promoting factor 2) E06 Hs.513617
NM_004530 MMP2 Matrix metallopeptidase CLG4/CLG4A 1.674 2
(gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase) E07
Hs.297413 NM_004994 MMP9 Matrix metallopeptidase CLG4B/GELB 1.9097
9 (gelatinase B, 92 kDa gelatinase, 92 kDa type IV collagenase) E08
Hs.436100 NM_004557 NOTCH4 Notch homolog 4 INT3/NOTCH3 1.2002
(Drosophila) E09 Hs.131704 NM_003873 NRP1 Neuropilin 1 CD304/
1.1755 DKFZp686A03134 E10 Hs.471200 NM_003872 NRP2 Neuropilin 2
NP2/NPN2 1.4373 E11 Hs.707991 NM_002607 PDGFA Platelet-derived
growth PDGF-A/ 1.2002 factor alpha polypeptide PDGF1 E12 Hs.514412
NM_000442 PECAM1 Platelet/endothelial cell CD31/PECAM-1 11.9037
adhesion molecule (CD31 antigen) F01 Hs.81564 NM_002619 PF4
Platelet factor 4 CXCL4/ 2.9966 (chemokine (C-X-C SCYB4 motif)
ligand 4) F02 Hs.252820 NM_002632 PGF Placental growth factor,
D12S1900/PGFL -1.1865 vascular endothelial growth factor-related
protein F03 Hs.77274 NM_002658 PLAU Plasminogen activator, ATF/UPA
1.6396 urokinase F04 Hs.143436 NM_000301 PLG Plasminogen
DKFZp779M0222 1.8834 F05 Hs.125036 NM_020405 PLXDC1 Plexin domain
containing DKFZp686F0937/ 3.4184 1 TEM3 F06 Hs.528665 NM_021935
PROK2 Prokineticin 2 BV8/KAL4 1.8446 F07 Hs.201978 NM_000962 PTGS1
Prostaglandin- COX1/COX3 1.2086 endoperoxide synthase 1
(prostaglandin G/H synthase and cyclooxygenase) F08 Hs.532768
NM_002615 SERPINF1 Serpin peptidase EPC-1/PEDF 1.1121 inhibitor,
clade F (alpha- 2 antiplasmin, pigment epithelium derived factor),
member 1 F09 Hs.68061 NM_021972 SPHK1 Sphingosine kinase 1 SPHK
1.192 F10 Hs.301989 NM_015136 STAB1 Stabilin 1 CLEVER-1/FEEL-1
4.357 F11 Hs.89640 NM_000459 TEK TEK tyrosine kinase, CD202B/TIE-2
-1.2805 endothelial (venous malformations, multiple cutaneous and
mucosal) F12 Hs.170009 NM_003236 TGFA Transforming growth TFGA
3549.3357 factor, alpha G01 Hs.645227 NM_000660 TGFB1 Transforming
growth CED/DPD1 1.1837 factor, beta 1 G02 Hs.133379 NM_003238 TGFB2
Transforming growth TGF-beta2 1.3787 factor, beta 2 G03 Hs.494622
NM_004612 TGFBR1 Transforming growth AAT5/ACVRLK4 1.7695 factor,
beta receptor I (activin A receptor type II-like kinase, 53 kDa)
G04 Hs.164226 NM_003246 THBS1 Thrombospondin 1 THBS/TSP -1.0619 G05
Hs.371147 NM_003247 THBS2 Thrombospondin 2 TSP2 -1.203 G06
Hs.522632 NM_003254 TIMP1 TIMP metallopeptidase CLGI/EPA -1.1147
inhibitor 1 G07 Hs.633514 NM_003255 TIMP2 TIMP metallopeptidase
CSC-21K 1.2864 inhibitor 2 G08 Hs.701968 NM_000362 TIMP3 TIMP
metallopeptidase HSMRK222/ 1.8834 inhibitor 3 (Sorsby K222 fundus
dystrophy, pseudoinflammatory) G09 Hs.241570 NM_000594 TNF Tumor
necrosis factor DIF/TNF-alpha 4.0652 (TNF superfamily, member 2)
G10 Hs.525607 NM_006291 TNFAIP2 Tumor necrosis factor, B94 1.8834
alpha-induced protein 2 G11 Hs.73793 NM_003376 VEGFA Vascular
endothelial VEGF/VEGF-A 2.4509 growth factor A G12 Hs.435215
NM_005429 VEGFC Vascular endothelial Flt4-L/VRP 446.7529 growth
factor C H01 Hs.534255 NM_004048 B2M Beta-2-microglobulin B2M
-1.2983 H02 Hs.412707 NM_000194 HPRT1 Hypoxanthine HGPRT/HPRT
-1.2894 phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) H03
Hs.523185 NM_012423 RPL13A Ribosomal protein L13a RPL13A 1.1837 H04
Hs.544577 NM_002046 GAPDH Glyceraldehyde-3- G3PD/GAPD -1.146
phosphate dehydrogenase H05 Hs.520640 NM_001101 ACTB Actin, beta
PS1TP5BP1 -1.0329 H06 N/A SA_00105 HGDC Human Genomic DNA HIGX1A
1.8834 Contamination H07 N/A SA_00104 RTC Reverse Transcription RTC
1.7451 Control H08 N/A SA_00104 RTC Reverse Transcription RTC
1.7451 Control H09 N/A SA_00104 RTC Reverse Transcription RTC
1.7695 Control H10 N/A SA_00103 PPC Positive PCR Control PPC 1.8067
H11 N/A SA_00103 PPC Positive PCR Control PPC 1.7818 H12 N/A
SA_00103 PPC Positive PCR Control PPC 36695.9527
Example 3
[0171] We therefore tested the hypothesis that MMIC, as defined by
the novel marker ABCB5.sup.3, specifically relate to the phenomenon
of vasculogenic mimicry whereby melanoma cells form channels
capable of conducting nutrients from peripheral blood and thus
serving as surrogates for mature tumour vessels.sup.4. Because we
posited that this phenomenon may be more robust during early stages
of tumour formation before cancer angiogenesis fully develops, we
evaluated experimentally-induced human-derived melanomas grown as
tumour xenografts in the subcutis of immunodeficient mice and in
the dermis of human skin xenografted to immunodeficient mice (FIG.
2), the latter a humanized model whereby human melanoma develops in
the context of the human stromal microenvironment.sup.13. While
only peripheral tumour vessels expressed the mature endothelial
marker, CD31, more interior regions of the melanomas exhibited
formation of CD31-negative anastomosing channels with histologic,
histochemical (PAS-D and laminin reactivity), and ultrastructural
findings consistent with established features of vasculogenic
mimicry.sup.4 (FIG. 2a-d). By electron microscopy, lumen-like
spaces in these regions were lined by basement membrane-like
material and viable melanoma cells and contained erythrocytes
surrounded by finely granular matrix consistent with plasma,
suggesting communication with the systemic circulation.sup.4. By
immunohistochemistry and in situ hybridization, channels expressed
ABCB5 protein and mRNA, respectively (FIG. 2f-h), which also
correlated in vitro when assayed across a panel of human melanoma
cell lines (FIG. 4), and the architecture of ABCB5.sup.+ channels
in xenografted tumours was identical to that focally detected in
patient-derived melanomas (FIG. 2f, inset). An identical pattern
was also observed for CD133 mRNA (not illustrated), an additional
marker for tumourigenic melanoma cells.sup.14 and melanoma
progression.sup.15. Anti-ABCB5 mAb systemically administered in
vivo localized to channels, further confirming their systemic
perfusion as well as the intimate association of ABCB5.sup.+
melanoma cells with channel lumens (FIG. 2i). Double-labeling
demonstrated co-localization of the human endothelial markers CD144
and TIE-1 with ABCB5.sup.+ cells forming channels (FIG. 2j,k).
Tumours initiated by melanoma cell lines expressing the green
fluorescence protein (GFP) transgene confirmed the presence of
melanoma cells lining channels that co-expressed
melanoma-associated GFP and CD144 (FIG. 2e), as well as human
melanoma--but not human xenograft-associated class I major
histocompatibility complex (MHC) antigens (not illustrated). These
data show that the formation of perfused vessel-like channels in
human melanoma is mediated by the ABCB5.sup.+ MMIC subpopulation
found to selectively display gene profiles and differentiation
capacity consistent with its participation in tumour
vasculogenesis.
Example 4
[0172] We next reasoned that if vasculogenic channel formation
mediated by ABCB5.sup.+ MMIC was functionally required for their
capacity to efficiently initiate and drive melanoma growth,
depletion of MMIC to low levels should inhibit the
melanoma-associated vasculogenic response. To evaluate
tumourigenesis and vasculogenesis in a bioassay most relevant to
human primary melanoma, we again utilized a human skin/murine
xenograft model whereby melanomas develop in the relevant dermal
microenvironment of human skin and express architectural features
and evolutionary growth patterns more akin to naturally occurring
lesions.sup.13. Intradermal orthotopic transplantation of
2.times.10.sup.6 unsegregated A375 cutaneous melanoma cells (ABCB5
positivity: 5.2.+-.5.1%; mean.+-.s.e.m., n=9) (FIG. 3a) or
heterotopic transplantation of 2.times.10.sup.6 unsegregated uveal
melanoma cells previously assayed for vasculogenic
differentiation.sup.4,16 (MUM-2B and MUM-2C, ABCB5 positivity:
2.46.+-.0.46% and 3.81.+-.1.04%, respectively; mean.+-.s.e.m.,
n=3-4) (FIG. 3a) to human skin resulted in tumour formation three
weeks following microinjections in 14 of 14 recipient skin grafts
(A375: n=6, MUM-2B: n=4, MUM-2C: n=4 replicates) when assessed
histologically in serial sections of each human skin xenograft in
its entirety (FIG. 3b,c). In contrast, intradermal transplantation
of equal numbers of ABCB5.sup.+-depleted melanoma cells resulted in
histologically-assessed tumour formation in only 6 of 14 recipient
skin grafts (P<0.002) (FIG. 3b,c) and histologically-determined
mean tumour volumes (TV) were significantly reduced in recipients
of ABCB5.sup.+-depleted vs. unsegregated melanoma inocula
(TV=2.8.+-.1.8 mm.sup.3 vs. 10.9.+-.6.9 mm.sup.3, respectively;
mean.+-.s.e.m., P<0.005) (FIG. 3d). When vasculogenic channel
formation within tumours was evaluated using quantitative image
analysis technology to assess the pixilated density of laminin
immunoreactivity, significantly fewer channels per cross-sectional
area were detected in tumours that formed from MMIC-depleted
inocula compared to those that originated from unsegregated tumour
cell grafts (A375, P<0.0032; MUM-2B, P<0.0005; MUM-2C,
P<0.0059) (FIG. 3e,f). In aggregate, these findings show in
relevant xenograft models of early melanoma development the
participation of ABCB5.sup.+ MMIC in the genesis of vasculogenic
channels, and the interdependency of MMIC-derived channel formation
and tumour growth.
[0173] Discovery of MMIC-driven vasculogenesis identifies selective
differentiation plasticity as a novel CSC-specific function through
which these tumourigenic cancer subpopulations may provide a
specific growth advantage to developing tumours. Our finding of a
propensity of MMIC to differentiate selectively into cells capable
of serving a defined tissue function required for more efficient
tumour growth parallels hallmark characteristics of physiological
stem cells, which similarly give rise to cell lineages capable of
serving specific roles required for maintenance of tissue
homeostasis through defined differentiation programs. Importantly,
we find that MMIC-dependent tumourigenesis and vasculogenesis are
operative not only in human melanoma to murine skin
xenotransplantation models but also upon human melanoma to human
skin transplantation. Therefore, our results provide initial
evidence that the tumour-sustaining role of human CSC identified in
xenotransplantation assays does not merely reflect the limited
ability of human tumour cells to adapt to growth in a foreign
(mouse) milieu, as has been postulated based on the results of
murine tumour transplantation experiments utilizing histocompatible
murine hosts.sup.17
[0174] The now widely-accepted concept of cancer angiogenesis
advanced by Folkman in 1971 states that human cancers are
critically dependent upon tumour-related blood-vessel growth and
development.sup.18. In addition to classical angiogenesis whereby
cancer cells, including CSC.sup.19, induce in-growth of mature,
CD31-positive vessels from surrounding stroma.sup.20, evidence has
been generated that cancer cells may also directly form surrogate
vessel-like spaces by the process of vasculogenic mimicry whereby
aggressive human melanomas develop patterned networks composed of
periodic acid-Schiff (PAS)- and laminin-reactive basement membranes
and associated perfusable channels formed by tumour cells that
express some but not all endothelium-related genes and
proteins.sup.4. The present study identifies the cells and
underlying mechanisms responsible for vasculogenic mimicry, and
establishes that in addition to self-renewal, MMIC selectively
express vasculogenic genes and form channels consistent with the
function of promoting nutrition to rapidly growing tumours. Thus,
cancer angiogenesis and MMIC-driven vasculogenesis may represent
independent yet potentially interrelated mechanisms whereby
aggressive and metabolically-active tumours obtain those nutrients
requisite for critical stages of growth and evolution. This may be
particularly important during tumour initiation and early phases of
tumourigenic growth when hypoxia-dependent, mTOR-driven
angiogenesis from surrounding stroma has not fully
evolved.sup.21.
[0175] Recently, proof-of-principle has been established for the
potential therapeutic utility of the CSC concept.sup.3,22.
Therefore, identification of a vasculogenic mechanism whereby MMIC
may contribute to tumour growth has potentially important
therapeutic implications. Previous studies revealed that normally
resistant human melanoma cells are rendered sensitive in vitro to
the effects of chemotherapeutic agents by mAb- or siRNA-mediated
blockade of ABCB5.sup.5,6, and that mAb binding to ABCB5 is
sufficient to induce an effective anti-melanoma immune response via
antibody-dependent cell-mediated cytotoxicity (ADCC) in vivo.sup.3.
Now, recognition of the role of MMIC in tumour vasculogenesis will
also permit development of strategies focused on inhibition of the
relevant molecular pathways integral to endothelial-directed CSC
plasticity. Moreover, the spatial localization of the MMIC
component to channels that communicate with the systemic
circulation may render this important determinant of cancer
virulence particularly vulnerable to therapeutic targeting.
Example 5: Vasculogenic/Angiogenic Pathways in Human Melanoma
[0176] We investigated gene relationships based on Ingenuity
Pathway Analysis. We prepared a graphical representation of pathway
activation across ABCB5.sup.+ MMIC. Genes that were overexpressed
in ABCB5.sup.+ relative to ABCB5.sup.- human melanoma cells were
represented by red nodes (circles) and those expressed at lower
levels were represented by black nodes. Black lines were drawn
between genes to show known interactions. Known gene functions in
vasculogenesis and angiogenesis, and genes known as relevant drug
targets were annotated (red lines) (FIG. 1a). We examined
expression of vasculogenic/angiogenic pathway members by RT-PCR in
ABCB5.sup.+ MMIC. Results of this anaylsis are shown in FIG. 1b. We
used dual color flow cytometry using ABCB5 phenotype-specific cell
gating to determining FLT1 (VEGFR-1) protein expression of
ABCB5.sup.+ MMIC (FIG. 1c, top) and ABCB5-melanoma cells (FIG. 1c,
bottom). We examined CD144 expression in ABCB5.sup.+ MMIC or
ABCB5.sup.- melanoma cell subpopulations by immunofluorescence
staining prior to (t=0 h) and upon 48 h of culture (t=48 h) in the
presence of 100 ng/ml VEGF.sup.11. Representative
immunofluorescence staining for CD144 expression (Texas red) are
shown in FIG. 1d, with nuclei counterstained in blue (DAPI). Mean
percentages (mean.+-.s.e.m., n=3 replicate experiments) of cells
staining positively for CD144 in each sample are shown on the
right. We examined CD144 expression in melanoma cells in the
presence of 100 ng/ml VEGF as in above, but in the presence or
absence of anti-FLT1 (VEGFR-1) blocking mAb or isotype control mAb.
Representative immunofluorescence staining for CD144 expression
(Texas red) by melanoma cells cultured for 48 h (t=48 h) are shown
in FIG. 1e, with nuclei counterstained in blue (DAPI). Mean
percentages (mean.+-.s.e.m., n=3 replicate experiments) of cells
staining positively for CD144 in each sample are shown in the far
right panel. We examined tube formation by phase contrast light
microscopy of melanoma cells cultured for 24 h (t=24 h) in the
presence of 100 ng/ml VEGF and the presence or absence of anti-FLT1
(VEGFR-1) blocking mAb or isotype control mAb (FIG. 1f). Number of
tubes/microscopy field (mean.+-.s.e.m., n=3 replicate experiments)
and tube length (.mu.m) (mean.+-.s.e.m., n=3 replicate experiments)
are illustrated for the different experimental conditions on the
far right panels, respectively. We examined the differentiation
potential of ABCB5.sup.+ and ABCB5.sup.- human melanoma cells along
a adipogenic pathway (FIG. 1h, Oil Red O staining, nuclei are
counterstained with hematoxylin) and osteogenic pathway (FIG. 1i,
Alizarin Red staining). Myogenic differentiation potential of
ABCB5.sup.+ and ABCB5.sup.- human melanoma cells was also examined
(FIG. 1j). Absence of myogenin staining (FITC, green) was detected
in ABCB5.sup.+ or ABCB5.sup.- human melanoma cells (nuclei are
counterstained with DAPI).
Example 6: MMIC-Driven In Vivo Vasculogenesis
[0177] We investigated MMIC driven vasculogenesis in vivo. Sections
of human melanoma growing at melanoma cell injection site within
human dermis of skin xenograft to NOD/SCID mouse were
conventionally-stained by hematoxylin and eosin (FIG. 2a). We also
examined by immunohistochemistry the expression of human CD31 which
indicated angiogenic response at perimeter of melanoma within human
xenograft. (FIG. 2b, broken line represents interface of tumour
nodule with dermal connective tissue). We used periodic-acid Schiff
(PAS) stain (with diastase), an immunochemical stain of
CD31-negative interior regions of melanoma xenografts, to reveal
numerous anastomosing channels (FIG. 2c, inset is laminin
immunohistochemistry indicating identical pattern). We conducted
transmission electron micrographs of interior regions of melanoma
xenografts (FIG. 2d), and found that lumenal spaces containing
blood products (erythrocytes) are lined by melanoma cells and
associated basement membrane-like extracellular matrix. We examined
the interior zone of melanoma xenograft derived from cells
expressing GFP transgene and immunohistochemically stained for
endothelial marker CD144 (red chromogen); results are shown in
(FIG. 2e). We found that CD144 expression is confined to cells
forming lumen-like spaces lined by cells that co-express GFP and
CD144 (indicated as yellow-orange). We also performed
immunohistochemistry, at low (FIG. 2f) and high (FIG. 2g)
magnification, for ABCB5 protein; our results show that reactivity
is restricted to anastomosing channels identical to those seen in
FIG. 2c. The inset in FIG. 2f depicts similar formation of
ABCB5-reactive channels in a patient-derived melanoma biopsy. We
performed in situ hybridization for ABCB5 mRNA (FIG. 2h). Our
results reveal a channel pattern corresponding to that of ABCB5
protein expression (compare with FIG. 2f; inset is sense control).
We examined the expression of ABCB5 in melanoma xenografts after
intravenous administration in vivo (FIG. 2h). Detection of
anti-ABCB5 mAb was accomplished using anti-mouse Ig
immunohistochemistry; note localization to channels (inset
represents anti-mouse Ig staining after intravenous administration
of irrelevant isotype-matched control mAb). Dual-labeling
immunofluorescence microscopy was performed for both ABCB5 (green),
CD144 (red), and ABCB5 & CD144 (mix) (FIG. 2j) and ABCB5
(green), TIE-1 (red), and ABCB5 & TIE-1 (mix) (FIG. 2j).
Example 7: Interdependency of MMIC-Driven Vasculogenesis and
Tumourigenesis
[0178] We examined ABCB5 expression by flow cytometry; ABCB5 or
control staining (FITC, F11) was plotted against forward scatter
(FSC) for human A375, MUM-2B, and MUM-2C melanoma cell inocula.
Representative data is shown in FIG. 3a. We examined histologic
sections of melanomas that developed from three unsegregated and
ABCB5-depleted melanoma cell lines injected intradermally into
human skin xenografts. Representative sections are shown in FIG.
3b. We used histology to determine tumour formation rate (%) 3
weeks following intradermal transplantation of unsegregated vs.
ABCB5.sup.+-depleted human A375, MUM-2B or MUM-2C melanoma cells
(2.times.10.sup.6/inoculum) into human skin/Rag2.sup.-/- chimeric
mice (n=5, respectively). (FIG. 3c). We determined histological
tumour volumes (mean.+-.s.e.m.) 3 weeks following intradermal
transplantation of unsegregated vs. ABCB5.sup.+-depleted human
A375, MUM-2B or MUM-2C melanoma cells (2.times.10.sup.6/inoculum)
into human skin/Rag2.sup.-/- chimeric mice. (FIG. 3d). We performed
immunohistochemistry for laminin. Our results showed the extent of
channel formation in melanomas that developed from unsegregated or
ABCB5.sup.+-depleted melanoma cell inocula derived from A375,
MUM-2B or MUM-2C lines injected intradermally into human skin
xenografts (arrows=necrosis). (FIG. 3e). We performed image
analysis of laminin immunoreactivity for melanomas derived from
unsegregated and ABCB5.sup.+-depleted cell inocula. Data are shown
in FIG. 3f; y-axis is percent of pixelated area with reactivity
(mean.+-.s.e.m.); solid bar represents tumours derived from
unsegregated melanoma cells, open bars represent tumours derived
from ABCB5.sup.+-depleted cells (A375, P<0.0032; MUM-2B,
P<0.0005; MUM-2C, P<0.0059).
Example 8: Correlation of ABCB5 Protein and mRNA Expression Across
Human Melanoma Cell Lines
[0179] We examined ABCB5 and tubulin expression in a panel of human
melanoma cell lines by western blot analysis (FIG. 4a). We examined
relative ABCB5 mRNA expression (log 2) in a panel of human melanoma
cell lines plotted against ABCB5 protein expression as determined
by ratios of ABCB5 89 kD western blot band intensity and tubulin
western blot band intensity for each human melanoma cell line.
(FIG. 4b). Data points are as follows: 1, SK-MEL-2; 2, SK-MEL-5; 3,
SK-MEL-28; 4, MDA-MB-435; 5, UACC-62; 6, UACC-257; 7, M14; 8,
MALME-3M. Spearman Rank Correlation r (corrected for ties).
Example 9: CSC-Associated Genes Identified at the Protein Level
[0180] Using cell surface immunostaining and flow cytometry we
identified additional genes to be differentially regulated at the
protein level in ABCB5+ CSC versus ABCB5- cancer bulk populations.
These are all immunomodulatory molecules and the ones upregulated
in ABCB5+ cells may be relevant to the escape from
immunosurveillance and be resposible for resistance to
immunotherapy in malignant melanoma, i.e. when the genes
overexpressed on ABCB5+ cells are targeted, melanoma is predicted
to be sensitized to immune attack and therapy.
TABLE-US-00008 TABLE 8 Upregulated in ABCB5+ CSC compared to ABCB5-
bulk cancer populations: MHC class II CD28 CD86 PD-1 CD40-L 4-1BB-L
B7-H4 GITR
TABLE-US-00009 TABLE 7 Downregulated in ABCB5+ CSC compared to
ABCB5- cancer bulk populations MHC class I CD80 PD-L1 ICOS-L
REFERENCES FOR DETAILED DESCRIPTION AND EXAMPLES
[0181] 1 M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez et al., Proc
Natl Acad Sci USA 100 (7), 3983 (2003); D. Bonnet and J. E. Dick,
Nat Med 3 (7), 730 (1997); C. A. O'Brien, A. Pollett, S. Gallinger
et al., Nature 445 (7123), 106 (2007); L. Ricci-Vitiani, D. G.
Lombardi, E. Pilozzi et al., Nature 445 (7123), 111 (2007); S. K.
Singh, C. Hawkins, I. D. Clarke et al., Nature 432 (7015), 396
(2004). [0182] 2 T. Schatton and M. H. Frank, Pigment cell &
melanoma research 21 (1), 39 (2008). [0183] 3 T. Schatton, G. F.
Murphy, N. Y. Frank et al., Nature 451 (7176), 345 (2008). [0184] 4
A. J. Maniotis, R. Folberg, A. Hess et al., Am J Pathol 155 (3),
739 (1999). [0185] 5 N. Y. Frank, A. Margaryan, Y. Huang et al.,
Cancer Res 65 (10), 4320 (2005). [0186] 6 Y. Huang, P. Anderle, K.
J. Bussey et al., Cancer Res 64 (12), 4294 (2004). [0187] 7 L.
Chin, L. A. Garraway, and D. E. Fisher, Genes Dev 20 (16), 2149
(2006). [0188] 8 G. I. Keshet, I. Goldstein, O. Itzhaki et al.,
Biochem Biophys Res Commun 368 (4), 930 (2008). [0189] 9 J. F.
Sousa and E. M. Espreafico, BMC cancer 8, 19 (2008). [0190] 10 N.
Y. Frank, A. T. Kho, T. Schatton et al., J Cell Biol 175 (1), 99
(2006). [0191] 11 K. Nishiyama, K. Takaji, Y. Uchijima et al., J
Biol Chem 282 (23), 17200 (2007). [0192] 12 D. Fang, T. K. Nguyen,
K. Leishear et al., Cancer Res 65 (20), 9328 (2005). [0193] 13 I.
Juhasz, S. M. Albelda, D. E. Elder et al., Am J Pathol 143 (2), 528
(1993). [0194] 14 E. Monzani, F. Facchetti, E. Galmozzi et al., Eur
J Cancer 43 (5), 935 (2007). [0195] 15 W. M. Klein, B. P. Wu, S.
Zhao et al., Mod Pathol 20 (1), 102 (2007). [0196] 16 E. A. Seftor,
P. S. Meltzer, D. A. Kirschmann et al., Clin Exp Metastasis 19 (3),
233 (2002). [0197] 17 P. N. Kelly, A. Dakic, J. M. Adams et al.,
Science 317 (5836), 337 (2007). [0198] 18 J. Folkman, N Engl J Med
285 (21), 1182 (1971). [0199] 19 S. Bao, Q. Wu, S. Sathornsumetee
et al., Cancer Res 66 (16), 7843 (2006); R. J. Gilbertson and J. N.
Rich, Nat Rev Cancer 7 (10), 733 (2007). [0200] 20 B. N. Perry and
J. L. Arbiser, J Invest Dermatol 126 (10), 2160 (2006). [0201] 21
M. Guba, P. von Breitenbuch, M. Steinbauer et al., Nat Med 8 (2),
128 (2002). [0202] 22 Z. F. Yang, D. W. Ho, M. N. Ng et al., Cancer
Cell 13 (2), 153 (2008); S. Bao, Q. Wu, Z. Li et al., Cancer Res 68
(15), 6043 (2008). [0203] 23 N. Y. Frank, S. S. Pendse, P. H.
Lapchak et al., J Biol Chem 278 (47), 47156 (2003). [0204] 24 D.
Donovan, N. J. Brown, E. T. Bishop et al., Angiogenesis 4 (2), 113
(2001).
[0205] Having thus described several aspects of at least one
embodiment of this invention, it is to be appreciated various
alterations, modifications, and improvements will readily occur to
those skilled in the art. Such alterations, modifications, and
improvements are intended to be part of this disclosure, and are
intended to be within the spirit and scope of the invention.
Accordingly, the foregoing description and drawings are by way of
example only.
Sequence CWU 1
1
18120DNAArtificial SequenceSynthetic Olignucleotide 1tgccttttac
tttcgtgtgg 20221DNAArtificial SequenceSynthetic Olignucleotide
2ccaaattcct gttttgcttc a 21320DNAArtificial SequenceSynthetic
Olignucleotide 3ccccacctta tcctgacgta 20420DNAArtificial
SequenceSynthetic Olignucleotide 4cgtgtgtcca cctcatcatc
20520DNAArtificial SequenceSynthetic Olignucleotide 5gaggcagggg
aaaatagagg 20620DNAArtificial SequenceSynthetic Olignucleotide
6tctcccgaaa ggttgaaatg 20720DNAArtificial SequenceSynthetic
Olignucleotide 7cgcttactct gttggggtct 20820DNAArtificial
SequenceSynthetic Olignucleotide 8tctccagcaa aatgatgtgc
20922DNAArtificial SequenceSynthetic Olignucleotide 9tggcaactgc
ttttatgttc tg 221020DNAArtificial SequenceSynthetic Olignucleotide
10tccatagggt gatggtcaaa 201121DNAArtificial SequenceSynthetic
Olignucleotide 11gctgaggaat ccacccaatc t 211220DNAArtificial
SequenceSynthetic Olignucleotide 12agcctgaatg gccttttgtg
201318DNAArtificial SequenceSynthetic Olignucleotide 13cctggcaccc
agcacaat 181420DNAArtificial SequenceSynthetic Olignucleotide
14agtactccgt gtggatcggc 201545DNAArtificial SequenceSynthetic
Olignucleotide 15taatacgact cactataggg atgtctggct ttttcccttc ttgac
451645DNAArtificial SequenceSynthetic Olignucleotide 16gatttaggtg
acactataga aattcaagct ggacgaatga cccca 451742DNAArtificial
SequenceSynthetic Olignucleotide 17taatacgact cactataggg agcagcccca
ggacacagca ta 421841DNAArtificial SequenceSynthetic Olignucleotide
18gatttaggtg acactataga gacccaagac tcccataaag c 41
* * * * *